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ABSTRACT
The application of micro- and nanoparticles as drug carrier systems
represents a highly promising approach to biopharmaceutically im-
prove the administration of drugs. The interaction of particles with
tissues of the human body will be determined by their size and most
importantly surface characteristics. Consequently, modification of the
particle surface with bioadhesive molecules could represent a potent
means for controlling the residence time and localization of particles in
the body.
In the present thesis it was investigated to what extent ionic and
biorecognitive interactions can be employed for mediating the adhesion
of particles to epithelial and endothelial cells. By adsorption of the
cationic polyelectrolyte poly(ethylene imine) (PEI) the zeta potential of
negatively charged polymer particles was inverted. As a consequence of
this surface modification a 3-fold higher binding of microparticles and
5-fold higher binding of nanoparticles to artificial intestinal epithelium
was observed. However, a general transfer of these results to other cell
types does not seem possible since positively charged particles were
not characterized by preferential binding to primary endothelial cells.
In order to enhance the specific bioadhesion of micro- and nanopar-
ticles, covalent conjugation with wheat germ agglutinin (WGA) was
employed. As a consequence of the interaction between the surface-
bound lectin and carbohydrates in the glycocalyx, a 73-fold enhanced
binding as compared to plain colloids was observed. This underlines
that modification with lectins represents a promising concept for im-
proving the bioadhesive properties of particulate drug carrier systems.
Usually, bioadhesion studies are performed under stationary con-
ditions. However, upon peroral as well as parenteral administration
hydrodynamic forces will act on the particles. This might substantially
influence their interaction with the tissue. In order to facilitate stud-
ies on the effects of flow on bioadhesion, a miniaturized chip-based
microfluidic system was developed. By controlled generation of sur-
face acoustic waves (SAWs) fluids can be controllably actuated in this
tissue-culture compatible device. Thereby, hydrodynamic conditions
comparable with those in the gastrointestinal tract and in the circulatory
system can be generated in vitro. This flow model was employed to in-
vestigate the influence of shear forces on the binding of WGA-modified
and plain microparticles to epithelial monolayers. Clear discrepancies
between the number of cell-associated particles under stationary and
flow conditions were observed. These results illustrate that an inte-
gration of flow into preclinical biopharmaceutical test systems might
enable an improved understanding of bioadhesion in a physiological
environment.
The developed tissue-chip hybrid for flow studies as well as the
techniques for surface modification and particle detection will represent
versatile tools for future studies dealing with the biopharmaceutical
optimization of drug administration.
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ZUSAMMENFASSUNG
Der Einsatz von Nano- und Mikropartikeln als Trägersysteme stellt
einen vielversprechenden Ansatz zur biopharmazeutisch verbesserten
Applikation von hochpotenten etablierten und Biotech-Wirkstoffen dar.
Die Interaktion der Partikel mit Geweben des menschlichen Körpers
wird abgesehen von der Partikelgröße vorwiegend durch die chemische
Struktur der Partikeloberfläche bestimmt. Folglich kann durch Modi-
fikation der Oberfläche mit bioadhäsiven Molekülen die Lokalisation
und Verweildauer der partikulären Arzneiform im Körper grundlegend
beeinflusst werden.
Im Rahmen der vorliegenden Dissertation wurde untersucht, in-
wiefern elektrostatische oder biorekognitive Wechselwirkungen aus-
genützt werden können, um die Bindung von Nano- und Mikropar-
tikeln an humane epitheliale und endotheliale Zellen zu erhöhen.
Die negative Oberflächenladung von Polymerteilchen wurde durch
Beschichtung mit dem kationischen Polyelektrolyt Polyethylenimin
invertiert. Durch diese Ladungsumkehr konnte eine 3-fach erhöhte
Bindung von Mikropartikeln und eine 5-fach erhöhte Bindung von
Nanopartikeln an ein Gewebekulturmodell des humanen Dünndarms
erzielt werden. Ein generelles Übertragen dieser Ergebnisse auf an-
dere humane Zelltypen ist jedoch nicht uneingeschränkt möglich, da
beispielsweise an primären humanen Endothelzellen keine bevorzugte
Bindung von positiv geladenen Partikeln nachgewiesen werden konnte.
Zur Erhöhung der spezifischen Bioadhäsivität wurden Nano- und
Mikropartikel kovalent mit Weizenkeimlektin derivatisiert. Die Wech-
selwirkung dieses zuckerbindenden Proteins mit Bestandteilen der zel-
lulären Glykocalyx erhöhte die Bindungsraten an Caco-2 Einzelzellen
73-fach im Vergleich zu nicht modifizierten Partikeln. Dadurch kon-
nte bestätigt werden, dass die Konjugation mit Lektinen ein vielver-
sprechendes Konzept im Rahmen der Entwicklung bioadhäsiver Wirk-
stoffträger darstellt.
Standardgemäß werden Bioadhäsionsstudien unter stationären Be-
dingungen durchgeführt. Sowohl nach peroraler als auch nach par-
enteraler Applikation wirken jedoch Scherkräfte, die die Interaktion von
Wirkstoffträgern mit dem Gewebe maßgeblich beeinflussen. Um eine
Untersuchung der Bioadhäsivität von Partikeln unter annähernd physi-
ologischen Bedingungen zu ermöglichen, wurde ein miniaturisiertes
und dadurch potentiell parallelisierbares Flussmodell entwickelt. In
diesem chipbasierten System werden mittels oberflächenakustischer
Wellen hydrodynamische Kräfte erzeugt, die vergleichbar mit jenen im
Darm und in den Blutgefäßen sind. Untersuchungen mit lektinmodi-
fizierten Mikropartikeln zeigten, dass deutliche Diskrepanzen zwischen
den zellgebundenen Partikelmengen unter stationären und dynamis-
chen Bedingungen bestehen. Eine Integration von hydrodynamischen
Parametern in präklinische biopharmazeutische Testmodelle erscheint
demnach äußerst sinnvoll und könnte die Aussagekraft dieser Modelle
deutlich erhöhen.
Die vorliegenden Ergebnisse zeigen, dass sowohl das entwickelte
Chipmodell als auch die erarbeiteten Techniken zur Partikelmodifika-
7
tion und -detektion vielseitig anwendbares Potential für die biophar-
mazeutische Optimierung der Applikation von Wirkstoffen bieten.
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Part II
MAIN SECT ION

INTRODUCTION
Micro- and nanoparticles offer promising characteristics as drug deliv-
ery systems. Using suitable encapsulation techniques, hydrophilic and
hydrophobic small molecules as well as proteins and peptides can be
loaded into colloids.[1, 3] Hence, the active pharmaceutical ingredient is
protected from premature degradation prior to and after administration
to the patient. Most importantly, however, the surface of the drug carrier
system can be chemically and structurally functionalized.[4] Thereby,
the residence time of the formulation in the body can be prolonged and
the biodistribution profile can be shifted towards specific cell types and
tissues.
It is the aim of the present thesis to contribute to this thematic
area by improving our current understanding of the interaction of
surface modified particles with human cells. Since the size of particles
is a decisive physical parameter that has to be known prior to any
experimental studies, an introductory work will deal with the effects of
excipients on the determination of nanoparticle size by dynamic light
scattering techniques (1.1.1).
An array of approaches has been established for the surface modifi-
cation of colloids. To provide an overview of the field, the underlying
considerations and experimental realization of functionalization tech-
niques will be discussed (1.1.2). The focus in this review of current
literature is set on micro- and nanoparticles made of the intensely in-
vestigated polymer poly(D,L-lactide-co-glycolide) (PLGA). However,
the involved strategies are certainly not limited to particles produced
from this polymer but can be translated to a multitude of materials.
In the specific topics of the thesis, two particular surface modifi-
cation approaches will be investigated regarding their effect on the
bioadhesion of colloids.
Firstly, wheat germ agglutinin (WGA), a carbohydrate-binding pro-
tein will be employed to improve the cell-binding of micro- and nanopar-
ticles by attachment to the cellular glycocalyx.[5] The fundamental in-
teraction characteristics of WGA with a cell culture model of the human
intestine will be elucidated in 1.1.3 on the basis of histological local-
ization by transmission electron microscopy (TEM). In the subsequent
section the elaboration of a technique for the fluorescence-labelling
of lyophobic colloids will be described (1.2.1). By using these track-
able particles as probes, the bioadhesive effects resulting from surface
functionalization with molecules of interest can be investigated. This is
exemplarily illustrated in a study which determines the cytoadhesion
achieved by conjugation with WGA or human serum albumin (HSA)
(1.2.2).
Secondly, negatively charged micro- and nanoparticles will be coated
with the cationic polyelectrolyte poly(ethylene imine) (PEI) to inves-
tigate the role of particle surface charge on bioadhesion. Generally,
the cell membrane of eukaryotic cells is negatively charged,[6] which
suggests that positively charged carriers will preferentially bind due
to ionic interactions. Whether modifications of particle surface charge
are indeed a suitable means to improve bioadhesion will be investi-
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gated with in vitro cell culture models of endothelium and intestinal
epithelium (1.2.3).
Micro- and nanoparticles as drug carrier systems will behave differ-
ently from dissolved drug molecules upon administration to the human
body. In order to allow for the development of efficient particulate
formulations several fundamental parameters affecting the interaction
of particles with the organism have to be investigated. Flow will dis-
proportionately affect small molecules and particles.[7] How this can
affect the performance of drug carrier systems will be discussed in
an introductory section (2.1.1). Pertaining to bioadhesion, flow is ex-
pected to affect the binding of particles to tissues due to hydrodynamic
forces. In order to estimate to which extent this factor will influence
drug delivery with particles, reliable and versatile flow models have
to be at hand. In the present thesis the development of a microfluidic
system for this purpose will be reported. The device is operated by a
state-of-the-art chip-based pumping technology which actuates fluids
in a contact-free manner without the need for tubing. The underlying
pumping principle relies on surface acoustic waves (SAW) which can
be controlledly induced on a piezoelectric chip substrate (2.1.2).[8, 9]
By using cell monolayers grown in microchannels in combination with
the SAW-chip, a miniaturized in vitro tissue model is generated. This
setup is used to investigate the effect of flow on the adhesion of WGA-
and bovine serum albumin (BSA)-conjugated microparticles to artificial
intestinal tissue (2.2.1).
As highlighted, SAW-devices have high potential for miniaturization.
This will be exploited for the development of a parallelized in vitro flow
model which in addition facilitates the use of microplate readers for
detection of cell-associated absorbance, luminescence and fluorescence
(2.2.2).
Finally, potential improvements of currently used systems for drug
permeation studies across cell monolayers are discussed. At this, empha-
sis will be placed on the simulation of flow and a potential alternative
to currently used filter membranes will be presented (2.2.3).
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1.1.1 Stabilizer-induced viscosity alteration biases nanoparticle sizing via
dynamic light scattering
Stabilizer-Induced Viscosity Alteration Biases Nanoparticle Sizing
via Dynamic Light Scattering
Christian Fillafer, Michael Wirth, and Franz Gabor*
Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Life Sciences,
UniVersity of Vienna, Vienna, Austria
ReceiVed February 23, 2007. In Final Form: June 14, 2007
The size dependent features of colloids at the nanometer scale have been issues of increasingly intensive research.
In order to be able to correctly relate characteristics to certain size-populations, accurate and reliable particle sizing
by dynamic light scattering (DLS) is a main prerequisite. So far, the complexity of the systems due to the presence
of surfactants, proteins, and so forth in the nanoparticle suspensions has not been accounted for. In this work, practically
relevant quantities of the frequently used PEO-PPO triblock copolymer surfactant Pluronic F-68 were studied for their
effect on the size determination of nanoparticles by DLS. Induced changes in the tenside-content of the nanosphere
suspension were monitored using a photometric assay and were correlated to the respective variances in mean particle
size. These measurements showed that alterations in the range from 0.005 to 2% of Pluronic content are associated
with shifts in diameter of 200 nm-particles by as much as 65 nm. The considerable changes that were found have
been attributed to the surfactant-concentration-dependent fluctuations in the viscosity of the nanoparticle suspension,
which affect the dimensions of colloids calculated according to the Stokes-Einstein relation.
Introduction
The diversity of the exceptional features of nanoparticles is
manifold, ranging from the photostability of semiconductor
quantum dots1,2 to the passive accumulation of nanoparticulate
drug delivery vehicles in tumor sites due to the enhanced
permeability and retention (EPR) effect.2,3 These characteristics
have in common that they cannot be generalized for submi-
crometer colloids but rather are dependent on the material
properties and, very importantly, the actual size of the particles.
In the case of quantum dots, this is strikingly illustrated by the
precise interdependence between the particle’s diameter and the
wavelength at which fluorescence is emitted. However, not only
the physical properties of nanoparticles but also their interaction
with cells, subsequent intracellular trafficking, and therefore
possible toxicity have been increasingly discussed issues.4-7 It
is assumed that these characteristics are governed in a similarly
gravemanner by the dimensions of the colloids. The first evidence
of such size dependence has been given by studies on the cellular
and tissue uptake of nano- versus microparticles in the 1990s.
It was shown that the uptake efficiency of 100 nm colloids is
15-250-fold higher as comparedwith that of 1-10 µmparticles
in a rat in-situ intestinal loop model.7 Similar tendencies toward
the enhanced uptake of smaller particles were reported by Jani
et al. using radiolabeled 50 nm-3 µm polystyrene microspheres
in a rat in-vivo study.8
Although it has been known for several years that distinct size
differences are inflictedwith differential cellular uptake, account
has been given lately that even very small alterations in size
influence the cell association and intracellular processing of
nanoparticles.9,10 Lai et al., for example, recently showed that
small polymeric nanoparticles (<25 nm) but not larger ones
(>42 nm) enter cells via a nondegradative pathway.10
Beyond the impact on the uptake of nanoparticles, the physical
size also determines the biodistribution behavior of the colloids.
In case of the EPR effect, this is illustrated by the accumulation
of particles in the range from 70-200 nm because only such are
suited to pass the fenestrated endothelium of tumor blood
vessels.11
These issues make clear that an accurate determination and
knowledge of the physical dimensions of the particles are crucial
prerequisites not only for toxicity studies but also for the rational
design of nanoparticulate drug-delivery devices.
Currently, the method of choice for sizing nanoparticles in
suspension is dynamic light scattering (DLS). If performed under
standardized conditions, results obtained with this technique are
rather comparable and reproducible. However, nanoparticle
suspensions in practice represent complex and changing systems,
which in most cases contain not only the dispersed colloids but
also varying amounts of stabilizers, salts, proteins, and so forth.
These substances not only physicochemically interact with the
particles but also alter the properties of the dispersant. In the
production process of single- or double-emulsion solvent
evaporation techniques, for example, large amounts of surfactant
serve the purpose of avoiding coalescence during the solidification
of the nanodroplets. In the course of further treatments and
modifications of the particles, however, the tenside content of
the suspension and thus the viscosity vary considerably.Although
such variations are expected to occur frequently and with a
* Corresponding author. E-mail: franz.gabor@univie.ac.at. Phone:
(+43)-1-4277-55406. Fax: (+43)-4277-9554.
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1.1.1.1 Abstract
The size dependent features of colloids at the nanometer scale have
been issues of increasingly intensive research. In order to be able to
correctly relate characteristics to certain size-populations, accurate and
reliable particle sizing by dynamic light scattering (DLS) is a main
prerequisite. So far, the complexity of the systems due to the presence
of surfactants, proteins, and so forth in the nanoparticle suspensions
has not been accounted for. In this work, practically relevant quanti-
ties of the frequently used poly(ethylene oxide)-poly(propylene oxide)
(PEO-PPO) triblock copolymer surfactant Pluronic F-68 were studied
for their effect on the size determination of nanoparticles by DLS. In-
duced changes in the tenside content of the nanosphere suspension
were monitored using a photometric assay and were correlated to the
respective variances in mean particle size. These measurements showed
that alterations in the range from 0.005 to 2% of Pluronic content are
associated with shifts in diameter of 200 nm-particles by as much as 65
nm. The considerable changes that were found have been attributed to
the surfactant-concentration-dependent fluctuations in the viscosity of
the nanoparticle suspension, which affect the dimensions of colloids
calculated according to the Stokes-Einstein relation.
1.1.1.2 Introduction
The diversity of the exceptional features of nanoparticles is manifold,
ranging from the photostability of semiconductor quantum dots,[10, 11]
to the passive accumulation of nanoparticulate drug delivery vehicles
in tumor sites due to the enhanced permeability and retention (EPR)
effect.[11, 12] These characteristics have in common that they cannot
be generalized for submicrometer colloids but rather are dependent
on the material properties and, very importantly, the actual size of
the particles. In the case of quantum dots, this is strikingly illustrated
by the precise interdependence between the particle’s diameter and
the wavelength at which fluorescence is emitted. However, not only
the physical properties of nanoparticles but also their interaction with
cells, subsequent intracellular trafficking, and therefore possible toxicity
have been increasingly discussed issues.[13, 14, 15, 16] It is assumed
that these characteristics are governed in a similarly grave manner by
the dimensions of the colloids. The first evidence of such size depen-
dence has been given by studies on the cellular and tissue uptake of
nano- versus microparticles in the 1990s. It was shown that the up-
take efficiency of 100 nm colloids is 15-250-fold higher as compared
with that of 1-10 µm particles in a rat in-situ intestinal loop model.[17]
Similar tendencies toward the enhanced uptake of smaller particles
were reported by Jani et al. using radiolabeled 50 nm-3 µm polystyrene
microspheres in a rat in vivo study.[18] Although it has been known
for several years that distinct size differences are inflicted with differ-
ential cellular uptake, account has been given lately that even very
small alterations in size influence the cell association and intracellular
processing of nanoparticles.[19, 20] Lai et al., for example, recently
showed that small polymeric nanoparticles (<25 nm) but not larger
ones (>42 nm) enter cells via a nondegradative pathway.[20] Beyond
the impact on the uptake of nanoparticles, the physical size also deter-
mines the biodistribution behavior of the colloids. In case of the EPR
effect, this is illustrated by the accumulation of particles in the range
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from 70-200 nm because only such are suited to pass the fenestrated
endothelium of tumor blood vessels.[21] These issues make clear that
an accurate determination and knowledge of the physical dimensions
of the particles are crucial prerequisites not only for toxicity studies but
also for the rational design of nanoparticulate drug delivery devices.
Currently, the method of choice for sizing nanoparticles in suspension
is DLS. If performed under standardized conditions, results obtained
with this technique are rather comparable and reproducible. However,
nanoparticle suspensions in practice represent complex and changing
systems, which in most cases contain not only the dispersed colloids
but also varying amounts of stabilizers, salts, proteins, and so forth.
These substances not only physicochemically interact with the parti-
cles but also alter the properties of the dispersant. In the production
process of single- or double-emulsion solvent evaporation techniques,
for example, large amounts of surfactant serve the purpose of avoiding
coalescence during the solidification of the nanodroplets. In the course
of further treatments and modifications of the particles, however, the
tenside content of the suspension and thus the viscosity vary consid-
erably. Although such variations are expected to occur frequently and
with a practical impact, to the best of our knowledge, the importance of
the factor viscosity on DLS measurements has not been accounted for.
In the present contribution, the existence and dimensions of such ef-
fects were investigated using the PEO-PPO triblock copolymer Pluronic
F-68 and PLGA nanospheres as a model system. Pluronics, which are
also referred to as poloxamers because of their surface activity and a
wide range of tuneable hydrophilicity-lipophilicity balance, have been
extensively used in the production and coating of colloids made from
materials such as polystyrene,[22, 23, 24] poly(lactic acid) (PLA),[25, 26]
poly(D,L-lactic-co-glycolic acid) (PLGA),[27, 28, 29, 30, 31] poly(β-malic
acid-co-benzyl malate),[32] chitosan,[33] and solid lipid nanoparticles
(SLN).[34]
1.1.1.3 Experimental Section
Materials Resomer® RG503H (PLGA, 50:50 lactide/glycolide, in-
herent viscosity 0.32-0.44 dL g−1, acid number >3mg of KOH g−1) was
purchased from Boehringer Ingelheim (Ingelheim, Germany). Pluronic®
F-68, ammonium thiocyanate, and cobalt(II) nitrate hexahydrate were
obtained from Sigma (Vienna, Austria). All other chemicals used were
of analytical purity.
Preparation of PLGA nanospheres PLGA nanospheres were pre-
pared by a water-in-oil-in-water solvent-evaporation technique.[35]
Briefly, 400 µL of distilled water was emulsified with a solution con-
taining 400 mg of PLGA in 2 g of ethyl acetate by sonication for 60
s (sonifier, Bandelin electronic UW70/HD 70; tip, MS 72/D, Berlin,
Germany). Following the addition of 6 mL of a 10% aqueous solution
of Pluronic F-68, the emulsion was sonicated again for 50 s, yielding
the (w/o)/w emulsion that was poured into 100 mL of a 1% aqueous
solution of Pluronic F-68. After mechanical stirring (600 rpm) for 1 h
at room temperature, the residual ethyl acetate was removed under
reduced pressure. The resulting nanosphere suspension was filtered (1
µm pore size) to eliminate aggregates.
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Particle size analysis and processing of the nanospheres The
mean particle size and distribution were determined by DLS (Zetasizer
Nano ZS, Malvern Instruments Ltd, U.K.). All measurements were
carried out in triplicate at 20°C after 5 min of equilibration time.
The removal of Pluronic was practically achieved by diafiltration. For
this, 20 mL of a PLGA nanosphere suspension was repeatedly washed
with 40 mL of distilled water on a tangential flow filtration system
based on an ultrafiltration membrane (Vivaflow 50; 100,000 molecular
weight cut-off (MWCO) poly(ether sulfonate), Sartorius Vivascience
GmbH) which was operated by a peristaltic pump (MV-CA 8, Ismatec,
Glattbrugg) at a system pressure of 2.5 bar.
Quantification of the PEO-PPO block copolymer Pluronic F-68
was quantified using a photometric assay relying on the complexation
of a purple cobalt thiocyanate reagent with the copolymer.[36] The
cobalt thiocyanate reagent used for the photometric quantification was
prepared by dissolving 20 g of ammonium thiocyanate and 3 g of
cobalt(II) nitrate·6H2O in 100 mL of distilled water. Ethanol (80 µL,
96%), ethyl acetate (200 µL), cobalt thiocyanate reagent (100 µL), and
the sample (50, 150, or 250 µL, depending on the concentration range)
were mixed in a 2 mL Eppendorf cup. Following centrifugation of
the precipitated complex at 10,400 rpm for 1 min (Centrifuge 5804R,
Eppendorf), the supernatant was removed. After the tube walls and
pellet were washed with ethyl acetate, the precipitate was dissolved in
2 or 0.5 mL of acetone, and the absorbance at 328 nm was determined
using a U-3000 UV/vis spectrophotometer (Hitachi).
Viscosity measurements The dynamic viscosities of aqueous solu-
tions of Pluronic were determined according to run-time measurements
on a microviscometer (AMVn, Anton Paar GmbH, Graz) at 20°C us-
ing calibrated capillary/ball sets at an angle of inclination of 60°. The
densities of the samples that are required to calculate the viscosities
were determined with an oscillating U-tube densitometer (Anton Paar
GmbH, Graz). All measurements were performed in triplicate with wa-
ter as a reference, and the dynamic viscosity η was calculated according
to (1.1) with K as the calibration constant, t as the run time of the ball,
ρB as the density of the ball, and ρS as the density of the sample.
η = K t (ρB − ρS) (1.1)
1.1.1.4 Results and Discussion
To investigate concentration-dependent effects of Pluronic on the parti-
cle sizing of nanospheres, a method for the quantification of the tenside
is required. This was provided by a cobalt thiocyanate assay described
in the literature.[36] Modifications of the sample size as well as the
acetone volume for dissolution of the reagent/Pluronic complex low-
ered the detection limit of the assay and thereby allowed the direct
determination of the tenside in aqueous solutions in the range from 2.5
to 0.005%.
When the Pluronic content of a PLGA nanoparticle suspension was
analyzed in the course of diafiltration with distilled water, a rapid
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Figure 1: Polydispersity index (PdI) and mean particle size of PLGA nanopar-
ticles determined by dynamic light scattering (− •−) as well as the
respective content of Pluronic F-68 in the suspension (solid bars) in
course of purification by diafiltration.
decrease in the concentration was observed, reaching the detection
limit of the photometric assay after four washing steps (Figure 1).
Starting with a PLGA nanosphere suspension containing 1.54%
Pluronic, 96.7±0.35% was removed during the first three washings,
and 99.74% of the tenside was removed after one more purification
step. Thus, a considerable amount of Pluronic contained in nanopar-
ticle suspensions prepared according to the double-emulsion solvent-
evaporation technique described above can be removed in a controllable
manner by diafiltration with distilled water. In parallel, possible shifts
in the particle size distribution were monitored by sizing the colloids
via dynamic light scattering after each washing step. Commonly used
purification methods such as (ultra)centrifugation impede the complete
redispersibility of the pellet into single nanospheres as a result of the
high rotation rates necessary for sufficient sedimentation. In contrast,
tangential flow filtration allows to study the implication of washed-out
surfactant in an unaffected manner.
These particle size measurements showed, concurrent with the previ-
ously discussed decrease in Pluronic content, that the sizes were notably
lowered from 259±7 to 196±6 nm within the first four purification steps
(Figure 1). During the next three washings, the suspension remained
rather stable as controlled by DLS, and the mean particle size was not
reduced below a threshold of about 195 nm.
These monitored size differences might partially be due to the des-
orption of surfactant molecules from the particle surface in the later
stages of the washing procedure. However, according to Baker and
Berg, size alterations in the hydrodynamic diameter of the colloids due
to the adlayer of Pluronic F-68 solely amount to 6 nm.[37]
Furthermore, the seeming drop in particle size by 63±6 nm can not
be attributed to a gradual degradation of the nanospheres because
otherwise the decrease would have progressed in the course of further
washing steps. It is also known from molecular weight loss studies of
microparticles made from PLGA with the same lactide/glycolide ratio
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Figure 2: TEM image of PLGA nanoparticles suspended in a 1.54% aqueous
solution of Pluronic, negative stained with uranyl acetate.
of 50:50 that the polymer decomposes rather slowly as illustrated by a
half-life (50% molecular weight loss) of 15 days.[38]
Thus, the apparent decrease in the mean particle size during the first
four washing steps might be attributed to the lowering of the Pluronic
concentration (Figure 1). To narrow the observed effect down to an
interference of varied Pluronic levels with DLS, the physical dimensions
of the particles suspended in a 1.54% aqueous solution of Pluronic were
analyzed by an independent imaging method (Figure 2). Indeed, as as-
sessed by TEM (Zeiss EM 902) measurements, the mean particle size of
the colloids is only about 200 nm compared with 259±7 nm determined
via the light scattering technique. To determine if the apparent decrease
in size during diafiltration is reversible, 0.5, 1, 1.5, and 2% tenside were
added to 1 mL aliquots of a purified nanoparticle suspension with a
Pluronic content of <0.005%. As illustrated in Figure 3 (open bars), this
results in a stepwise increase in the determined mean particle size with
rising Pluronic content. The cause of these reversibly controllable size
shifts was considered to be linked to particle size calculation by the DLS
instrument. Using this technique, the random movement of colloids
is monitored according to fluctuations in the intensity of the scattered
light. From this, a decaying exponential correlation function is derived,
and it contains the translational diffusion coefficient D. According to
the Stokes-Einstein relation (1.2), D is inversely proportional to the
dynamic viscosity η and the radius of an idealized sphere r with k as
the Boltzmann constant and T as the absolute temperature. Thus, if the
temperature is held constant, the diffusion coefficient for a sphere with
the given radius r will be solely dependent on the dynamic viscosity of
the suspension.
D =
k T
6πη r
(1.2)
Experimentally, the influence of Pluronic on this variable was con-
firmed by a determination of the dynamic viscosities of 0.5, 1, 1.5, and
2% aqueous solutions of tenside. While viscosity measurements impli-
cate shear stress of the sample, dynamic light scattering experiments
are performed under static conditions. If the fluid exhibits Newtonian
behavior, however, the viscosity can be extrapolated to that of a sys-
tem under no shear stress and thus can be applied for this purpose.
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Figure 3: Mean particle size of PLGA nanoparticles dispersed in aqueous solu-
tions of Pluronic F-68. Viscosity of water as dispersant property (open
bars, DLS instrument’s standard parameter). Results recalculated with
the respectively determined dynamic viscosities (solid bars).
Table 1: Dynamic viscosities of aqueous solutions of Pluronic F-68 determined
at 20 °C
dispersant dynamic viscosity at 20°C [mPas]
water (reference) 1.0100±0.002
0.5% aqueous solution of Pluronic F-68 1.0765±0.021
1% aqueous solution of Pluronic F-68 1.1595±0.009
1.5% aqueous solution of Pluronic F-68 1.2578±0.0001
2% aqueous solution of Pluronic F-68 1.3772±0.003
Because of the low polymer content used in the experiments, it can
be assumed that the determined viscosity of the fluid is rather shear-
independent. Measurements illustrated in Table 1 show that increasing
concentrations of the surfactant lead to incremental increases in the
dynamic viscosity of the solution. The effect of this increased viscosity
on the size calculation by the DLS instrument, as compared to that
of the standard dispersant water, was assessed by a re-evaluation of
the previous results from suspensions with different Pluronic content
using the respectively adjusted viscosities. Consequently, the sizes of
all samples were determined to be approximately 205 nm (Figure 3,
solid bars), which corresponds to that of the control sample with less
than 0.005% Pluronic as a reference.
Furthermore, preliminary results from viscosity measurements of
poly(vinyl alcohol) (PVA), another frequently used stabilizing agent for
the production of polymeric nanoparticles,[29, 39, 40] imply a similar
effect on nanoparticle sizing as observed for Pluronic. The viscosities
of 1 and 2% aqueous solutions of practically used PVA (MW~67,000)
were determined to be 1.735±0.002 and 2.922±0.012 mPas, respectively.
When extrapolating these viscosities to sizing results of nanospheres
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with a mean diameter of 200 nm, apparent increases to 425 nm (1%
PVA) and 687 nm (2% PVA) can be expected.
1.1.1.5 Summary
In the present work, it has been demonstrated that the results obtained
from nanoparticle sizing by dynamic light scattering are prone to
influences by tensides contained in the suspension. Practically relevant
concentration variances between 0.005 and 2% PEO-PPO surfactants
in a PLGA nanoparticle suspension are associated with significant
alterations of the determined mean particle size. This effect has been
attributed to the Pluronic concentration- dependent fluctuations in the
dynamic viscosity of the nanoparticle suspension, which directly affect
particle sizing by the dynamic light scattering technique. Because of the
general cause of this implication, it can be deduced that the presence
of any substance that might alter the suspension’s properties needs to
be considered.
To receive reliable results, the respective dynamic viscosities of the
samples that can be determined either directly by viscometry or in-
directly by quantification of the Pluronic concentration have to be
supplied for the size calculation process. This will provide more accu-
rate information on the actual size of the colloids, which is of special
importance for studies on size-dependent properties of nanoparticles.
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1.1.2 The role of surface functionalization in the design of PLGA micro- and
nanoparticles
Gerda Ratzinger, Christian Fillafer, Vera Kerleta, Michael Wirth, Franz
Gabor. The role of surface functionalization in the design of PLGA
micro- and nanoparticles. Critical Reviews in Therapeutic Drug Carrier
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1.1.2.1 Abstract
Nano- and microcarriers prepared from the biocompatible and biode-
gradable polymer PLGA are being extensively studied for drug-delivery
purposes. Apart from size, their fate in the body is mainly determined
by surface characteristics that govern the interaction of the particles
with their environment. The present review provides an overview of
the currently established concepts for the surface functionalization of
particles made from PLGA. In the first part, a concise description of the
material-borne surface features and the related functionalization strate-
gies are given, followed by current methods for the physical and chemi-
cal characterization of the particle surface. The second part highlights
the aims of functionalization, which include improved drug delivery,
vaccination, and imaging. Targeting approaches for site-specific deliv-
ery of drug-loaded particles to certain tissues or even to intracellular
targets are presented, as well as stealth coatings for a prolonged blood
circulation, labeling methods for imaging purposes, and strategies for
the immobilization of macromolecular drugs on the particle surface.
Finally, present limitations and future challenges will be discussed, with
a focus on the surface-modification procedure and essential demands
on functional particulate systems posed by the dynamic and complex
in vivo environment.
1.1.2.2 Introduction
As indicated by 3869 published research papers, 3351 issued patents,
and 393 disclosed theses by the end of July 2009, PLGA is one of the
most extensively investigated polymers for drug delivery and tissue
engineering.[41, 42] Although only a few pharmaceuticals are available
on the market to date (Table 2), the high number of patents compared
with research papers points to a powerful and promising excipient
and much commercial interest. PLGA offers unique properties for
drug-delivery purposes, such as worldwide approval for medical use,
biodegradability, biocompatibility, and controlled release. However,
some issues are not manageable by a single polymer, such as targeting
the diseased tissue, cellular uptake and preprogrammed intracellular
trafficking, and escaping the reticuloendothelial system (RES). Because
contact with the body and the consequences thereof are mediated via
the surface of the device, surface modification of sub-millimeter PLGA
particles by grafting with selected biomimetic ligands can meet some of
these ambitious challenges to pave the way toward a more efficacious
medication with reduced side effects and improved patient compliance.
At present, GMP-grade PLGA is marketed as Lactel® (Polymers
International, Pelham, AL), Medisorb® (Alkermes, Cambridge, MA),
Purasorb® (Purac resp. CSM, Amsterdam), and Resomer® (Boehringer
Ingelheim, Germany). Usually, the polymer is prepared by ring-opening
polymerization of the cyclic dimeric anhydrides, D,L-lactide and gly-
colide in presence of Sn(II)-2-ethyl-hexanoate, Zn, or Zn-lactate as a
catalyst.[43] Due to toxicological concerns regarding Sn and esterifi-
cation of the hydroxyl group at one end of the polymer chain, which
yields a more hydrophobic polymer, the latter two catalysts are pre-
ferred. In general, increasing the amount of catalyst generates more
polymerization nuclei so that the molecular weight (MW) of the poly-
mer decreases. Moreover, the higher reactivity of glycolide facilitates
formation of glycolide microblocks rather than lactide ones.[44]
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Figure 4: Strategies for surface modification of PLGA particles.
Most important for selection of the underlying mechanism of surface
modification is the choice of the chain-length controller. Employing
lactic acid to stop polymerization yields a polymer with a free carboxylic
end group (uncapped), whereas lactic acid ethyl ester yields end-capped
PLGA. Particles made from the carboxylate polymers, or so-called “H-
type” products, open two basic pathways for stable surface modification:
the covalent binding of bioactive moieties, preferably via carbodiimide,
and grafting via ionic interactions due to the negative surface charge of
particles (Figure 4). The third approach to surface modification relies on
the overall hydrophobicity of both “H-type” and “non-H-type” PLGA,
which allows adsorptive coating; however, this carries the risk of rapid
desorption of the coat in biological fluids due to swelling and erosion
of the particles.[23, 45, 46]
Generally, PLGA particles are prepared by so-called top-down pro-
cesses starting with the polymer. For preparation of microparticles from
PLGA, various techniques are available at the laboratory level, which
basically rely on solvent extraction/evaporation, phase separation, and
spray drying. According to the type of emulsion applied, several modi-
fications of solvent extraction/evaporation are distinguished. The o/w
technique relies on an emulsion prepared from a solution containing
PLGA and the hydrophobic drug in a volatile organic solvent and an
aqueous stabilizer solution. The organic solvent is removed by evapora-
tion or extraction into the continuous cohesive phase causing hardening
of the droplets. In the s/o/w method, instead of a solution, solid small-
sized drug material is processed as before. The incorporation of a
hydrophilic drug by the w/o/w method comprises emulsification of
a small volume of an aqueous drug solution in a PLGA-rich organic
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phase, followed by dispersion in a second aqueous phase containing a
stabilizer. Diffusion of the organic solvent through the second aqueous
phase and evaporation yields solid particles. In the o/o technique, the
first oily solution, usually acetonitrile, contains PLGA and a hydropho-
bic drug with a certain water solubility. The first oily solvent is then
extracted by the second oily solvent (e.g., cottonseed oil), leading to
hardening of the droplets.[47]
The second basic technique is phase separation or coacervation, com-
prising dispersion of a solid or emulsified drug in the solution of PLGA,
followed by the addition of a nonsolvent so that a co-acervate is formed
at the interface. In the case of PLGA, salting out is a modification of
this process in that the polymer is precipitated by the addition of water
to an emulsion of PLGA dissolved in organic, water-miscible solvent
and viscous PVA/salt solution.[48]
Finally, spray-drying is particularly suited for hydrophobic drugs
but problematic for hydrophilic drugs, especially proteins and small
batches.[49, 50] Alkermes, Inc. and Genentech, Inc. reported about
a cryogenic spray technique, also known as Alkermes’ ProLease®
technology, at the developmental scale for the preparation of Zn-
recombinant human growth hormone (Zn-rhGH)-loaded PLGA mi-
crospheres. Homogenized Zn-rhGH lyophilisate was dispersed in PL-
GA/dichloromethane and sprayed into liquid nitrogen. The organic
solvent was extracted from the frozen droplets step-wise with liquid
ethanol, first at –105°C and then at –40°C.[51]
The basic mechanisms for the formation of PLGA-nanoparticles are
similar to those for microparticles but require smaller droplet diameters
to enter the nanoscale. In the case of solvent extraction/ evaporation
higher energy input is usually provided by sonication, high-pressure
homogenization, or vigorous mechanical stirring.[52, 53] The nanopre-
cipitation technique relies on the interfacial deposition of PLGA by a
nonsolvent following the displacement of a semipolar solvent miscible
with water from a lipophilic solution, and yields nano- particles in
the range of 100 to 300 nm with narrow size distribution in a one-
step procedure.[54, 55, 56] Table 3 presents some basic parameters for
nanoparticle preparation (for more detailed information, the reader is
referred to some excellent reviews covering preparation of PLGA micro-
and nanoparticles).[3, 57, 2, 58, 1]
As confirmed by the long and successful history of the absorbable su-
tures called Vicryl® (Polyglactin®910 by Ethicon, Inc., now subsidiary
of Johnson & Johnson; 8% L-lactic acid and 92% glycolic acid), PLGA
matrices are biodegradable.[59] In the aqueous biological environment,
the polymer is first hydrated by adsorption of water and swelling of the
matrix, a process lasting for days to months. Both hydrophilicity and
crystallinity are key issues in this initial process. Among the different
types of PLGA, the polymer composed of equal amounts of lactic and
glycolic acid exhibits highest hydrophilicity and lowest crystallinity,
leading to the fastest degradation. Because free carboxylate groups
are more easily hydrated than ester moieties, the uncapped PLGA de-
grades faster than the end-capped polymer. This water uptake mediates
random hydrolytic scission of ester bonds, yielding water-insoluble
oligomers. Consequently, the mean MW of the polymer decreases but
the mass of the particle remains constant. Because the PLGA-oligomers
contain a free carboxylate on one end and ester hydrolysis is acid-
catalyzed, carboxylated oligomers promote further degradation and
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a decrease in pH. This so-called “acidic microclimate” is observed in
microparticles and in turn catalyzes scission of the polymer backbone.
As soon as the MW of the oligomers drops below about 5.2 kDa, the
oligomers become water-soluble, diffuse out of the matrix, and erosion
of the particle is indicated by mass loss.[60] As opposed to surface ero-
sion, homogeneous or bulk erosion is the mechanism generally accepted
for degradation of PLGA particles less than 300 ￿m in diameter.[61]
According to the degradation mechanism, a triphasic release profile is
most commonly observed in PLGA microparticles: The so-called first
burst effect, mainly due to release of surface-associated drug but also
to pore formation upon water-entry,[62] is followed by a lag phase with
diffusion-controlled slow release until erosion accelerates the release
again.[53, 63] As opposed to the situation in vitro, in vivo biodegra-
dation of PLGA was shown to be faster because of the plasticizing
effect of lipids, the release of radicals due to a local immune response,
autocatalytic cleavage of the polymer due to particle-aggregation, or
contribution of enzymes to degradation.[1, 64] Due to bulk erosion
upon biodegradation, it is expected that surface-modified PLGA par-
ticles retain their biorecognitive coating and thus their functionality
even during release of the active pharmaceutical ingredient (API), as
opposed to particles made from surface-eroding polymers.
Regarding in vivo administration, biocompatibility is another issue
for drug-delivery purposes. The tissue response after subcutaneous
injection of PLGA microparticles occurs in three phases:[38] Within the
first 2 weeks, a minimal acute or finally chronic inflammatory response
is observed at the site of administration associated predominantly with
monocytes. The second phase comprises the foreign body reaction,
which is associated with macrophages in the case of smaller micro-
spheres or foreign body giant cells in the case of large microspheres,
and the development of a fibrous capsule and granulation tissue. Upon
erosion, the particles of microspheres are phagocytosed within weeks
by either macrophages or foreign-body giant cells according to their
size. In addition, some long-term studies have reported inflammatory
responses, sometimes causing tissue necrosis but diminishing with
time. This was observed in 15-￿m PLGA particles and has also been
attributed to degraded oligomers.[65, 66] After intraperitoneal admin-
istration of PLGA particles, a similar response comprising chronic
inflammation and phagocytosis was reported in microparticles. How-
ever, nanoparticles caused minimal phagocytic activity, most likely due
to clearance from the peritoneum within 2 d.[67] Because the open
diameter of the smallest capillaries is 5 to 6 ￿m, particles smaller than 3
￿m can be administered intravenously. Hemocompatibility studies with
alendronate-loaded PLGA nanoparticles revealed no significant effect
on hemolysis, leukocyte number, platelet activation, activated partial
thromboplastin time, and complement consumption, and no cytotoxic
effects on endothelial cells of blood vessels.[68] With the use of simu-
lated blood fluid, however, the formation of 750-nm aggregates from
100-nm particles was observed and attributed to decreased electrostatic
repulsion due to adsorption of cations.[69] Finally, the end-products of
hydrolytic degradation of PLGA contribute to the biocompatibility of
PLGA. Lactate is converted to pyruvate, which enters the Krebs cycle
via acetylation of coenzyme A, and carbon dioxide, which is mainly
eliminated by respiration. Part of the glycolate is excreted directly via
the urine, another part is oxidized to glyoxylate, which is converted to
28 bioadhesive micro- and nanoparticles
glycine, serine, and pyruvate. Pyruvate again enters the Krebs cycle to
yield finally carbon dioxide and water.[60, 70]
As to the biocompatibility of PLGA, the utility of micro- and nano-
spheres as adjuvants for vaccination seems to be contradictory at the
first sight. The immune response, however, is modified by design:
particles less than 5 ￿m are taken up by antigen-presenting cells such
as macrophages or dendritic cells. Additionally, the large surface area
presents multiple copies of the adsorbed antigen. Finally, the matrix
traps and retains the antigen in local lymph nodes and protects it
from degradation, resulting in prolonged stimulation of the immune
system.[71] Considering these issues, nanoparticles seem to be best
suited for vaccination because they offer an increased surface area for
antigen adsorption, possibly enhanced immunogenicity due to higher
uptake rates, and are sterilizable by simple filtration.[72]
While the size of the PLGA particles is the key issue for successful
vaccination, the application of these powerful potential carriers for
certain therapeutic indications requires some further modifications to
meet given specific demands. Considering the physicochemical charac-
teristics of a preformed PLGA particle, the surface carboxylate groups
of uncapped PLGA allow for covalent and electrostatic conjugation of
ligands, whereas the hydrophobicity of the PLGA matrix can be ex-
ploited for adsorption of hydrophobic or even amphiphilic ligands. This
review is intended to give an overview about the current knowledge of
surface modification techniques, followed by a short description of the
methods available for characterization. Further chapters deal with the
different aims of functionalization, including nonspecific and specific
bioadhesion, improved internalization, preprogrammed intracellular
trafficking, imaging, prolonged circulation time, and stabilization of
biomacromolecules. After discussing future challenges (1.1.2.5) the
“Outlook” section (1.1.2.6) attempts to give a vision of this emerging
field of research.
1.1.2.3 Surface characteristics and related functionalization strategies
Carboxylate groups: covalent modification As outlined above,
PLGA is available in two forms: uncapped, i.e. containing terminal
carboxylate groups, and end-capped, i.e. terminated by an alkyl ester.
The terminal carboxylates are often used for covalent conjugation of
ligands either to the dissolved polymer prior to particle formation or
to surface-exposed carboxylic groups of preformed particles. Owing
to the high stability of covalent linkages, these approaches are gener-
ally preferable to other immobilization strategies in order to guarantee
efficient functionalization. Many chemically sensitive ligands, such as
proteins or peptides, should not be coupled to PLGA prior to particle
preparation because they are prone to denaturation by organic solvents
or shear stress during the emulsification process. Moreover, for a num-
ber of applications, the immobilized ligands have to be displayed at the
particle surface. To meet these requirements, covalent coupling to the
surface of preformed PLGA particles may be advantageous.
There are only few chemical groups that specifically react with car-
boxylates. Because carboxylic acids are rather weak nucleophiles in
aqueous solutions, they do not easily couple via nucleophilic addition.-
[73] The most important chemical reaction for the covalent modification
of PLGA carboxylates is the carbodiimide-mediated cross-linking with
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amine-containing molecules. In this process, the carboxylic group reacts
with a carbodiimide to yield an O-acylisourea intermediate, which is
highly reactive and forms amide bonds with amine nucleophiles. Most
importantly, the reaction works in aqueous buffers under mild condi-
tions, including neutral pH, which makes it applicable to proteins, pep-
tides, and other easily degradable molecules. At this, the water-soluble
derivative 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDAC) can
either be used alone or together with N-hydroxysuccinimide (NHS)
or sulfo-NHS. While the O-acylisourea intermediate is prone to rapid
hydrolysis, sulfo-NHS, and NHS give more stable active ester inter-
mediates, which finally react with the amine. The increased stability
may result in a higher coupling efficiency. Moreover, the application of
the succinimide enables a two-step procedure for conjugation, which
may be advantageous for ligands that bear not only amine but also
carboxylic groups in order to avoid cross-linking. To saturate unre-
acted binding sites, an excess of small amine-containing ligands such
as glycine or ethanolamine may be used. Until now, the carbodiimide
method has been successfully used for conjugating a broad range of dif-
ferent amine-containing molecules, especially targeters such as peptides,
lectins, and antibody fragments, but also polycations.[74, 75, 76, 77]
To enable the coupling of ligands that cannot directly react with
carboxylate groups, various spacers such as diamines, polyamines,
or dihydrazides may be applied.[78] Depending on their length and
flexibility, spacers may enable or enhance the conjugation of certain
ligands with barely accessible reactive groups. Moreover, they can
influence the orientation of coupled ligands, which might have an
impact on their bioactivity.
Although the number of carboxylic groups available for coupling to
the particle surface has been criticized for being limited, it has proven
sufficient to obtain a targeting effect, as already confirmed by enhanced
particle-cell interactions.[75] However, for efficient coupling to PLGA
carboxylates, the presence of steric stabilizers such as PVA or poloxamer
should be considered, because the adsorbed stabilizer may compromise
the reaction via steric hindrance.[79, 80]
Surface charge: coating via ionic interactions Nano- and mi-
croparticles made from uncapped PLGA are characterized by a negative
surface charge at physiological pH. Primarily, this charge is due to car-
boxyl groups that arrange at the liquid/particle interface in the course
of the preparation procedure. Because the pKas of the carboxyl groups
of lactic and glycolic acid are 3.86 and 3.83, respectively, these groups
increasingly exist in their dissociated form with increasing the suspen-
sion’s pH above 4. Making use of these ionized groups, the particle
surface can be coated with cationic polyelectrolytes via ionic interac-
tions. The adsorption of polyelectrolytes onto the surface of particles
in suspension is complex and influenced by several parameters. The
packing and structure of the adsorbed layer is widely determined by
the particle surface charge density, polyelectrolyte charge density, as
well as by the pH and ionic strength of the suspension. The degree of
dissociation of ionizable groups on particle surface and polymer can
be varied by adjusting the pH, thus regulating the affinity between the
surface and the polyelectrolyte.
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In addition to pH, ionic strength is also decisive for the structure
of adsorbed polymer.[81] Generally, in aqueous solutions of low ionic
strength, polyelectrolytes have an expanded and rather rigid conforma-
tion due to intrachain repulsive forces. The adsorption of such stretched
polymer molecules onto particles can lead to compensation of the sur-
face charge, but does not necessarily introduce a surplus of cationic
groups.[82] However, for most applications, an inversal of the negative
surface charge by the cationic polyelectrolytes is desired. This can be
achieved by adsorption from solutions containing appropriate amounts
of salt. Increasing the solution’s ionic strength leads to screening of re-
pulsive intra- and interchain interactions, and consequently the polymer
can adopt coiled and more flexible conformations. Due to this structural
flexibility and reduced interpolymer repulsion, the adsorption of coiled
polyelectrolytes can lead to higher deposition densities. Because not
all of the ionized groups participate in binding to the particle, an over-
compensation of surface charge, and thus inversal of the ζ-potential,
occurs.[83] However, if the ionic strength of the adsorption medium
exceeds a specific threshold, the charges on the polymer and on the
particle surface might be screened to such an extent that adsorption is
drastically reduced.[81]
Coating of negatively charged particles has been found to be ad-
vantageous for several applications. The positive charges imparted at
the particle surface, for example, efficiently complex anionic macro-
molecules such as plasmid DNA (pDNA), and this has received con-
siderable interest for the formulation of vaccines. Moreover, decoration
with polycations is considered to be a rather unspecific but simple
approach to enhance the adhesion of particles to mucus[84, 85] and
cells.[86, 87, 88, 89] The mechanisms involved and possible influences
of coating with cationic polyelectrolytes on internalization[86] and en-
dosomal processing[90] will be discussed later. To make use of these
potential benefits, natural, processed natural, and synthetic polyelec-
trolytes have been employed for the coating of negatively charged PLGA
nano- and microparticles. These include protamine,[89] chitosan,[84,
88, 91, 92, 93, 94, 95, 96, 97, 98, 99] gelatine,[100] diethylaminoethyl
dextran,[101] Eudragit® RL/RS,[85] PEI,[102, 103, 104, 105, 106] and
poly(L-lysine) (PLL).[46, 87, 103, 107, 108, 109]
Protamine sulfate is an arginine-rich protein (approximately 4 kDa)
that shares structural similarities with the human immunodeficiency
virus (HIV) tat peptide and is characterized by membrane-translocating
and nuclear-localizing activity.[110] Possibly due to these membrane-
penetrating properties, microparticles coated with cationic protamine
possessed transfection activity in HEK cells and increased immuno-
genicity compared with plain particles.[89]
A considerable number of studies have addressed the usability of
chitosan for the surface modification of nano- and microparticles made
from PLGA. Chitosan, which is a partially deacetylated derivative
of the polysaccharide chitin, is commercially available in a variety
of MWs and degrees of deacetylation (DD). The considerable vari-
ety of these materials is reflected in the studies dealing with coating,
which report use of chitosans with MWs of approximately 48 kDa (DD:
75%–80%),[98, 99] 50 kDa (DD: 80%),[93] over 50 kDa (DD: 85%),[84]
88 kDa (DD: 85%),[96] as well as MWs of 150 and 150 to 400 kDa.[95]
Primarily, surface modification of PLGA particles has been achieved
by using chitosan/PVA blends as stabilizers in course of the parti-
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cle preparation procedure.[84, 91, 92, 94, 96, 97] The incorporation
of chitosan in the particle surface can be confirmed qualitatively by
derivatization of the introduced amino groups with NHS-poly(ethylene
glycol)-biotin, subsequent addition of Oregon Green®-streptavidin,
and flow-cytometric analysis of the particle-associated fluorescence
intensity.[94] Similarly, an assay using fluorescamine can be used to gain
information on the qualitative and quantitative degree of polyamine
adsorption.[83, 94, 96, 105] This assay is based on the reaction of the
nonfluorescent compound fluorescamine with primary amino groups,
yielding fluorescent pyrrolinones (excitation/emission: 390/475–490
nm).
As an alternative for the quantification of chitosan, complexation of
the anionic dye Orange IIC with ammonium groups in acidic solution
has been reported.[83] According to a systematic study by Guo et al.,
the amount of adsorbed chitosan increases with the polyelectrolyte
concentration employed. As illustrated by fitting experimental data to
adsorption isotherm models, the coating mechanism involved complies
with a multilayer adsorption behavior on a heterogeneous surface.[96]
Although adsorption in course of the preparation procedure is a facile
and supposedly effective approach, it only offers limited control over
the conformation and quantity of adsorbed polyelectrolyte. In this re-
gard, the adsorption of chitosan onto preformed PLGA particles from
solution seems preferable and has been achieved.[88, 93, 99, 98] Chi-
tosan adsorption from solution is a spontaneous process governed
by the electrostatic interactions of the polyamine with the negatively
charged particle surface. However, additional anchoring of adsorbed
polymer molecules can occur via hydrophobic interactions.[83] In a
detailed study, the coating of PLA nanoparticles, which are expected
to bear similar surface characteristics to PLGA particles, with various
chitosans has been investigated. It was found that the amount of ad-
sorbed polymer increased with rising MW with a deposition maximum
for chitosan of approximately 150 kDa. Adsorption was also increased
for chitosans with lower DD. Supposedly, less-deacetylated polymer
chains exhibit reduced interactions with the aqueous solvent and con-
sequently tend to adopt condensed conformations. In conjunction with
decreased interpolymer repulsion at the surface, this leads to higher
mass deposition rates.[83]
In contrast to chitosan, which bears a rather rigid carbohydrate back-
bone, synthetic polyamines such as PEI and PLL are characterized
by enhanced polymer flexibility and higher charge densities. In the
case of PEI, which is commercially available in linear and branched
forms ranging from MW <1 kDa to 1.3 × 10³ kDa, every third atom is
a nitrogen atom that can be ionized by protonation. While linear PEIs
mainly consist of secondary amino groups, branched PEIs are charac-
terized by a theoretical primary to secondary to tertiary amine ratio of
1:2:1. These polymers have found widespread use for gene delivery in
vitro and in vivo owing to an enhanced interaction with the negative
cell membrane, the “proton sponge” effect, and the high potential for
complexing anionic macromolecules (plasmid deoxyribonucleic acid
(pDNA), antisense oligonucleotides).[111, 112, 113] To confer these fea-
tures on PLGA nano- and microparticles, coating with PEI in course of
the preparation procedure,[102, 103, 104, 114, 115] or onto preformed
particles[105, 106] has been investigated. Yang et al. also showed that a
layer-by-layer approach is feasible by using dextran sulfate as an anionic
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counter-polyelectrolyte.[106] While in most studies, PEIs with a MW
of 25 to 70 kDa have been used, high-MW compounds (600–1000 kDa)
have also been employed. From a toxicological point of view, the latter
seems questionable because the systemic administration of 800-kDa
PEI has caused considerable toxicity, possibly due to a high potential
for erythrocyte agglomeration.[112] Coating with branched PEI (MW
approximately 25 kDa) has been shown to generate PLGA particles
with a distinctly increased surface binding capacity for pDNA.[104, 105]
Furthermore, successful polyamine adsorption was indicated by a clear
increase of the buffering capacity towards HCl compared with plain
particles.[105] Trimaille et al. studied the coating of PLA nanoparticles
with branched PEI (MW approximately 10 and 25 kDa), and found
that the optimum pH for ionization of surface carboxyl groups and
polyelectrolyte amino groups was 5.8. The amount of nonadsorbed PEI
was determined by a Coomassie blue assay. Moreover, visual proof of
surface-deposited polymer was given by scanning electron microscopy
(SEM). Consistent with theory, coating from solutions with low ionic
strength resulted in the adsorption of flat molecules and a ζ-potential
of approximately 1 mV, while coating in the presence of higher salt
concentrations led to the deposition of coiled polymers and charge
inversion.[82]
The synthetic polycation PLL has also been used for coating of nega-
tively charged PLGA particles via ionic interactions in several studies.
As with PEI, low MW polymers should be applied to avoid toxic side
effects.[116] According to Cui et al., ionization of the ε-amino groups of
PLL (MW approximately 150–300 kDa) by titration can be used to reg-
ulate the hydrophile-lipophile balance and secondary structure of the
polyamine.[107] By using a reaction assay for the quantification of PLL
via o-phthaldialdehyde, it was found that a dissociation degree of ￿68%
and an α-helix content of ￿50% is needed for sufficient surface entrap-
ment of the polymer and stable microparticle formation. An alternative
and quite promising approach has relied on the coating of preformed
PLGA particles with multifunctional PLL-g-PEG polymers.[46, 108, 109]
Two syntheses of PLL-g-PEG have been described in the literature.
Spencer et al. conjugated a PLL backbone (MW approximately 20 kDa)
with N-hydroxysuccinimidyl esters of methoxypoly(ethylene glycol)
propionic acid (MW approximately 2 kDa) and attained a grafting ratio
of lysine units to PEG chain of 3.5:1.[46, 108, 45] Thereby, sufficient
ε-amino groups were still available for electrostatic interactions with
surface carboxyl groups of the particles.[46, 108] By using PLL back-
bones grafted with methoxy-capped PEGs, protein-repellent coatings
can be introduced to PLGA microparticles.[108] Moreover, it has been
shown that PLL can be conjugated with arginine-glycine-aspartic acid
(RGD)-capped PEGs and that subsequent adsorption of the PLL-g-PEG-
RGD onto preformed microparticles yields target specific carriers.[46]
An alternative approach to the synthesis of PLL-g-PEG has been re-
ported by Kim et al.[109] The terminal primary amino group of a PLL
backbone (MW approximately 2 kDa) with carbobenzoxy-protected
ε-amino groups (ε-CBZ-PLL) was conjugated to carbodiimide-activated
COOH-PEG-folate (MW approximately 3.4 kDa). Upon removal of CBZ
with hydrogen bromide in acetic acid and coating of PLGA nanoparti-
cles with polycationic PLL-g-PEG-folate, an enhanced binding of the
colloids to folate receptor overexpressing cells was observed.[109] The
direct electrostatic immobilization of a proteinaceous targeting agent
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at the particle surface has been achieved by Kou et al., who expressed
a single-chain antibody with a polylysine tag in Escherichia coli and
characterized its adsorption onto PLGA nanospheres.[117]
As reported, the coating of nano- and microparticles made from
PLGA by adsorption of polycations can be realized by two techniques.
The hydrophile-lipophile balance and concentration of polyamine gov-
ern the incorporation of polyelectrolyte chains into the particle surface
and matrix in course of the preparation procedure. In contrast, adsorp-
tion of polycations onto preformed particles is dominated by electro-
static interactions with negatively charged surface groups. However,
the advantages and limits for pharmaceutical applications of either of
the coating approaches have rarely been discussed. In general, system-
atic studies dealing with the effects of polyelectrolyte MW and charge
density, solution pH, and ionic strength on the adsorption process
are scarce for PLGA particles. Moreover, most reports in the literature
lack a clear description of the adsorption protocol and specifications
regarding the pH and ionic strength of the medium used for ζ-potential
measurements. Without these parameters, the contribution of free car-
boxyl groups to the measured ζ-potential cannot be estimated correctly.
The necessity of a critical interpretation of the ζ-potential is further
illustrated by the fact that even particles prepared from end-capped
PLGA exhibit a negative ζ-potential,[31] probably due to the adsorp-
tion of anions to the particle surface. In this context, the impact of
stabilizers or surfactants on the surface carboxyl density of PLGA parti-
cles has not been addressed sufficiently. Although the formation of a
nonremovable corona on the particle surface has been reported with
PVA,[114, 29, 118] it is not clear to what extent the coating via ionic inter-
actions is affected. Finally, since the anchoring stability of an adsorbed
polyelectrolyte layer can be drastically compromised by electrolytes,
tensides, and proteins,[119] investigations carried out in physiological
media are needed to identify potential limits of polyelectrolyte coatings
for pharmaceutical applications.
Hydrophobicity: adsorption of amphiphiles Due to the rather
hydrophobic nature of PLGA, hydrophobic or amphiphilic molecules,
polymers, and other substances may be adsorbed via hydrophobic inter-
actions. Adsorption is defined as the accumulation or concentration of
materials of one phase at the interfacial surface of the other phase.[120]
The extent of adsorption increases with a decreasing solubility of an
adsorbate in a solvent. The strong attraction between hydrophobic
molecules and surfaces in water is a mainly entropic phenomenon.[121]
In this section, adsorption that is predominantly based on hydrophobic
interactions is described. Because protein adsorption is also strongly
determined by electrostatic interactions, it is discussed separately.
During particle preparation via the solvent evaporation technique or
similar procedures, an organic solution of PLGA is emulsified in an
aqueous medium. In order to avoid coalescence, the dispersed organic-
phase droplets must be prevented from contacting each other. This
can be achieved by adding amphiphilic substances such as surfactants,
polymers, or proteins that arrange themselves at the polar-apolar inter-
face forming mono- or multibilayers.[122] Stabilizing polymers adsorb
at the interface and may extend into both phases, preferably into the
continuous phase. The polymer fractions located at the outside of the
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droplets repel each other and therefore stabilize the emulsion. After sol-
vent removal and particle solidification, amphiphiles are still necessary
to complement the electrostatic stabilization of the suspension. While
some stabilizers are adsorbed at the particle surface in a reversible
manner, others may be physically entrapped in the particle matrix and
build a residual layer at the surface that resists washing. Therefore,
the choice of a certain stabilizer governs the surface characteristics
of PLGA particles and can be exploited for designing carriers with
tailored features. Moreover, even preformed particles may be exposed
to hydrophobic molecules in order to achieve a surface-modification
via adsorption.
PVA is one of the most frequently used emulsifiers for the prepara-
tion of micro- and nanoparticles from PLGA and related polymers. PVA
is prepared by partial hydrolysis of poly(vinyl acetate) and therefore
consists of rather hydrophobic vinyl acetate moieties and rather hy-
drophilic vinyl alcohol moieties. Upon particle preparation via a solvent
evaporation technique, PVA and PLGA form an interconnected network
at the interface with PVA anchored via its hydrophobic vinyl acetate
moieties.[118] While PVA has been suspected to be carcinogenic,[123,
124, 125] the International Agency for Research on Cancer regards
it as “not classifiable as to carcinogenicity to humans.”[126] Another
commonly used group of emulsifiers are the poloxamers (Pluronics®),
which are amphiphilic ABA triblock copolymers consisting of a hy-
drophobic poly(propylene glycol) (PPG) middle block and two hy-
drophilic PEG outer blocks. They are approved by the FDA for topical,
oral, and parenteral application,[127] and are listed in the European
Pharmacopoeia. Concerning the thickness of the adsorption layer, which
depends on the hydrophobicity of the particle surface and the HLB
of the respective Pluronic® type, the values in the literature range
from 3 nm to even 20 nm.[30, 128] At high concentrations, Pluronic®
hemimicelles are adsorbed. Further emulsifiers include semisynthetic
derivatives of cellulose, such as methylcellulose and hydroxypropyl-
methyl cellulose, and polysorbates (Tween®).[1] However, for Tween
20, a strong toxicity was observed by a dramatically increased para-
cellular transport of [14C]sucrose in a blood-brain barrier endothelial
cell culture.[129] In addition to nonionic stabilizers, ionic surfactants
have also been assessed. Cationic emulsifiers such as cetyltrimethylam-
monium bromide (CTAB), dimethyl dioctadecyl ammonium bromide
(DDAB), and 1,2-dioleoyl-1,3-trimethylammoniopropane (DOTAP) were
used during particle preparation to stabilize the emulsion owing to
their amphiphilic properties. At the same time they furnish the result-
ing particles with a positive surface charge that allows the adsorp-
tion of DNA.[130, 131] Accordingly, anionic emulsifiers like sodium
dodecyl sulfate (SDS) and dioctyl sodium sulfosuccinate (DSS) were
employed for the preparation of PLGA particles with negative surface
charge in order to enable the adsorption of antigens for immunization
purposes.[132, 133] Nevertheless, for toxicity reasons the repertory of
possible surfactants for parenteral administration is limited and some
of the mentioned emulsifiers such as SDS will not be applicable.
Recently, there have been some approaches to substitute traditional
nonbiodegradable surfactants by fully degradable alternatives. Phos-
pholipids, especially those with saturated chains such as 1,2-didecanoyl-
phosphatidylcholine (DDPC) or 1,2-dipalmitoylphosphatidylcholine
(DPPC), were proposed as efficient emulsifiers for the preparation
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of PLGA nanospheres.[134] Compared with PVA, a higher emulsi-
fying efficiency was observed for DPPC, which was attributed to a
more complete surface coating. In another approach, PLGA nanopar-
ticles were coated with a pegylated-lipid envelope composed of PEG-
distearoylphosphatidyl-ethanolamine (PEG-DSPE), phosphatidylcholine,
and cholesterol, resulting in the formation of a so-called nanocell.[135]
Upon encapsulation of a drug within the PLGA matrix and incorpo-
ration of a second lipophilic agent within the envelope, a temporal
release of the two drugs was reported. Hydroxyethyl starch (HES)
is a well-established plasma volume expander that could be an in-
teresting alternative to the nonbiodegradable PEG.[136] HES can be
hydrophobically modified by the formation of fatty acid esters. Us-
ing HES laurate for stabilization, PLGA nanoparticles with a narrow
size distribution and a mean particle size of 110 nm were prepared
and further characterized in protein adsorption assays using HSA and
fibrinogen.[128] Therefore, HES laurate provided a stealth character
comparable to Pluronic® F127 and even superior to Pluronic® F68,
which was also confirmed by in vitro phagocytosis assays with murine
macrophages. Another promising approach is the use of alkylpolyglu-
cosides, which are nonionic surfactants consisting of glucose units and
a fatty alcohol.[125]
The adsorption characteristics of amphiphiles also play an impor-
tant role in the covalent surface modification of PLGA particles. In the
presence of PVA, the conjugation of polyclonal antibodies to PLGA
nanoparticles was reduced by 48%.[79] In the presence of high concen-
trations of Pluronic® F68, ligand coupling decreased by up to 65%.[80]
Thus, easily removable emulsifiers may be preferred in order to en-
able access to the PLGA carboxylate groups. However, there are an
increasing number of studies that exploit the irreversible adsorption of
amphiphilic molecules for the functionalization of PLGA particles. This
might be achieved either by using high-affinity emulsifiers that remain
stably associated with the particle surface and confer an inherent ad-
ditional functionality to the particles in order to alter their interaction
with cells, or by covalent coupling of targeters and other substances to
surface-anchored emulsifiers.
Currently, there are attempts to prepare particles with a specific
surface functionality in a one-step procedure by enhancing the sur-
face activity of functional molecules. The vitamin-PEG conjugate D-α-
tocopheryl polyethylene glycol 1000 succinate (TPGS) is an amphiphilic
and water-soluble derivative formed by conjugation of vitamin E succi-
nate with PEG.[137] TPGS inhibits P-glycoprotein- mediated drug trans-
port and might thus improve the bioavailability of P-gp substrates.[138]
A similar approach was assessed for vitamin D using cholecalciferol
polyethylene glycol succinate (CPGS).[139] Amphiphilic derivatives
of hyaluronic acid were used as surfactants for the preparation of
PLA nanoparticles.[140] The resulting particles bound preferentially
to chondrocytes owing to hyaluronate-targeting of the CD44 receptor.
As a versatile modification platform, avidin-fatty acid conjugates were
prepared and added to the PVA solution upon microparticle prepa-
ration via solvent evaporation.[141] This process should allow for a
quick immobilization of various biotinylated ligands to surface-exposed
avidin, which resulted in a maximum of 2.5 ￿g biotin-phycoerythrin
(240 kDa) per milligram of polymer. For a new approach in vaccination,
lipopolysaccharides have been added to the stabilizer solution during
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particle preparation to act as inflammasome-activating adjuvants.[142]
By contrast, aiming at an enhanced blood and tissue compatibility,
certain salts or amino acid complexes of heparin have been used for the
preparation of microparticles.[143] Nevertheless, it has to be considered
that a major fraction of surface-associated heparin and TPGS can be
removed from the particle surface by repeated washing.[144] In general,
the adsorption of amphiphilic molecules for a specific surface modifica-
tion is a rapid and convenient method, provided that the interaction is
strong enough to resist premature desorption.
Several biorecognitive molecules are not amphiphilic and cannot
be physically entrapped during particle preparation; therefore, these
molecules need to be immobilized to preformed particles. The classic ap-
proach to couple ligands to terminal PLGA carboxylate groups exposed
at the particle surface may often not be feasible due to steric hindrance
or inappropriate coupling chemistry. As an alternative, covalent con-
jugation to certain functional groups that are present at the particle
surface due to physically entrapped stabilizers has been reported. Glu-
taraldehyde was used to couple lectins to PVA- or BSA-stabilized PLA
microspheres.[145] When two adjacent hydroxyl groups of PVA formed
an acetal with glutaraldehyde, the remaining aldehyde group could
then either react with the lectin or with another PVA molecule resulting
in PVA cross-linking.
Alternatively, a multifunctional epoxy linker that reacts with PVA
hydroxyl groups and with amine groups of a ligand was used for
the conjugation of transferrin and the tat peptide to surface-anchored
PVA.[146, 147] However, it should be considered that PVA is not
biodegradable and only low-MW PVA is quickly eliminated from the
body. In animal studies, medium- and high-MW PVA have been found
deposited in various organs.[124] Thus, cross-linked PVA might not
be eliminated from the body and may accumulate in certain organs,
causing inflammatory reactions. For another approach, antibodies were
coupled to surface-anchored PVA via cyanogen bromide, which cre-
ates a link between PVA hydroxyl groups and primary amines.[148]
Although the reagent is well established for the preparation of ma-
trices for affinity chromatography, its applicability in drug-delivery
systems might be limited due to its acute toxicity. To overcome the
PVA-shielding effect, PVA was replaced by poly(ethylene-alt-maleic
acid) (PEMA), which contains carboxylic acid side chains and thus al-
lows for carbodiimide-mediated coupling of amine-containing ligands
to the surface-anchored stabilizer.[149] Similarly, when the hydroxyl
groups of Pluronic® F127 were succinylated, the resulting carboxylated
poloxamer could be used as an emulsifier for the preparation of PLGA
nanoparticles followed by covalent coupling of a peptide via a modified
carbodiimide method.[150] In addition to neutral or carboxylated sta-
bilizers, cationic amphiphiles were used to introduce reactive groups.
Polylysine that is usually immobilized at negatively charged surfaces
via electrostatic interactions is unable to stabilize emulsions at neutral
pH due to its high charge density. Upon the addition of sodium hydrox-
ide, however, the polypeptide becomes amphiphilic and the secondary
structure is shifted from random-coil to α-helix. Under these condi-
tions, the polypeptide was applied as a surfactant for the preparation
of PLGA microparticles by a solvent evaporation technique.[107] The
surface-anchored polylysine was then coupled via its ε-amino groups
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to thiol groups of a synthetic peptide using the bifunctional crosslinker
sulfo-N-(γ-maleimidobutyryloxy)succinimide (GMBS).[151]
To conclude, surface adsorption of different substances via hydropho-
bic interactions has an impact on the stability of the suspension, the
access to PLGA carboxylate groups for covalent surface modification,
and can even be exploited for imposing certain characteristics to the
surface itself. The main prerequisite for the latter approach is a strong
hydrophobic interaction, which resists desorption during repeated
washings. For the future, only biocompatible stabilizers should be ap-
plied, and should either be biodegradable or at least easily eliminated
via urinary or biliary excretion.
Protein adsorption The adsorption of proteins to the surface of
PLGA particles is discussed separately, because it relies on a combi-
nation of hydrophobic and electrostatic interactions. On the one hand,
protein adsorption is being exploited for the preparation of carriers
for therapeutic proteins or protein vaccines as well as for targeting
purposes. On the other hand, the adsorption of blood proteins upon
parenteral administration is most often unwanted because it leads to a
rapid clearance of administered colloids via the RES. Protein adsorption
to the particle-liquid interface also has an impact on the stability of
a suspension. Moreover, adsorption phenomena may even affect the
release of encapsulated protein drugs.
To elucidate the mechanisms that govern protein adsorption, model
proteins containing different amounts of charged amino acids were
used. Amphoteric molecules often have their maximum adsorption
capacity at the isoelectric point, where the net charge of the adsorbate
becomes zero.[120] Nevertheless, a strong dependence on electrostatic
interactions has also been described. An examination of the surface
affinity of proteins with different isoelectric points from 4.6 to 10.7
under varying pH conditions revealed that protein adsorption was
significantly enhanced by attractive electrostatic interactions, while a
certain extent of binding even took place under electrostatically re-
pulsive conditions via non-Coulomb forces.[152] In another study, the
positively charged model protein lysozyme was adsorbed onto nega-
tively charged nanoparticles prepared from either PLGA alone or from
blends with the strongly negative poly(styrene-co-4-styrene sulfonate)
(PSS). Increasing lysozyme loading was observed with enhanced nega-
tive surface charge.[153] When the negative charge of PLGA particles
was increased with anionic surfactants such as SDS or DSS for particle
preparation, recombinant p55 gag protein from HIV-1 or antigens from
Neisseria meningitidis type B could be adsorbed to the charged particles.
A potent immune response was elicited upon immunization of mice,
and was superior to that achieved by co-administration of antigen and
PVA-stabilized PLGA microparticles.[132, 133]
Upon adsorption of positively charged protein, the initially negative
ζ-potential of the particle surface shifts towards zero and the particles
start to aggregate.[153] Because electrostatic repulsion is probably the
most important factor for maintaining stable suspensions, the impact
of protein adsorption must not be neglected.
Another interesting aspect is the influence of nonspecific protein
adsorption on the release of encapsulated protein drugs.[154, 155] When
the inner surface of the particles expands in the course of polymer
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degradation, increasing amounts of the therapeutic protein may be
adsorbed, which results in a slower release. Generally, the type of
interaction with the surface seems to affect the release kinetics of the
adsorbed protein. A stronger contribution of electrostatic interactions
was associated with a quicker release compared with predominantly
hydrophobic interactions.[153] In contrast to hydrophobic interactions,
electrostatic forces are affected by changes in pH or salt concentration.
Sensitive proteins that would be degraded during encapsulation
due to shear forces or organic solvents or during covalent coupling
might thus be immobilized via simple adsorption to the particle sur-
face. The functionality of adsorbed proteins was assessed for different
applications. For targeting purposes, transferrin-coated PLGA nanopar-
ticles were prepared by incubation of blank nanoparticles with the
protein.[129] The uptake of the transferrin-grafted particles into blood-
brain barrier cells was increased 20-fold compared with blank nanoparti-
cles and 2-fold compared with BSA-coated particles. This effect could be
inhibited by an excess of free transferrin, which points to selective endo-
cytosis. Upon comparing covalently immobilized and surface-adsorbed
monoclonal antibodies, it was reported that only the nanoparticles with
adsorbed antibody were specifically taken up into MCF-10A neo-T
cells.[156] This observation was attributed to an inactivation of the
antibody during the carbodiimide-mediated coupling procedure.
To conclude, the adsorption of various proteins to PLGA particle
surfaces has been described as a rapid and simple alternative for the de-
livery of sensitive proteins and for the immobilization of targeters. The
main problems, however, have not been addressed adequately so far.
The stability of the adsorptive protein-particle interaction under physi-
ological conditions remains questionable because adsorbed molecules
may be displaced by competitive adsorption of other substances, for
example, by plasma proteins. Moreover, pH and ionic strength influ-
ence the affinity of the adsorbed protein to the surface. Finally, particles
that easily adsorb proteins at their surface are expected to be rapidly
opsonized and eliminated by the RES, which might limit their appli-
cability in vivo. Thus, the most important aspect concerning protein
adsorption is generally not how to enforce it, but how to reduce it.
Strategies to reduce opsonization via the so-called stealth effect are
discussed in one of the following sections.
Methods for surface characterization Several sensitive and so-
phisticated techniques are available for the physicochemical charac-
terization of PLGA-particles, including their surface properties. It is
obvious that a single method cannot cover the whole spectrum of an-
alytical questions, and thus the available techniques listed in Table 4
need to be combined to fully elucidate the surface modification of
particles.
Size and polydispersity represent key parameters not only for biodis-
tribution and clearance but they are also useful as a rough estimate
of the particle surface available for coupling. Laser diffractometry, dy-
namic light scattering (also known as photon correlation spectroscopy),
and, less frequently, multi-angle laser light scattering after asymmetric
flow-field flow-fractionation represent light scattering techniques for
particle size determination. Due to multiple pitfalls associated with
these techniques, it is highly recommended to confirm particle size by
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an imaging technique.[163] These microscopic methods, including SEM,
TEM, cryo-TEM, and, recently, atomic force microscopy (AFM) provide
additional information about particle morphology (see 1.1.2.5).
For determination of the specific surface area, the Brunauer-Emmett-
Teller method, which relies on adsorption-desorption isotherms of N2
and Kr gases at the particle surface, is applied. Although this method is
preferably used to characterize porous microparticles and the associated
initial burst release,[182, 183] it might also be a versatile tool for the
determination of the surface area available for coupling of ligands
considering porosity, size, and polymer composition of PLGA micro-
and nanoparticles.
In addition to the surface morphology and size, two additional param-
eters describing the characteristics of particles are their surface charge
and hydrophobicity. The surface charge strongly influences the stability
of aqueous nanosuspensions and particle-cell interactions.[172, 173]
Usually, the surface charge is assessed via the mobility of the particles
in an electrical field, and is expressed as electrophoretic mobility (￿) or
converted to zeta (ζ) potential, which represents the potential at the hy-
drodynamic shear plane of the particle. For the theoretical background
and calculation of mobility and ζ-potential the reader is referred to
Agnihotri et al.[170] The surface charge is dependent on the degree of
ionization of particle surface groups and on ion adsorption. In practice,
ζ-potential measurements are highly sensitive to the conductivity of the
dispersant medium and its pH. Generally, values above 30 mV indicate
physically stable PLGA-particle suspensions that are widely stabilized
via electrostatic repulsion.[171]
Surface hydrophobicity can influence the adsorption of excipients
and proteins. Whereas the contact angle measurements of water, octane
drops, and air bubbles are only applicable to PLGA films,[175] the
hydrophilicity and conversely the hydrophobicity of particles can be
determined by a Rose Bengal adsorption assay.[165, 177] Nanoparticles
are incubated with an aqueous solution of the hydrophilic dye, spun
down, and the dye content in the supernatant is determined by spec-
trometry at 564 nm. From the difference between blank and sample, the
amount of dye adsorbed by the nanoparticles is calculated considering
the density and diameter of the particles. In addition, hydrophobic
interaction chromatography (HIC) proved useful to monitor changes
in particle surface hydrophobicity upon modification with hydrophilic
ligands.[174]
X-ray photoelectron spectroscopy (XPS), also called electron spec-
troscopy for chemical analysis, is routinely applied for particle surface
analysis. The samples are prepared on substrates such as glass slides
or aluminum foil by drop casting of aqueous particle suspensions fol-
lowed by drying. X-ray irradiation causes emission of photoelectrons
with specific binding energies according to the electron core level at
the site of ejection. The peak intensity is proportional to the atomic
concentration within the sample. XPS provides qualitative information
about the surface chemistry and quantitative information about the
element composition and functional groups at the particle surface with
high sensitivity, usually 1 atom in 1000.[29] Unfortunately, interpre-
tation of the spectra is complex because varying ligand coverage of
the particle surface and/or the penetration depth in the range of 2
to 10 nm might lead to interference between strong signals from the
underlying PLGA matrix and only weak signals from the modified
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surface. In addition, precise quantification of data may be difficult.[176]
Nevertheless, XPS analysis at a penetration depth of 10 nm revealed
that rhodamine was not present at the surface of PLGA nanoparticles
but rather was embedded in the core.[114] Additionally, XPS has proven
to be a powerful tool to detect the presence of a chitosan or PVA shell
on PLGA nanoparticles.[166, 176]
A surface analytical technique complementary to XPS is secondary
ion mass spectrometry (SIMS). At this, secondary ions emitted from
the particles under high vacuum are analyzed according to their mass/
charge (m/z) ratio. Compared with XPS, SIMS offers the advantage
of detecting all elements including their isotopic distribution, has low
detection limits and a low penetration depth of only 1 nm of the particle
surface,[180] but the drawback of sample damage. Time-of-flight (TOF)-
SIMS is preferentially applied for mass analysis of high-MW samples,
and static SIMS (SSIMS) is used to collect the mass spectra of thermally
labile organic compounds. Both complementary surface analytical tech-
niques, XPS and SSIMS, have been employed to determine residual
surfactant at the surface of PLGA nanoparticles after purification by cen-
trifugation or gel-permeation chromatography.[29] Moreover, XPS and
TOF-SIMS have been applied for the surface characterization of PLGA
microparticles after vaccine antigen adsorption. Although some amino
acid residues known to be specific for certain proteins were identified
by TOF-SIMS, the spectra were too complex to provide specific informa-
tion about protein identity and quantity. However, the combination of
the two techniques allowed for the identification and quantification of
both the protein and the surfactant adsorbed at the outermost surface
and revealed that the antigen concentration decreased with increasing
surfactant concentration.[181]
Whereas the chemical composition of polymers can be elucidated
by Fourier transform infrared (FTIR) spectroscopy, the attenuated to-
tal reflectance (ATR) mode is applied for surface characterization.
After spreading the nanoparticle suspension onto the ATR crystal
and drying with nitrogen, it was possible to detect the presence of
positively charged chitosan and surfactant at the surface of PLGA
nanoparticles.[92]
In addition, the adhesive capacity of surface modified particles and
their binding specificity were assessed by the resonant mirror system,
an optical biosensor based on the phase shift of an incident beam that
occurs in reflected light, which passes through a prism underlying
the resonant mirror. This label-free technique allows monitoring of the
interaction between a dissolved molecule or a dispersed nanoparticle
of interest (ligate) and its biospecific partner (ligand) immobilized at
the waveguide sensing surface. Depending on the extent of binding,
a change in the resonance angle is observed. Using this technique,
the interaction between biotinylated nanoparticles and Neutr-Avidin-
coated surfaces was assessed. Strong and specific binding was ob-
served, but no equilibrium, presumably due to the rearrangement of
nanoparticles.[178]
Among the fluorometric methods, fluorescence microscopy and flu-
orometry allow for the detection and quantification of fluorescence-
labeled ligands coupled onto the particle surface. Flow cytometry, re-
lying on forward versus side scatter analysis of a few thousand single
microparticles in a sheath flow one by one, offers a multiparametric
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analysis in terms of size, granularity, and fluorescence intensity after
surface modification with fluorescence-labeled ligands.[80]
MicroRaman spectroscopy allows for studying molecule vibrations
in micron-sized materials due to their interaction with photons. Accom-
plishing a penetration depth in the micrometer range, this technique
comprises the surface and the core of particles. Applying this technique,
the distribution of drug crystals in PLGA microparticles was found to
be close to the surface in high-MW PLGA matrices but was located in
the core of low-MW PLGA.[164]
Perhaps the most important aspect of surface characterization is
the interaction of the functionalized nano- and microparticles with
the biological environment, which requires either ex vivo studies with
human cell culture models or in vivo studies in animals.
1.1.2.4 Aims of functionalization
Modified bioadhesion and potential internalization
Nonspecific mechanisms A rather nonspecific approach to enhancing
the binding of polymer particles to human cells makes use of the net
negative charge of the extracellular face of the plasma membrane. Al-
though the quantitative and qualitative compositions of the charged
groups contributing to the overall negative ζ-potential on different cell
types have not been fully resolved yet, it seems clear that negative
charges generally prevail.[6] Theoretically, these charges bear a consid-
erable potential for attractive electrostatic interactions with positively
charged drug carriers, and consequently might be exploited to increase
the cell-binding[184, 86] and transfection efficiency of particulate car-
rier systems.[185] Nano- and microparticles prepared from uncapped
PLGA and stabilized by PVA or poloxamers, however, are usually
negatively charged due to free surface carboxyl groups. To induce a
positive ζ-potential on these particles, several coating techniques with
cationic excipients have been developed. As expected, PLGA nanopar-
ticles coated with didodecyl dimethyl ammonium bromide (DMAB)
preferentially associated with the negative endothelial layer in a femoral
artery ex vivo model.[186] This led to a 7- to 10-fold enhanced delivery
of an antiproliferative agent compared with plain particles.
Interestingly, the density of negative charges in the vasculature was
found to be further increased in malignantly transformed tissue.[187]
Supposedly, this is due to an induced exposure of anionic phospho-
lipids, most likely phosphatidylserine, on the cell membrane. This
surplus of negative charges compared with the normal vasculature, in
combination with the reportedly low pH in tumors, could be exploited
for the accumulation of cationic drug carriers or imaging agents.[98]
In addition to increasing cytoadhesion, coating with cationic excipi-
ents also affects the internalization rate and intracellular processing
of particles. While negatively charged polystyrene beads were only
taken up to a low extent by macrophages and dendritic cells (DC),
positively charged beads were readily internalized and induced matu-
ration of DCs.[86] These positively charged particles were characterized
by a similarly high cell-binding affinity to antigen-presenting cells
(APC) as immunoglobulin G-modified beads. This led to phagocytosis
and subsequent engulfment in tightly apposed phagosomes, which
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do not undergo maturation. In contrast, albumin-modified particles
were taken up in loosely apposed phagosomes, which rapidly fuse
with lysosomes.[90] Thus, coating of drug and vaccine carriers with
cationic polyelectrolytes could not only result in enhanced uptake into
APCs, but also in intraphagosomal protection of the payload to be
delivered. However, in addition to these promising reports with in vitro
and ex vivo setups, studies performed under physiological conditions
are rare. In particular, it is not clear to what extent the adsorption of
serum proteins alters the cationic charge density of the particle sur-
face, and consequently effectiveness of the electrostatic bioadhesion
approach. This issue deserves attention, especially since a recent report
indicated that the adsorption of serum onto PLL-coated polystyrene
(PS) microspheres leads to reduced uptake into DCs compared with
untreated cationic beads.[184] The probably limited influence of particle
surface charge in the presence of serum was also indicated by Roser
et al., who observed no differences in the blood circulation times and
biodistribution of cationic, anionic, and neutral albumin nanospheres
in rats.[188]
If not administered via the parenteral or topical route, drug-carrier
systems will encounter the sticky, viscous, and elastic mucus layer
that lines all mucosal tissues.[189, 190] Due to its constant secretion,
transport, and excretion, mucus functions as a dynamic protective
barrier that efficiently removes foreign materials from the body. This
severely limits the residence time and thus efficiency of sustained-
release drug-carrier systems. Therefore, mucoadhesion and mucopene-
tration have been investigated as approaches to counteract premature
removal[190, 191] and to enhance transport of particulate drug carriers
through the mucin mesh to underlying tissues.[189]
Polymers utilized to formulate mucoadhesive drug-delivery sys-
tems have comprised polyanions, polycations, and thiolated polymers.
Polyanions such as poly(acrylic acid) (PAA) and sodium carboxymethyl-
cellulose and their derivatives supposedly bind to mucus via hydrogen
bonding. In contrast, polycations such as chitosan are anchored by
a combination of hydrogen bonds and electrostatic interactions with
sulfonic- or sialic acid groups of glycosylated moieties of mucus.[190] To
transfer mucoaffinity to PLGA nano- and microparticles, coating with
mucoadhesive polymers such as PAA,[192, 39] chitosan and thiolated
derivatives,[84, 93, 97, 192, 193] PEI,[114] and Eudragit® RL/RS[85]
has been investigated. As opposed to particles prepared in the presence
of poloxamer 188 and PVA, PLGA nanoparticles produced with PAA as
a stabilizer were indeed characterized by mucoadhesive properties.[39]
According to Yamamoto et al., surface modification of particles with
chitosan led to higher retention rates in the lungs of guinea pigs after
administration by nebulization compared with plain colloids.[93] The
prolonged pharmacological action of calcitonin co-administered in these
particles was attributed to the mucoadhesive properties and probably
an opening of tight junctions. Furthermore, it was shown that chitosan-
coated PLGA nanoparticles exhibit higher binding to a rat everted
intestinal sac model than PAA- and alginate-modified controls.[192]
These proof-of-principle studies illustrate that mucoadhesive properties
can be integrated into a priori non-mucoadhesive particles made from
PLGA by surface coating. Whether PLGA is suitable as a sustained-
release polymer for mucoadhesive systems, however, is questionable.
Even if mucoadhesion is established, the particles are expected to be
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removed from the body at a rate similar to that of mucus turnover.
However, these turnover rates range from about 20 min in the nasal
tract to 10 to 20 min for the luminal layer in the respiratory tract and
4 to 6 h in the gastrointestinal tract,[189] and thus lie well below the
degradation half-life of PLGA.
Very recently, it has been found that mucopenetrating nanoparti-
cles can be engineered with potential advantages over traditional mu-
coadhesive formulations. While mucoadhesive particles adhere to the
outer luminal mucus layer, which is rapidly cleared, mucopenetrat-
ing nanoparticles are supposed to diffuse into low-viscosity aqueous
pores of the mucin mesh and to thereby reach deeper adherent mucus
layers.[189, 194] The surface functionalization rationales that are used to
generate mucopenetrating properties have been deduced from studying
nature. Using fluorescence recovery after photobleaching and multiple
image photography, Olmsted et al. investigated the diffusion of viruses
and polystyrene particles (59–1000 nm) in human cervical mucus.[195]
While viruses with a net neutral surface charge such as human papil-
loma virus (approximately 55 nm) and Norwalk virus (approximately
38 nm) diffused as rapidly in mucus as in saline, negatively charged
polystyrene particles were trapped and adhered to mucin via hydropho-
bic interactions. From these and similar findings, it was proposed that
sufficiently small particles with a neutral surface charge would exhibit
minimal interactions with mucus and thus be able to diffuse relatively
unhindered.[189, 194]
A well-established strategy to render the particle surface inert and
neutral is based on the modification with PEG. Upon conjugation
of polystyrene nanoparticles with high surface densities of low-MW
PEGs of 2 and 5 kDa, particles with enhanced diffusivity in mucus
were generated.[196] In contrast, conjugation with higher-MW PEG
(>10 kDa) might induce mucoadhesive properties due to the increased
penetration of longer polymer chains into the mucin network. After
surface modification with PEG, nanoparticles with mean diameters of
200 and 500 nm, which are clearly larger than the reported mucin mesh
pore size (10–200 nm), diffused in mucus at rates only 4- to 6-fold slower
than in water.[197] Consequently, surface modification with PEGs of
appropriate MW might drastically improve the transport of particles
toward the underlying epithelium.
Making use of the same principle, but via a different approach to
surface modification, PLGA nanoparticles have been rendered muco-
penetrating.[198] Avidin-decorated particles (170 ± 57 nm) were pre-
pared by using palmitate-avidin/PVA blends as stabilizer in course
of the preparation procedure. By adding different amounts of biotiny-
lated PEG to these particles, varying degrees of grafting were achieved.
By increasing the surface grafting density of PEG, an increase in the
diffusivity of the PLGA nanoparticles in human cervical mucus was
observed.[198] Increased diffusion coefficients in mucus upon alteration
of the surface charge of particles have also been monitored without
PEGylation.[199] By modification of PLGA nanoparticles with DDAB
and subsequent loading with plasmid DNA, 10-fold higher diffusion
rates were achieved compared with negatively charged polystyrene
nanoparticles of similar size. These reports seem promising for the
delivery of drugs, genes, or antigens through the mucus barrier to
the underlying epithelium. However, the therapeutic advantages of
mucopenetrating particles over mucoadhesive systems have yet to be
1.1 introductory works 47
proven in vivo. Furthermore, PEG-decorated nanoparticles will be ex-
pected to have a low uptake rate into epithelial cells due to the hy-
drophilic surface coating. In this regard, grafting of mucopenetrating
nanoparticles with low-MW targeting moieties, which enhance uptake
into epithelial cells, might be advantageous.
Biorecognitive mechanisms Bioadhesion can be enhanced by a biorecog-
nitive interaction between particle surface-immobilized active targeters
and tissue-characteristic structures at the cell surface. These targets
comprise a broad range of receptors, including cell-adhesion molecules,
carriers, and other membrane proteins or glycoproteins. The fundamen-
tal problem is the identification of appropriate tissue-specific targets.
However, few of them are uniquely present in only one single tissue and
it is thus important to consider the relative selectivity of the targeted
moiety in relation to the potency of the delivered drug. Moreover, these
tissue markers have to be accessible to allow for an interaction with
the targeted particles. The route of administration is also crucial for
successful targeting. If a drug-delivery system attaches to the target
cells via noninternalizing epitopes, high local drug concentrations at
the outer surface of the target cell may result in a higher therapeu-
tic efficacy than free drug released in the circulation. However, even
upon localized release, only part of the drug will enter the target cells.
Therefore, most strategies focus on internalizing epitopes. As ligands
for active targeting, proteins such as antibodies or lectins, as well as
peptides and peptide-analogs, aptamers, vitamins, and other natural-
derived, semisynthetic, or synthetic molecules that bind to certain target
structures with high affinity and specificity are applicable.
The application of antibodies for clinically applied immunocon-
jugates is a well-established strategy in cancer treatment. Similarly,
drug-delivery devices might be guided to their target cells via surface-
immobilized immunoglobulins. Antibodies against the human epider-
mal growth factor receptor (EGFR; HER) for targeted breast cancer
therapy,[200, 201] against the siglec-7 (CD33-like) receptor that is ex-
pressed on most acute myeloid leukemias,[202] and against the Fas
(CD95/Apo-1) death receptor[79] mediated enhanced PLGA nanoparti-
cle internalization. Antibodies against VEGFR-2 (vascular endothelial
growth factor receptor-2) for systemic targeting to angiogenic sites in
prostate tumors resulted in enhanced cytoadhesion of microparticles.-
[148] To mimic leukocyte adhesion to inflamed endothelium, PLGA
microspheres were decorated with two different ligands, an antibody
against ICAM-1 (intercellular adhesion molecule-1) and the selectin
ligand sialyl LewisX for glycotargeting.[203]
Glycotargeting is another extensively studied strategy that relies
on the specific interaction between nonenzymatic sugar-binding pro-
teins, so-called lectins, and certain carbohydrate moities.[204] Either
endogenous lectins or, inversely, endogenous sugars serve as targets.
A prominent group of mammalian lectins are the selectins, a family of
adhesion receptors, which can be addressed by the above-mentioned
sialyl LewisX. Another example is the galactose-specific asialoglyco-
protein receptor, which is expressed at the surface of hepatocytes and
overexpressed in hepatocarcinoma. Recently, pDNA-loaded cationic
nanoparticles were prepared from a blend of PLGA and DOTAP fol-
lowed by adsorption of the asialoglycoprotein receptor ligand asialofe-
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tuin for targeted delivery to liver tumor cells.[205] In a mouse xenograft
tumor model, complete tumor regression was reported for 75% of mice
treated with these targeted gene carriers.
For targeting cartilage, PLA nanoparticles were coated with the gly-
cosaminoglycan hyaluronate, which has a high affinity to the CD44
receptor that is present at the surface of chondrocytes and other articular
cells.[140] Nevertheless, the majority of glycotargeting approaches relies
on lectin-mediated targeting to specific carbohydrates. Each mammalian
cell bears a sugar coat, the so-called glycocalyx, which is composed of
the oligosaccharide moieties of membrane-anchored proteoglycans, gly-
colipids, and glycoproteins. The glycosylation pattern is not only tissue-
specific, but may also change upon malignant transformation.[206]
Screenings of the binding pattern of a range of plant lectins with dif-
ferent carbohydrate binding specificities to different cell types pave
the way for lectin-mediated targeting.[207, 208, 209, 210, 211] More-
over, sugars are also present in the mucus and the extracellular matrix.
WGA, the lectin derived from Triticum vulgare, specifically interacts with
N-acetyl-D-glucosamine and sialic acid residues. These sugars form
part of the intestinal mucus and the glycocalyx of human intestinal
epithelium.[212] Moreover, they are present in the glycosylated extracel-
lular domain of the EGF (epidermal growth factor) receptor.[213] WGA
and WGA-decorated PLGA particles are not only cytoadhesive, but may
even be taken up into enterocytes via receptor-mediated endocytosis,[5]
which might open the way to improved peroral drug delivery.
Not only enterocytes may be targeted in the intestine, but also M
cells being addressed in peroral immunization. Thus, allergen-loaded
PLGA microparticles were functionalized with the α-L-fucose-specific
Aleura aurantia lectin (AAL) for binding to the glycocalyx of murine M
cells.[214] In mice, peroral gavage of the targeted formulation resulted
in a favorable shift from a Th2-type allergic to a Th1-type immune
response. Similar results were obtained with the α-L-fucose-specific
UEA-1 (Ulex europaeus agglutinin-1).[215] However, the glycosylation
pattern of M cells exhibits species-related variations, and for human
M cells targets other than α-L-fucose will be necessary.[215] In ad-
dition to peroral application, there are also possible targets in other
tissues demanding other routes of application. For example, human
macrophage-like THP-1 cells preferably internalized WGA-modified
PLGA nanoparticles,[211] which might enable a new approach for the
treatment of infectious diseases provoked by intracellular pathogens.
Furthermore, lectin binding to bladder cancer cells might be exploited
for designing targeted drug carriers with a prolonged residence time in
the bladder upon instillation.[210]
Another strategy is targeting of the transferrin receptor, which plays
an essential role in the iron metabolism of cells and is overexpressed in
certain tissues such as the liver, epidermis, intestinal epithelium, vascu-
lar endothelium of the brain capillary, certain blood cells, and malignant
tissues. Functionalization of paclitaxel-loaded PLGA nanoparticles with
transferrin enhanced the antiproliferative activity of the encapsulated
drug in MCF-7 and drug-resistant MCF-7/Adr breast cancer cells,
which was attributed to a sustained intracellular drug retention.[146]
Transferrin has also been proposed for brain delivery of nanoparti-
cles. In an attempt to study the endocytosis of targeted particulates by
blood-brain barrier cells, an in vitro model of the blood-brain barrier
made of co-cultured endothelial cells and astrocytes was incubated
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with transferrin-coated PLGA nanoparticles.[129] The interaction was
found to be specific and caveolae-mediated endocytosis was proposed.
Other approaches are aimed at mimicking the interaction of different
bacteria with their hosts. Various bacteria such as Yersinia, Shigella,
Salmonella, and Listeria species enter the body through the intestine
aided by enteroinvasive proteins. The Yersinia adhesin invasin binds
to a subset of β1 integrin receptors at the apical membrane of M cells,
leading to host cell invasion.[216] Although β1 integrin expression is
generally limited to the basolateral membranes of polarized epithelia,
there is evidence that they also occur at the apical side of M-cells.[217]
A large fusion protein containing the carboxyl terminal 479 amino acids
of invasin (MBP-Inv479) was covalently coupled to the surface of PLGA
nanoparticles.[218] For these modified particles, an enhanced interac-
tion with invasin-binding cells was reported that could be inhibited
by free MBP-Inv479 or the competing ligand RGD, which points to a
specific interaction with integrins. Another approach is based on the
neuronal transport of tetanus toxin. The nontoxic C fragment of tetanus
toxin binds with high affinity to the neuronal ganglioside GT1b, which
leads to efficient endocytosis and retrograde transport from the distal
axonal terminus to the neuronal cell body, thus allowing it to bypass the
blood-brain barrier and enter the central nervous system. This transport
mechanism seems promising for new treatment opportunities in neu-
rodegenerative diseases. To study a possible strategy for targeted drug
delivery to neurons, PLGA nanoparticles were surface-modified with
tetanus toxin.[219] Flow-cytometric studies with neuroblastoma, liver,
and endothelial cells revealed selective targeting to the neuroblastoma
cells.
Proteinaceous targeters also bear some possible disadvantages: they
may elicit undesirable immune responses; they are degraded by pro-
teolytic enzymes; they change their conformation under unfavorable
conditions, which may impair their binding properties; their biotech-
nological production is often subject to a significant batch-to-batch
variability; it is often difficult to immobilize these large molecules in an
adequate orientation being favorable for cell interactions; due to their
size they provide a large area for possible nonspecific binding and may
thus counteract a stealth effect regardless of an existing PEG coat; and
they are generally rather expensive. Most of these problems might be
avoided by using peptides or peptidomimetics instead.
Respective binding peptides may be identified by affinity selection
such as phage display, yeast surface display, messenger RNA display, or
peptide-on-bead display.[220] The most prominent peptide for target-
ing purposes is the cell-binding motif RGD, which efficiently triggers
integrin-stimulated cell adhesion.[221] The affinity of RGD-containing
peptides to different integrins is influenced by the conformation of the
RGD-containing loop and by the neighboring amino acids. Cells differ
as to their typical integrin pattern, which may be exploited with an
appropriate RGD-containing peptide. Surface-grafted RGD was em-
ployed as a model ligand to demonstrate the specific uptake of targeted
stealth PLGA microparticles by phagocytes in vitro.[46] In another ex-
ample, enhanced delivery of drug to integrin-overexpressing cancer
cells upon RGD functionalization was reported.[222] Upon oral immu-
nization in a mouse model, RGD grafting was reported to provoke a
slightly enhanced immune response, which was attributed to M-cell
targeting.[223] The targeting effect observed in the in vitro co-culture
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model was, however, more pronounced than the in vivo results. Thus,
a partial degradation of the RGD peptide in the gastrointestinal tract
was suspected and alternative peptide analogues were tested.[224] Per-
oral immunization of mice with PLGA nanoparticles that were grafted
either with an RGD peptidomimetic or a leucine-aspartic acid-valine
tripeptide derivative revealed increased immunoglobulin G production.
However, there were differences observed depending on the relative
affinity of the targeters to M cells and APCs, which probably induced
different induction pathways.
For delivery to the pulmonary epithelium, the above-mentioned
ICAM-1 has been proposed, which is expressed on inflammatory
and immune effector cells, fibroblasts, and endothelial and epithe-
lial cells, and is up-regulated in some types of carcinomas (e.g., lung
carcinoma).[150] ICAM-1 may not only be targeted by antibodies, but
also by the cyclic peptide cyclo-(1,12)-PenITDGEATDSGC (cLABL).
Conjugated to PLGA nanoparticles, cLABL enhanced the endocytosis
into human umbilical cord vascular endothelial cells with up-regulated
ICAM-1 and into A549 lung epithelial cells.[150, 225] In an attempt
to enable PLGA nanoparticles to cross the blood-brain barrier, PLGA
was derivatized with different short peptides that were similar to syn-
thetic opioid peptides.[226] Functionalized fluorescent-labeled particles
were tested in an in vivo experiment with rats. In contrast to plain
PLGA particles, confocal microscopic analyses of tissue cuts revealed
some penetration into the cerebral tissue with some of the modified
particle preparations. Recently, PLGA was conjugated with the glycosy-
lated heptapeptide H2N-Gly-L-Phe-D-Thr-Gly-L-Phe-L-Leu-L-Ser(O-
β-D-Glucose)-CONH2 (g7) and loperamide-loaded nanoparticles were
prepared.[227] In vivo nociceptive testing in rats using the hot plate
test revealed an extraordinary analgesic effect of these functionalized
drug-loaded carriers, which was attributed to a successful transport of
loperamide across the blood-brain barrier.
Aptamers are DNA or RNA oligonucleotides with unique tertiary
conformations, which allow for antigen binding with high affinity and
specificity. They are nonimmunogenic and highly stable in a wide
range of pH and temperatures and in the presence of organic sol-
vents. Docetaxel-loaded PLGA nanoparticles were surface modified
with the A10 2’-fluoropyrimidine RNA aptamer, which binds to PSMA
(prostate-specific membrane antigen) that is overexpressed in prostate
cancer.[228] In a mouse xenograft tumor model, the targeted particles
gave promising results, inducing complete tumor regression in five of
seven mice at a 109-day survivability of 100%.
Interestingly, vitamins can also be exploited for targeting purposes.
The most prominent representative of this group of targeters is fo-
late (vitamin B9), a small, innocuous, and nonimmunogenic molecule,
which is accessible for conjugation via its γ-carboxylate group with-
out losing its binding properties. Moreover, it is highly stable in the
presence of organic solvents and under different pH and temperature
conditions. Folate is taken up into cells either by the ubiquitous low-
affinity folate carriers or by high-affinity folate receptors, which occur
only in a limited range of tissues such as certain tumor cells and acti-
vated macrophages.[229] In contrast to the carrier, the folate receptor
is also able to endocytose folate-linked cargo, which makes it an in-
teresting target in cancer and inflammation therapy. Folate-decorated
doxorubicin-loaded PLGA particles were not only taken up into folate
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receptor-overexpressing KB cells to a higher extent than nontargeted
carriers in an in vitro experiment, but they also reduced tumor growth
in vivo in a xenograft mouse model.[230] An enhanced particle uptake
into KB cells was also observed with PLL-PEG-folate coated PLGA
nanoparticles.[109] Doxorubicin-loaded nanoparticles prepared with
vitamin E TPGS-folate exhibited significantly higher cytotoxicity toward
C6 glioma cells than free drug or the nontargeted formulation.[231]
In addition to folate, other vitamins such as thiamine (vitamin B1)
or cobalamine (vitamin B12) might also provide interesting targeting
opportunities.[232, 233] Furthermore, low-MW synthetic molecules may
be applied for active targeting. In an approach to selectively deliver
drug carriers to bone, PLGA was modified with the bisphosphonate
alendronate, which has a high affinity to hydroxyapatite, the major
inorganic component of bone and teeth.[234]
However, even the highest affinity and selectivity of a ligand-target
interaction will sometimes not suffice for successful nanoparticle de-
livery because various barriers may limit the access of a particulate
carrier. Upon peroral administration, particles need to overcome the
mucus barrier in order to interact with the underlying cells.[215] In
solid tumors, the diffusion of targeted nanoparticles is impaired, and in
dense, avascular tissues such as cartilage, the extracellular matrix limits
the entry of drug carriers.[220] Moreover, functionalized carriers are
only efficient if they are not prematurely eliminated. Thus, systemically
administered particulates require a combination of optimum targeting
and optimum stealth characteristics.
Directed intracellular trafficking For some applications, it may
be sufficient to deliver a drug to a certain tissue, while others must
be delivered to a specific intracellular target. These targets can be lo-
cated in the cytoplasm or, for proteins or siRNA, in the nucleus; for
DNA, antisense oligonucleotides or DNA intercalators in mitochon-
dria; and for antiapoptotic drugs, in other compartments.[235, 236] For
successful gene delivery, directed intracellular delivery remains the
main challenge. First of all, the mechanism of particle uptake into the
cell seems to affect their intracellular sorting and thus the extent of
possible exocytosis.[146] The fraction that remains inside the cell has to
evade lysosomal degradation. Subsequently, the carrier or its respective
payload has to migrate through the cytoplasm to the specific target. In
the case of gene delivery, the vehicle or its respective payload finally
has to enter the nucleus.
One possible mechanism for endosomal escape of polymeric vectors
via an intrinsic endosomolytic activity is described by the proton sponge
hypothesis.[237] Due to their high buffer capacity, branched polyamines
such as PEI or polyamidoamine (PAMAM) dendrimers that contain
numerous secondary and tertiary amines counteract the acidification
during endocytic trafficking.[238] Moreover, the resulting influx of ions
leads to osmotic swelling, and finally to the rupture of the endosomes
and the release of their content into the cytoplasm. This mechanism has
been exploited with PEI-PLGA nanoparticles with surface-immobilized
DNA for gene delivery to pulmonary epithelium.[102] Upon incubation
of Calu-3 human airway submucosal epithelial cells with DNA-loaded
nanocarriers, a rhodamine-labeled plasmid DNA that drives the expres-
sion of a green fluorescent protein was primarily found in lysosomes.
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However, a low amount of green fluorescent protein was also detected,
which pointed to endosomal escape and nuclear delivery of a certain
percentage of the administered DNA.
Recently, PEI-PLGA nanoparticles have been loaded with a DNA
vaccine encoding a Mycobacterium tuberculosis latency antigen.[239]
The particles stimulated human monocyte-derived dendritic cells and
induced their maturation, which was concluded from an increase in
the expression of surface markers and the secretion of cytokines that
was comparable to the positive control. In mice, pulmonary application
resulted in more efficient immunization than intramuscular application,
which was attributed to a more efficient uptake. In another study, PEI-
PLGA particles were prepared either by PEI adsorption or by covalent
coupling via the carbodiimide chemistry.[105] The ζ-potential of the
PEI-conjugated PLGA particles amounted to approximately +35 mV,
which was significantly higher than for PEI adsorption (+10 to 24 mV).
Uptake studies in RAW murine macrophages and subsequent deter-
mination of the gene and protein expression revealed a high amount
of PEI-modified particles in the cytoplasm and a successful transfec-
tion, whereas unmodified particles were accumulated in phagolyso-
somes. For PEI and other polycations, cytotoxicity issues should be
considered.[113] Surface-conjugated PEI seems to exhibit a lower cyto-
toxicity than free PEI.[105] In addition to the proton sponge hypothesis
for polycations, a mechanism for endosomal escape has been proposed
also for PVA-stabilized PLGA nanoparticles.[240] Upon uptake into
human arterial smooth muscle cells, their intracellular localization
pointed to an endosomal escape of the particles, which was attributed
to a cationization of the particle surface in acidic pH followed by a
localized destabilization of the endo-lysosomal membrane.
A recent approach for direct delivery to the cytoplasm relies on
conjugation with “cell-penetrating peptides” or “protein-transduction
domains” that mediate membrane transport.[236, 241, 242] One promi-
nent representative of this group is the viral protein tat, which might
be responsible for cell penetration by lipid raft-dependent macropino-
cytosis[243] and for the delivery of genetic material to the nucleus.[241]
Fluorescence-labeled tat-PLGA nanoparticles were incubated with hu-
man keratinocytes HaCaT, which resulted in higher fluorescence in-
tensities at the cell membrane and in the cytoplasm upon confocal
laser scanning microscopic imaging than was observed for nontargeted
particles.[244] Another example of a cell-penetrating peptide is the argi-
nine peptide (RRRRRRRRCK-fluorescein isothiocyanate [FITC]).[245]
Another barrier for intracellularly migrating drug-delivery systems
is the cytoplasm itself. The cytoplasm is crowded with proteins, cy-
toskeletal filaments, and other organelles. Thus, particles greater than
500 kDa or 20 nm are largely immobile unless there is some kind of
assisted transport.[246] Among others, intracellular transport of or-
ganelles relies on active transport mechanisms that are mediated by
cytoskeleton-dependent motor proteins such as myosin, kinesin, and
dynein. Particle-tracking experiments revealed that some PEI/ DNA
complexes are actively transported by motor proteins along micro-
tubules similar to endogenous organelles or invading pathogens.[247]
An interesting approach for the active intracellular transport of PLGA
particles relies on a mechanism that is used by several bacteria such
as Listeria monocytogenes.[248] The protein ActA, which is expressed
at the bacterial surface, initiates actin polymerization by interacting
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with host cell proteins and thus promotes actin-based motility. PLGA
particles with surface-adsorbed ActA also were found to polymerize
actin, which resulted in comet-tail propulsion. Interestingly, this effect
was only observed for anionic carriers, whereas cationic PLGA-PEI
particles did not form comet tails. Although the direction of this kind
of transport was random, it enabled the particles to overcome restricted
diffusion, and thus the carriers were able to reach the perinuclear re-
gion. Interestingly, actin-based motility was about 100-fold faster than
passive diffusion and larger particles moved quicker than smaller ones.
Last but not least, therapeutic genes have to be delivered to the nu-
cleus. All types of transport, active as well as passive, into and out of
the nucleus have to pass through nuclear pore complexes.[246] While
small molecules of up to 40 kDa or 10 nm may overcome this barrier
by passive diffusion, molecules over 45 kDa must contain a nuclear
localization signal to be recognized by importins, which mediate the
nuclear transport. The upper size limit for active transport through the
nuclear pore complexes is reported to be about 40 to 60 nm. However,
it may not always be necessary to deliver the whole carrier into the
nucleus. Instead, the payload may be released in the perinuclear region,
facilitating transport through the nuclear pore complexes. Recently, the
delivery of nuclear localization signal peptide-functionalized PLGA
nanoparticles to the nucleus was reported.[249] Briefly, FITC-loaded
PLGA nanoparticles were prepared and covalently grafted with amino-
PEG-coated quantum dots. The remaining quantum dot-amine groups
were coupled with thiol-terminated nuclear localization signal peptides.
Upon modification, the diameter of the particles increased from 72
to 168 nm. The modified particles were tested for their uptake into
HeLa (human cervical cancer) cells and their intracellular localization
was analyzed by confocal laser scanning microscopy, revealing that
targeted nanocarriers not only attained the cytoplasm, but also the
nucleus. However, the modified carriers widely surpassed the reported
size limit of the nuclear pore complexes. Therefore, the authors hy-
pothesized that the carriers were able to pass due to size losses upon
degradation, but PLGA is usually not degraded that quickly (see 1.1.2.2)
and, more importantly, it is generally difficult to distinguish between
labeled carriers and released marker. Encapsulated fluorescent dye is
quickly released from the hydrophobic PLGA matrix, and some of
the quantum dots might be cleaved from the PLGA surface. Thus, the
observed fluorescence might not necessarily represent the localization
of the PLGA carriers. This was highlighted by a comparison between
PLGA nanoparticles that physically encapsulated Nile red and PLGA
nanoparticles prepared from fluoresceinamine-coupled polymer.[250]
Xu et al. reported that the increase in intracellular fluorescence inten-
sity observed with physically entrapped markers was a result of dye
transfer rather than particle uptake.
To sum up, there are still several crucial open questions about the
fate of endocytosed PLGA particles and potential intracellular targeting
strategies. Targeting to organelles other than the nucleus (such as mito-
chondria) is still in its beginnings.[236] For further elucidation, labeling
procedures should be applied that guarantee a stable association of
the marker with the carrier throughout the whole study. Despite the
mentioned challenges, the increasing knowledge about the mechanisms
of intracellular pathogen trafficking might enable new strategies for
organelle-specific delivery in the future.[251, 252]
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Prolonged circulation time When “foreign” nano- or micropar-
ticles are injected into the bloodstream, these materials are rapidly
cleared from systemic circulation. This removal is the consequence of
a coordinated interplay between the adsorption of serum proteins at
the particle surface and a subsequent uptake of the colloids by cells
of the RES. Phagocytosis of particles is predominantly achieved by
Kupffer cells in the liver, but also by macrophages in the spleen and, to
a lesser extent, by macrophages in the bone marrow. It has been known
since 1903 that specific serum proteins are involved in the labeling
of particles as “foreign.”[253] These opsonins can be categorized into
immune opsonins, which interact with receptors on macrophages to
stimulate endocytosis (immunoglobulin G and complement proteins
C3 and C3b) and nonimmune opsonins (fibronectin, C-reactive protein,
tuftsin, mannose-binding protein, and lipopolysaccharide-binding pro-
tein), which alter the particle’s surface characteristics and thus render
it more adhesive to phagocytes.[254] In contrast to opsonins, dysop-
sonins such as IgA and α1-acid glycoprotein have been suggested to
function as adsorptive serum components that play a regulatory role in
inhibiting phagocytosis.[254, 255, 256] For a more detailed discussion
of the mechanisms underlying the sequestration of particles from the
bloodstream, the reader is directed to excellent reviews from recent
years.[254, 256, 257, 258, 259, 260, 261]
As a consequence of the efficient removal by cells of the RES, it
arises that if the spleen or liver are not the primary targets of nanopar-
ticulate delivery systems, the particles will have to be disguised in
order to evade the body’s defense mechanisms and to avoid inflam-
matory responses. Appropriate engineering of stealth particles will
consequently be necessary for the successful application of nano- and
microparticles as circulating drug reservoirs with controlled release
properties, as artificial oxygen carriers, as vasculature imaging agents,
and as passive and active targeting devices.[262] In order to reduce
the interaction of particles with macrophages and to limit protein ad-
sorption, adaption of the particle size and surface coating techniques
have been proposed. Generally, keeping the size of the particles un-
der 100 nm seems to be advantageous for prolonging blood half-life.
Supposedly, this is due to the low surface area per particle, in combi-
nation with the high curvature that does not promote adsorption of
the proteins needed for complement activation in a proper geometric
configuration.[262, 256, 261] The complement system consists of more
than 20 plasmatic proteins with enzymatic or binding capabilities and
some receptors on cells. Adsorption of serum complement proteins and
subsequent activation of the complement cascade can be determined
with the complement activation assay,[261, 263, 264] and should always
be validated by using zymosan particles as a positive control.[259] In
addition to particle size, high charge density, and hydrophobicity of
the surface have been identified as characteristics that promote serum
protein adsorption.[256, 261] This is in agreement with theoretical pre-
dictions indicating that ionic and hydrophobic interactions, along with
an entropy gain caused by changes in protein conformation, represent
the driving forces for protein adsorption.[265] Consequently, in order
to render biodegradable PLGA nanoparticles long-circulating, the hy-
drophobic and negatively charged particle surface has to be shielded.
1.1 introductory works 55
This is expected not only to decrease opsonization but also to minimize
interactions with macrophages.
To hydrophilize colloids, coating techniques with hydrophilic macro-
molecules have been investigated. While polysaccharides such as dex-
tran and heparin have been employed for this purpose and might be
advantageous due to their biodegradability,[266] most studies have
used PEG and its co-polymers for surface modification. Because PEG
contains a high number of ether groups that can bind water molecules
via hydrogen bonding, their anchoring at the particle surface introduces
a highly hydrated hydrophilic coating layer. This flexible layer sterically
stabilizes the particles, screens underlying surface charges, and reduces
the interfacial free energy, thus minimizing attractive forces for protein
adsorption.[261] In practice, the introduction of a PEG layer is accom-
panied by a decrease of the particle’s ζ-potential due to a shift of the
shear plane away from the particle surface.[263, 174] The efficiency of
protein repulsion is dependent on the MW of the PEG, the distance
between the surface grafting points, and the conformational flexibility
of the PEG chains.[261] For a detailed review on the interconnections
between these parameters see Vonarbourg et al.[261]
According to a theoretical model,[267] the optimal distance between
two terminally attached PEG chains should be in the range of 1 nm to
repulse small proteins (approximately 2 nm) and around 1.5 nm to re-
pulse large proteins (6–8 nm).[268] These theoretical predictions imply
that the particle surface has to be entirely covered by the PEG coating
to achieve sufficient repellence, and have been confirmed in studies
with PLA nanoparticles.[269, 179] Due to the wide variety of particle
matrix materials and grafting techniques described in the literature, it
is difficult to identify an optimal PEG chain length. However, coating
with PEGs in the MW size range between 1.5 to 3.5 kDa at appropriate
grafting densities seems to generate a high degree of protein repul-
sion in most systems.[261] Generally, techniques for the PEGylation of
PLGA nanospheres have comprised the production of particles from
blends of PLGA/PEG-PLGA,[270, 271, 272, 273, 274, 275] the use of
PEG-co-polymers as surfactants in course of the particle preparation
procedure,[31, 174, 276] as well as the adsorptive coating of preformed
particles with PEG-co-polymers.[46, 277, 108, 109, 31, 278]
By introducing hydrophilic PEG-blocks to the hydrophobic PLGA
backbone, polymers with amphiphile characteristics can be prepared.-
[279] Despite higher water uptake into the particle matrix, particles
prepared from PEG-PLGA oligomers are expected to be character-
ized by similar degradation characteristics as particles prepared from
PLGA.[280] Upon cleavage of the ester bonds, the PEG molecules
will be liberated from the carrier and excreted mainly via the kid-
neys if the MW is in the range of 1 to 20 kDa.[279] The preparation
of nano- and microparticles from PEG-PLGA can be achieved with
or without additional stabilizer by emulsification solvent evaporation
procedures, solvent displacement, salting out,[281] and hydrodynamic
flow focusing,[282] respectively. The surface density of PEG chains can
be controlled by varying the ratio of the PLGA/PEG-PLGA blends
used for particle preparation. In combination with the MW of the PEG,
surface density determines whether the coating layer will mainly exist
in a brush- or mushroom-like conformation.[279, 261]
As illustrated by studies with PLA/PEG-PLA blends, the majority
of PEG chains orient themselves towards the outer aqueous phase in
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the course of particle formation.[179] When incubated with serum and
subsequently analyzed regarding the particles’ protein adsorption pat-
tern by 2D-PAGE, protein-repellent properties were already observed
at blending ratios of 0.5:99.5 (PEG-PLA:PLA). However, the highest
protein repellence compared with nanoparticles prepared from plain
PLA was observed with blending ratios of at least 5:95 and a conjugate
of PLA (MW approximately 45 kDa) with a PEG chain of at least 5
kDa MW.[179] The calculated distance between two terminally attached
PEGs in this system corresponded to about 1.4 nm, which is in the
theoretically predicted range for optimal protein repulsion.[268] In
relation to these findings, a recent study has indicated that nanoparti-
cles made from PEG-PLGA might be characterized by an even higher
resistance to protein adsorption.[272] When comparing the protein
adsorption capacity of particles made from co-polymers of PEG with
the polyesters poly(ε-caprolactone) (PCL), PLA, and PLGA, the high-
est degree of polymer core protection from opsonization was ob-
served for PLGA-PEG. Similarly prepared PEGylated PLGA nanoparti-
cles have not only exhibited low protein adsorption, but also altered
biodistribution.[271, 273, 274] In order to be able to track the nanoparti-
cles in vivo and to determine their uptake into different tissues, 125I-
cholesterylaniline was encapsulated as radiolabel. Upon intravenous
injection in rats, a clearly prolonged blood circulation half-life was ob-
served for the PEGylated nanoparticles (approximately 7 h) compared
with colloids produced from plain PLGA (approximately 15–35 s). Fur-
thermore, uptake of the particles into spleen and liver was drastically
reduced.[271] These results were confirmed by the same authors in
mice; however, it should be highlighted that the nanoparticles used in
all three studies exhibited a broad size distribution, as indicated by
polydispersity indices of ￿ 0.3.248 Using a similar approach to radio-
labeling, Li et al. encapsulated 125I-BSA as a model protein drug into
nanoparticles made from PLGA or PEG-PLGA.[270] After encapsula-
tion into PEGylated particles, the plasma half-life of BSA was increased
from 13.6 min for plain PLGA carriers to about 4.5 h. Moreover, the
biodistribution profile of PEG-PLGA particles was altered, indicating
increased localization of BSA-loaded particles in the spleen and lung
instead of the liver.[270]
In addition to the production of colloids from PEG-PLGA, PEGyla-
tion of preformed PLGA nano- and microparticles has been achieved by
surface modification with a variety of PEG-copolymers via hydropho-
bic or electrostatic interactions. Because a large body of research has
been generated on the successful coating of PS nanoparticles with
poloxamers and poloxamines in the 1980s and 1990s,[259, 262] surface
modification of PLGA with these block co-polymers of PEG and PPG
suggested itself. Indeed, addition of poloxamer 407 or poloxamine 904
or 908 during the preparation procedure or adsorption onto preformed
PLGA nanospheres generated long-circulating colloids with altered
biodistribution in rats and rabbits.[31] However, while 39% and 28% of
the administered dose of poloxamer 407- and poloxamine 908-coated
particles, respectively, were detected 3 h post injection, only about 5%
of plain and poloxamine 904-modified particles remained circulating
in the bloodstream. The rather high sequestration of poloxamine 904-
modified nanospheres was attributed to the comparably short PEG
blocks (4× MW approximately 0.6 kDa) compared with poloxamer
407 (2× MW approximately 4 kDa) and poloxamine 908 (4× MW ap-
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proximately 5 kDa). Interestingly, coating in course of the preparation
procedure or onto preformed particles led to similar alterations of the
biodistribution profiles.[31] This is remarkable, because it has been
shown that poloxamer 407 and poloxamine 908 adsorbed onto pre-
formed PLGA nanoparticles are displaced by serum proteins.[277] To
monitor the displacement rate, the two surfactants were radiolabeled
with 125I Bolton-Hunter reagent and adsorbed onto particles made
from PLGA and PS. Upon incubation in phosphate-buffered saline
(PBS) for 24 hours, a removal of ~5% of surfactant was monitored.
However, upon incubation in serum ~20% of surfactant was removed
from PS nanospheres. In the case of PLGA nanoparticles, displace-
ment was even more pronounced as illustrated by 71% removal of
poloxamer 407 and 78% of poloxamine 908.[277] Although the studied
PEG-copolymers are obviously rather weakly linked to the PLGA ma-
trix, these carriers were characterized by prolonged plasma half-lives
and a biodistribution shifted away from the liver.[278] When PEG-PLA
was used as the coating polymer, varying biodistribution profiles were
observed.[174] By coating PS and PLGA nanoparticles with PEG-PLA
copolymers or poloxamine 908, hydrophilic colloids were generated
(as monitored by HIC). However, while all coated PLGA nanospheres
were characterized by prolonged plasma half-lives upon injection in
rats, only PS particles coated with poloxamine 908 exhibited stealth
properties 3 h post-injection. Although the PS nanospheres coated with
PLA-PEG were characterized by an altered biodistribution shortly after
administration, no differences were observed after 3 h compared with
plain particles. This was attributed to potential differences in the affinity
of the PLA-block to PS and PLGA as particle matrix materials.[174]
The modification of preformed PLGA nano- and microparticles has
also been achieved using an electrostatic coating approach with PLL-
PEG.[46, 108, 109] The PEG segments are anchored to the particle
surface via ionic interactions between the polycationic PLL-backbone
and carboxyl groups at the particle interface. In addition, coating of
PLGA nanoparticles with protein-repellent carbohydrate derivatives
has been investigated.[128] HES, which is fully biodegradable, was con-
jugated to lauric acid, and the resulting amphiphilic HES-laurates were
used as a stabilizer in course of the production procedure. These PLGA
nanoparticles adsorbed similarly low levels of BSA and fibrinogen as
poloxamer 407-coated colloids. Moreover, reduced phagocytosis of the
HES-laurate-modified particles by a monocyte macrophage cell line
was observed.[128]
In conclusion, the coating of hydrophobic and negatively charged
PLGA nanoparticles with PEG or polysaccharide derivatives results in
hydrophilization of the particle surface. Even with theoretically opti-
mal PEG surface densities, no complete inhibition, only a reduction
of serum protein adsorption, was observed.[179] Nevertheless, several
reports have described a drastically increased plasma half-life and al-
tered biodistribution upon coating of PLGA nanoparticles with PEG,
indicating success of this approach for engineering long-circulating
nanoparticles. However, it remains to be addressed whether PEGy-
lated PLGA nanoparticles retain their long-circulating properties upon
repeated administrations. In the case of poloxamer- and poloxamine-
modified PS nanospheres, it has been shown that PEGylated particles
administered in a second injection 3 to 13 d after the first injection
are rapidly removed by the RES.[283] This was attributed to an ac-
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quired ability of liver and spleen macrophages to recognize the injected
colloids. Furthermore, it is not clear whether the coating techniques gen-
erate homogenous PEG layers at the particle surface. Using HIC, a study
has indicated that heterogeneities in surface coating might be responsi-
ble for the premature removal of fractions of PEGylated carriers.[263]
Finally, the introduction of cell-specific homing moieties at the protein-
repellent surface layer has been achieved recently and represents a
crucial step forward to fully exploring the potential of long-circulating
PLGA nanoparticles as targeted drug-carrier devices.[46, 109, 228]
Tracking Sensitive analytical detectability is a crucial prerequisite
for in vivo and in vitro studies dealing not only with biodistribution
and elimination kinetics, but also with cytoadhesion, cytoinvasion, and
intracellular trafficking of nano- and microparticles made from PLGA.
The most commonly employed labeling techniques are based on the
tagging of particles with fluorophores or radioisotopes.
Fluorescence labeling Fluorescence-based labeling techniques have been
the methods of choice to render polymer particles trackable for in vitro
cell interaction studies. The most frequently used concept is based
on the encapsulation of a fluorescent dye in the polymer matrix in
course of the preparation procedure of the particles. PLGA nano-
and microparticles have mainly been labeled with hydrophobic fluo-
rophores such as 1,1’-dioctadecyl-3,3,3’,3’-tetramethylindocarbocyanine
perchlorate (DiI),[128, 284] 3,3´-dioctadecyloxacarbocyanine perchlo-
rate (DiO),[165] BODIPY® 493/503,[285] BODIPY® FL,[286] coumarin
6,[46, 88, 198, 240] pyren,[93] or Nile red.[250] However, hydrophilic
dye molecules such as rhodamine 123,[227] rhodamine 6G,[287, 114]
rhodamine B,[288] dextran-rhodamine,[105] indocyanine green,[289]
as well as quantum dots,[290] have also been employed. Additionally,
Panyam et al. developed a dual labeling technique with coumarin 6 and
osmium tetroxide, yielding colloids that can be detected by fluorescence
and electron microscopy.[291] Dye-labeled PLGA conjugates primarily
have been synthesized by carbodiimide-mediated activation of the un-
capped polymer backbone and subsequent reaction either directly with
the fluorescein derivatives fluoresceinamine[250, 292] or fluorescein
cadaverine[75] or via a diamine spacer with carboxyfluorescein[293] or
FITC.[109] Moreover, Tosi et al. have described a method for synthesiz-
ing a versatilely applicable, biotin-capped derivative of PLGA. Particles
made from this polymer were tracked in tissue sections by electron
microscopy after reaction with a streptavidin-peroxidase conjugate and
subsequent incubation with
diaminobenzidine.[293] Speaking from experience in our laboratory,
the binding of avidin to biotin-modified nanoparticles, however, can be
clearly limited in the presence of proteins. This is probably due to pro-
tein adsorption at the particle surface, which leads to steric obscuration
of the small biotin binding site (unpublished results). Considering this,
a versatile two-step approach for the decoration of particles with biotin
as reported by Müller et al. seems more promising.[108] A cationic PLL-
g-PEG-biotin conjugate, which adsorbs to the negatively charged PLGA
surface via the PLL-block, was used to introduce sterically flexible
biotin for subsequent labeling with Oregon Green®-streptavidin.
1.1 introductory works 59
Furthermore, the covalent fluorescence labeling of preformed par-
ticles has been investigated. Following activation of surface carboxyl
groups and amination with ethylene diamine, the introduced amino
groups on PLGA microspheres were subsequently conjugated with
FITC.[294] In addition to this rather complicated two-step procedure,
direct surface modification of PLGA nano- and microparticles with
fluorescent entities also has been reported. The well-established carbodi-
imide chemistry was used to covalently immobilize fluorescein-tagged
proteins[295, 296] or amine-functionalized quantum dots.[249]
Radioactive labeling The techniques for the modification of PLGA parti-
cles with radioactive isotopes rely on similar rationales as fluorescence
labeling. Primarily, radioactive labeled particles have been used ana-
lytically to investigate the effect of surface modifications with PEG or
PEG-containing surfactants on the biodistribution of PLGA particles
in rodents.[270, 297, 298, 299, 300] In addition, the possibility of using
radioactive particles for the delivery of a radiation dose to tumor tis-
sue was discussed.[301] Several studies report the labeling of PLGA
particles by encapsulation of small molecules or proteins conjugated to
radioactive isotopes. These include 188Re-dimercaptosuccinic acid,[301]
111In-oxine,[31, 174, 297] 3H-paclitaxel,[302] 125I-cholesterylaniline,-
[271] 125I-tetanus toxoid,[84] and 125I-tagged BSA.[270] Direct labeling
of PLGA has been achieved by reaction of 14C-acetic acid anhydride
with terminal hydroxyl groups of the polymer chains.[303] Furthermore,
the widely used approach for the labeling of proteins and proteinaceous
colloids with metastable 99mTc by stannous reduction has been applied
to pre-formed PLGA particles.[298, 299, 300] While the reaction mech-
anism underlying the conjugation of 99mTc to proteins is clear,[304]
detailed information about the labeling of polymeric particles is scarce.
A lowering of the valency state of 99mTc by the reducing agent stannous
chloride and subsequent complexation with amine groups has been
proposed as the labeling mechanism for chitosan nanoparticles.[305]
The adsorption of 99mTc onto PLGA particles is probably driven by the
high affinity of multivalent cations for negatively charged interfaces.
Radiolabeling of PLGA nanoparticles has also been achieved by coat-
ing of plain colloids with radioactively tagged poloxamers and
poloxamines.[277, 299] The hydroxyl end group of the PEG-containing
surfactants is aminated and subsequently conjugated with 125I-hydroxy-
phenylpropionic acid. The interested reader is directed to Neal et
al.[277] for a comprehensive discussion of reaction schemes and for
alternative approaches to the radioactive labeling of PEGs.
In conclusion, it has to be highlighted that adequate labeling of
particles made from PLGA, especially using fluorescent dyes, is not
trivial. Although the degradation half-life of PLGA lies well beyond
the time scale of most in vitro cell-interaction studies, marker is al-
ready expected to be released from the particles in the course of
short experiments.[306, 250] As a rule of thumb, small hydrophilic
dye molecules cannot be efficiently loaded and are poorly retained
in the particle matrix. However, low-MW hydrophobic compounds
also suffer from premature release. As illustrated by recent reports,
the extent of this leakage probably has been underestimated so far
due to the use of protein- and lipid-free buffer systems for the lib-
eration tests.[250, 307] The consequences of this have not necessarily
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hampered the interpretation of studies using microparticles because
their relation to free label in physical size is unambiguous. However,
in the case of nanoparticles optical microscopy hits on its resolution
limits and discrimination between free marker molecules and parti-
cles becomes a tremendous challenge. The resulting susceptibility of
nanoparticle-cell interaction studies to misinterpretation has been dis-
cussed recently.[250, 307] Considering this, it becomes clear that results
solely based on fluorescence detection should be interpreted with par-
ticular care. To improve the value of studies in this field, limitations
of existing protocols have to be addressed and the development of
more effective labeling approaches is strongly needed. From the current
perspective, covalent modification of PLGA seems promising due to
the stable linkage between marker molecules and the polymer. The
encapsulation of hydrophobic, high-MW species such as quantum dots
might prove to be a valuable alternative, because their diffusion co-
efficients in the particle matrix are expected to be clearly lower than
those of low-MW compounds. In the long run, however, an integration
of ultrastructure-resolving techniques will be needed to fully resolve
the cytoadhesive and cytoinvasive properties as well as the subcellular
trafficking of polymer nanoparticles.
Stabilization of biomacromolecules Because it was shown in the
early 1990s that biomacromolecules can be encapsulated into PLGA
microspheres and might thereby be protected from degradation,[308]
numerous studies have investigated the delivery of peptides, proteins,
oligonucleotides, and DNA using carriers made from PLGA.[58, 309,
310] However, several difficulties have been found to be associated with
this concept. First, although the encapsulation of hydrophilic molecules
is feasible using water-in-oil-in-water solvent evaporation techniques,
the loading efficiency is often limited. Second, the dispersion steps in-
volved in particle preparation are associated with contact with organic
solvents and shear stress due to sonication or homogenization. These
processes might result in denaturation of the biomacromolecules during
encapsulation.[311, 312] In addition, molecules incorporated in a PLGA
matrix are increasingly exposed to an acidic microclimate by time. This
has been visualized recently by confocal laser scanning microscopy
and is a consequence of polymer hydrolysis and the accumulation of
degradation products in aqueous pores.[313, 314] While the stability of
drug released during the “first-burst” phase is not necessarily compro-
mised, pronounced degradation might occur over the course of later
stages of release.[315] Several strategies have been proposed for the
stabilization of labile biomacromolecules under these circumstances,
including complexation of proteins with zinc, the addition of PEG,
and co-encapsulation of antacid excipients.[312, 316] An alternative
approach to circumvent these limitations is based on the adsorption of
the biomacromolecules to be delivered onto the surface of preformed
nano- and microparticles made from PLGA.[104, 317]
Because the coating is applied to preformed particles, exposure of
the biomacromolecules to potentially deleterious solvent and shear
conditions is avoided. Furthermore, the release of the payload from
the carrier proceeds relatively quickly and is not strictly dependent
on the slow bulk erosion release kinetics of PLGA.[105] This might
prove especially advantageous in the case of vaccination, as a typical
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phagocytic cell only has a lifespan of several days.[185] Because it has
been reported by several groups that loading of biomacromolecules
onto the particle surface can provide sufficient protection against en-
zymatic degradation,[104, 130] the delivery of proteins,[103, 132, 133,
152, 294, 318, 319] plasma membrane preparations,[320] tumor cell
lysates,[320] oligonucleotides,[95, 321] and pDNA[74, 92, 102, 104, 105,
115, 130, 322, 323, 324, 325, 326] has been investigated. While direct
coating of plain PLGA particles has been achieved,[318, 327] precedent
surface functionalization with excipients has proven advantageous for
enhancing the efficiency of the subsequent coating. Heparin, for exam-
ple, is characterized by a high binding affinity to growth factors such
as FGF (fibroblast growth factor), VEGF (vascular endothelial growth
factor), HBEGF (heparin-binding epidermal growth factor), and TGF-β
(transforming growth factor-β). Making use of this affinity, Chung et
al. showed that conjugation of heparin to the surface of highly porous
uncapped PLGA particles via carbodiimide chemistry generates micro-
spheres with 4-fold higher FGF-loading capacity compared with plain
particles.[294]
Coating of PLGA particles with cationic polyelectrolytes or am-
phiphilic molecules can also enhance the binding capacity for biomacro-
molecules. PLGA nano- and microparticles have been regarded as
promising biodegradable antigen carriers and adjuvants for the formu-
lation of vaccines.[185, 328, 329, 330] Because vaccines made from puri-
fied preparations from pathogenic organisms or recombinant proteins
are often not sufficiently immunogenic, site-specific delivery systems
are needed to optimally present the antigen to the innate and adaptive
immune systems.[330] Nanoparticles might prove beneficial for this
purpose because they diffusively spread upon injection and can reach
lymph nodes.[185] To date, however, microparticles have been studied
more extensively. Due to their relatively large size, microparticles are
minimally taken up by nonphagocytic cells but can be internalized by
APCs such as macrophages or DCs. This passive targeting effect sup-
posedly leads to preferential delivery to APCs and has been reported
to be most pronounced for particles in the size range of 1 to 3 ￿m.[330]
Microparticles produced from PLGA have been investigated as po-
tential carriers for protein antigens. One approach is based on the
formation of particles from blends of end-capped PLGA and the an-
ionic amphiphile dioctyl sulfosuccinate. The resulting microparticles are
characterized by a negative ζ-potential and have been shown to adsorb
proteins such as ovalbumin, carbonic anhydrase, lysozyme, lactic acid
dehydrogenase, BSA,[152] the recombinant proteins MB1/MB2 from N.
meningitides,[152, 133] recombinant p55 gag from HIV-1,[132] and the
recombinant HIV envelope glycoprotein gp120dV2.[152, 319]In the lat-
ter, adsorptive coating of the particles retained the antigenic structure of
the glycoprotein, while encapsulation into PLGA microparticles did not.
According to protein quantification by size-exclusion chromatography
and the bicinchonic acid assay, the highest loading rate with gp120dV2
(isoelectric point approximately 8.5) was achieved at pH 5. This indi-
cates a preferential adsorption of positively charged protein molecules
onto the negatively charged carriers via ionic interactions.[319] The
importance of the isoelectric point in protein adsorption was confirmed
in MB1/MB2, in which the highest loading rates on negatively charged
PLGA microparticles were observed for the positively and noncharged
form of the protein, respectively.[133] In addition, positively charged
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microparticles have been investigated as protein carriers. Mandal et
al. used PEI- and PLL-coated PLGA microparticles for the delivery of
granulocyte-macrophage colony-stimulating factor (GM-CSF), which
is a differentiation factor for hematopoietic progenitor cells and may
act as an adjuvant.[103] Similar amounts of GM-CSF adsorption were
monitored on plain and polyamine-modified particles, hinting at a
dominant role of the hydrophobic PLGA matrix for this protein.
In recent years, gene-based vaccination has evolved as an alternative
to traditional vaccine strategies.[185, 310] The transfection of cells with
pDNA results in sustained intracellular antigen production, which in
turn can lead to a coordinated activation of humoral and cell-mediated
immune responses. Because delivery of naked pDNA is severely limited
due to premature enzymatic degradation,[331] alternative approaches
have been investigated using polymeric particles as carriers.[185, 330]
For example, particles were prepared containing encapsulated naked
or polyamine-complexed pDNA.[310, 332] Because naked pDNA is
prone to degradation in course of the particle preparation process,[311]
approaches based on the encapsulation of pDNA complexed with
PLL [331] or PEI [333, 334] have proven to be more promising. The
polyamines form stable complexes with pDNA due to electrostatic
interactions between amine and phosphate groups. This has been shown
to stabilize pDNA during particle formation and limits its susceptibility
to enzymatic degradation by DNAse I.[331] Furthermore, free amino
groups of the polyelectrolyte are expected to buffer the intraparticular
pH drop during polymer erosion, which will also contribute to the
stability of the formulation.[333]
As an alternative approach, pDNA has been loaded onto the surface
of PLGA particles modified with cationic surfactants or polyelectrolytes.
Several studies, especially those by Singh et al., have dealt with the
applicability of the cationic amphiphiles CTAB, DDAB, and DOTAP for
the introduction of positive charges at the surface of end-capped PLGA
microparticles during particle preparation.[130, 199, 322, 323, 325, 335]
Positively charged carriers, primarily modified with CTAB, have been
loaded with plasmids encoding antigens fromM. tuberculosis,[336] avian
metapneumovirus,[337] foot and mouth disease virus,[338] hepatitis B
virus,[339] hepatitis C virus,[335] HIV,[130, 322, 323, 325] and measles
virus.[340] By varying the amount of CTAB used for particle coating, the
loading efficiency and release rate of pDNA can be regulated.[323, 325]
The amount of pDNA associated with the microparticles was deter-
mined by agarose gel electrophoresis or after ultracentrifugation of
the loaded particles into an OptiPrep® density gradient, complexation
with ethidium bromide, and fluorometric analysis of the gradient frac-
tions. Compared with naked pDNA, CTAB-modified particles loaded
with pDNA were found to elicit higher immune responses, possibly
due to an adjuvant effect of the cationic particles.[130, 322, 323] The
sequential loading of two plasmids encoding the antigens p55 gag and
gp-140 of HIV-1 has also been reported.[325] While only low loading
levels were achieved for unmodified particles, the plasmids were effi-
ciently adsorbed to cationic PLGA particles. Furthermore, protection of
surface-adsorbed pDNA from degradation by DNAse I was observed
in vitro.[325] In contrast to these observations, Oster et al. have re-
ported that coating of negatively charged particles with CTAB does
not provide protection of pDNA against degradation by DNAse I.[104]
However, surface modification with branched PEI (MW approximately
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25 kDa) led to highly positive carriers that protect surface-adsorbed
plasmids from enzymatic cleavage. While naked pDNA was degraded
by DNAse I within 5 min, pDNA adsorbed onto PEI-coated particles
was stable for about 12 h. PEI/PLGA blends also have been frequently
used for the preparation of nanoparticulate transfection vectors that
bear a positive surface charge and have been successfully loaded with
plasmids.[102, 115] Moreover, covalent conjugation of PEI onto the par-
ticle surface has been investigated.[74, 105, 324] Polyamine anchoring
at the surface of preformed microparticles is probably a result of a
combination of electrostatic interactions and the formation of covalent
bonds via active esters. According to Pai Kasturi et al., covalently modi-
fied PEI-PLGA particles are characterized by 5-fold enhanced pDNA
adsorption efficiency compared with plain particles.[341] Furthermore,
it was observed that surface modification with linear PEI (MW approx-
imately 25 kDa) led to a quicker release of plasmid and decreased
buffering capacity toward acid titration compared with branched PEI
(MW approximately 70 kDa).
Whether these observations were due to varying degrees of complex-
ation of pDNA by linear and branched PEI could be investigated with
an ethidium bromide replacement assay.[82] By mixing plasmids with
ethidium bromide, pDNA with intercalated fluorophores was obtained.
Upon adsorption of pDNA prepared in such a manner onto PLA par-
ticles coated with branched PEI, different amounts of free “squeezed
out” ethidium bromide were detected. Coating with “coiled” PEI re-
sulted in particles with a high potency for DNA condensation and thus
high replacement of ethidium bromide. In comparison, particles coated
with PEI that had been adsorbed in a “stretched” conformation were
characterized by less free surface charges and a consequently decreased
potency for complexation.[82] Chitosan has also been used for the
preparation of positively charged PLGA nanoparticles that were sub-
sequently coated with plasmids [92] or antisense oligonucleotides.[95]
According to AFM studies, pDNA-chitosan complexes appeared to
form clusters at the particle surface.[92] Another interesting approach
for the introduction of a surplus of positive charges on uncapped
PLGA particles is the conjugation with PAMAM dendrimers.[326] Mi-
croparticles were conjugated with third- to sixth-generation PAMAM
dendrimers by carbodiimide coupling chemistry. As determined by
UV-spectrophotometric analysis (absorption, 260nm) of the coating
solution’s residual pDNA content, 5-fold higher pDNA loading ef-
ficiencies were obtained on PAMAM-modified compared with plain
particles. While the ζ-potential and buffering capacity toward acid
titration increased with increasing dendrimer generation, the transfec-
tion efficiency was constantly higher than that of pDNA-loaded plain
particles but was not influenced by dendrimer generation.[326]
The development of particle-based vaccination strategies has also
included the loading of microparticles with immunostimulatory sub-
stances. Nonmethylated nucleotide sequences containing cytosine linked
to guanine by a phosphodiester (CpG DNA) belong to this group of
molecules. Sequences containing the CpG motif are frequently found
in prokaryotic DNA, but in vertebrate DNA they do not occur as abun-
dantly in their nonmethylated form.[321] Because CpG DNA induces
the conversion of immature DCs to mature APCs, they are considered
to be a promising class of vaccine adjuvants. By adsorbing phospho-
rothioate oligonucleotides containing CpG on cationic PLGA micropar-
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ticles, a potent immunostimulatory effect was observed in mice com-
pared with free CpG.[321] Similarly, poly(inosine)-poly(cytidylic acid)
(poly(I:C)), which is a synthetic analog of viral double-stranded RNA
characterized by affinity for toll-like receptor 3, also serves as a mat-
uration signal for DCs.[342] Poly(I:C) electrostatically adsorbed onto
PLGA microparticles coated with cationic diethylaminoethyl dextran
was observed to be a more potent inductor of DC maturation compared
with the free soluble substance.[101]
As illustrated, the rationale of adsorbing plasmids, proteins, or anti-
sense oligonucleotides onto the surface of preformed particles repre-
sents a promising approach for gene- and antisense-delivery as well
as vaccination. Moreover, surface-based techniques offer the possibility
to co-deliver substances encapsulated in the particles. The feasibility
of this approach has been shown by adsorption of a plasmid encod-
ing luciferase onto the surface of PLGA microspheres with encapsu-
lated FITC-BSA.[105] These first proofs of principle could stimulate
the development of bifunctional vaccine formulations with pDNA/pro-
tein antigen at the particle surface for a “first burst” and encapsu-
lated pDNA/protein for sustained delivery to enhance the immune
response.[309] Moreover, biodegradable delivery systems carrying the
antigen and immunomodulatory substances could be prepared and
decorated with targeting moieties. However, for these approaches to
be successful, the surface adsorption protocols yielding high loading
efficiencies and protection of the biomacromolecules from degradation
have to be identified. It also remains to be addressed whether adsorp-
tive coating techniques generate sufficiently stable linkages, because
relatively quick displacement of proteins from the carrier system can
occur due to competitive adsorption of serum proteins.[103]
1.1.2.5 Future challenges
Despite the mentioned large number of successful proof-of-concept
studies, several challenges still have to be overcome on the way to
successful clinical application of surface-modified PLGA-based carri-
ers. Until now, most of the reported methods for the preparation and
surface modification of PLGA particles involved rather small batches.
A scale-up to large production volumes will certainly introduce addi-
tional challenges. Moreover, reasonable production costs will remain
an important prerequisite for successful application.
In order to prevent unwanted effects that might be caused by resid-
ual reagents, efficient purification methods are needed. The removal
of reagents applied for surface modification has rather been neglected
so far. Currently, particle suspensions are most often purified by meth-
ods that exploit the difference in size between the particles and the
employed reagents, such as centrifugation,[76, 77, 80, 343] ultracentri-
fugation,[201, 205] diafiltration,[344] size-exclusion chromatography,-
[218, 226] or dialysis.[234, 146] However, these methods are generally
intricate and time-consuming and they do not allow for a quantitative
elimination of unwanted reagents. Future functionalization strategies
will have to consider these limitations.
As a basis for further advancements, a more detailed understanding
of PLGA particle morphology is also required. Although electron mi-
croscopy enables a very high magnification, the resolution that may be
achieved upon imaging of PLGA particles is strictly limited. Due to
the low glass transition temperature of PLGA of about 40°C, the par-
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ticles quickly start to “melt” upon irradiation with the electron beam,
which may result in artifacts. So far, SEM has enabled valuable insights
concerning the size and porosity of PLGA microparticles.[345] With
cryo-TEM or via freeze-fracture replica, even PLGA particles in the
submicron range have been visualized.[159] However, the only reliable
information obtained was about the size and the overall shape of the
PLGA nanoparticles. Electron microscopy is a valuable complement
for other frequently used sizing techniques such as photon correlation
spectrometry, which can only determine the hydrodynamic diameter of
suspended particles and is influenced by numerous parameters.[344]
Because the molecules typically used for surface modification of PLGA
particles have a diameter of only a few nanometers at the largest, their
presence and conformation cannot be evaluated by currently available
electron microscopic techniques; at best, it is possible to distinguish
between smooth, rough, and porous surfaces.[114]
Alternatively, AFM (also known as scanning probe microscopy)[346]
has been explored to characterize the morphology of PLGA particles.
In AFM, the sample surface is scanned with a mechanical probe to
generate a topographic map of the sample. Additionally, this technique
can be used to gain information about the rigidity of the sample or
even about the affinity of ligand-receptor interactions. In contrast to
SEM, not only dry but also liquid samples can be imaged, and it is not
necessary to work under vacuum. Nevertheless, AFM is most useful
for the characterization of rather flat surfaces, and it is not possible to
examine steep walls or overhangs. Moreover, the particles need to be
immobilized prior to imaging, which is often a tedious task. Concerning
PLGA particles, the method is still in its infancy. So far, it is possible to
reliably determine only the particle size and shape and to distinguish
between smoother or rougher surfaces.[92]
Aside from the characterization of the nano- and microparticles them-
selves, their distribution in a complex organism and their interaction
with specific cells need to be investigated using appropriate models.
Typically, in vitro experiments are performed in stationary setups with
particles dispersed in buffer. However, the stability of plain and surface-
modified particles might be compromised substantially in physiological
media with high protein content.[99] It has been observed that charged
particles preferentially accumulate in certain tissues,[347, 348] but it
is not clear whether this is due to ionic interactions between particles
and endothelial cells or whether plasma protein adsorption or microag-
gregate formation also play a decisive role. To accurately study the
interaction of particles with tissues that are exposed to flow in vivo (en-
dothelium, urinary tract epithelium, gastrointestinal tract), alternatives
to currently used stationary assays have to be developed.[349, 296] Us-
ing a microfluidic flow chip, it has been shown recently that plain PLGA
microparticles are characterized by negligible bioadhesion in the pres-
ence of hydrodynamic drag.[296] Consequently, in order to engineer
drug carriers that efficiently adhere to a target tissue in the presence
of shear forces, sophisticated surface functionalization strategies might
have to be developed.
1.1.2.6 Outlook
In 2004, Nutropin Depot, the first and only marketed protein-loaded
PLGA microparticle formulation, was withdrawn from the market
because of high costs. This fact does not encourage further research
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in this area, but only at the first sight. Apart from profit and demand,
PLGA micro- and nanoparticles including covalently functionalized
ones will gain ground in three fields of application in future.
In the broad and sometimes sophisticated area of targeted therapy,
covalent conjugation of targeting ligands offers the advantage of sta-
ble attachment compared with possible detachment or even loss of
the ligand in the case of adsorptive immobilization. Additionally, the
biorecognitive ligand is antennary exposed toward the biological envi-
ronment, allowing optimal biointeraction compared with electrostatic
or adsorptive coating. The latter approaches sometimes suffer from
unknown folding of amphiphilic ligands, probably shielding the target
moiety, especially when cross-linking is required to stabilize the coat.
Nevertheless, two issues must be addressed: First, the biocompatibility
and biodegradability of surfactants used for the preparation of PLGA
particles has rarely been considered. Second, the covalent surface modi-
fication requires processing of the drug-loaded particle, which remains
time-consuming in spite of optimization. On the one hand, there is the
risk of premature drug loss due to the first burst effect; on the other
hand, this drawback might turn to an advantage when the release rate
is supposed to be controlled by diffusion and/ or erosion alone.
Targeted diagnostics will be another field of application for surface-
modified PLGA-nanoparticles. In particular, multi-labeling by simul-
taneous covalent immobilization at the surface of targeted particles
with contrast labels for magnetic resonance imaging (MRI), positron
emission tomography (PET), computerized axial tomography (CT), and
ultrasound[350] is a promising approach and beneficial for the patient.
In clinical practice, however, some combinations might be pointless.
Whereas fluorescent imaging is very useful in research, its utility in hu-
mans is highly questionable. With respect to patient comfort, imaging
should be feasible in one step, for example, by a combination of PET
and MRI. Finally, the most frequently stressed combination of therapy
and diagnosis (theranostics) by one particulate formulation might hit a
snag. Apart from the high costs for the health care system, the benefit
for a patient with an unknown disease remains questionable because
the particle will release the drug irrespective of sickness or health.
All in all, the increasing knowledge in surface modification of PLGA
particles will considerably contribute to realize Paul Ehrlich’s dream of
magic bullets for targeted therapy, although the bullets will be invisible
owing to their small size in the micro- or nanometer range.
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1.1.3 Cytoadhesion, internalisation and transcytosis of wheat germ agglu-
tinin (WGA) investigated by electron microscopy
1.1.3.1 Introduction
Associated with the external face of the plasma membrane of eukaryotic
cells is the glycocalyx which consists of sugar moieties of glycosylated
membrane lipids and proteins. Mainly, these contain galactose and
galactosamine, glucose and glucoseamine, sialic acid, mannose as well
as fucose. At maximum, carbohydrate side chains carry fifteen saccha-
ride residues. The composition of this carbohydrate coat differs between
cell types and is subject to variations upon malignant transformation
of a cell.[351] The glycocalyx thus represents a structure which can be
addressed to enhance the cytoadhesion of drug carriers to normal cells
and cancer cells in a potentially targeted way. In order to make use of
this rationale for drug delivery, lectins can be empolyed.
Lectins represent a group of proteins which specifically bind to
carbohydrates.[352] By screening a library of lectins, suitable candidates
are identified which mediate cytoadhesion to specific cell types. WGA
from triticum vulgare has been shown to exhibit high binding to bladder
cancer cells,[210] chondrocytes,[209] brain microvascular endothelial
cells,[353] as well as enterocyte-like cell lines such as Caco-2 cells.[354]
Moreover, the quantity of WGA-binding is increased upon malignant
transformation. WGA is a dimeric protein with MW ~36 kDa which
possesses two high and two low affinity binding sites for N-acetyl-
D-glucosamine and N-acetylneuraminic acid. Due to its binding to
enterocytes it has been discussed as a promising agent to enhance the
cytoadhesion and to thereby prolong the residence time of prodrugs
and drug carrier systems upon peroral administration.[5] Aside from
improving cytoadhesion, conjugation with WGA has been shown to
induce uptake of proteins [355] and possibly nanoparticles [285] into
cells. Moreover, evidence exists that WGA could serve as a shuttle to
mediate transcytosis across cell monolayers.[5]
To further understand these properties, the aim of the presented study
will be to investigate the cytoadhesion, internalisation and potential
transcytosis of WGA through Caco-2 cell monolayers. Caco-2 cells
morphologically and functionally resemble human enterocytes and
are an accepted cell model for permeability studies according to the
biopharmaceutics classification system (BCS). Thus, they have been
used extensively as an in vitro model for studies relating to intestinal
absorption.[356]Transmission electron microscopy will be employed to
resolve the temporal evolution of the ultrastructural localization of the
lectin.
1.1.3.2 Experimental setup
Cell culture The Caco-2 cell line was purchased from the Deutsche
Sammlung von Mikroorganismen und Zellkulturen (DSMZ; Braun-
schweig, Germany) and was used for the experiments between passage
35 and 54. Tissue culture reagents were obtained from Sigma (St. Louis,
USA) and Gibco Life Technologies Ltd. (Invitrogen Corp., Carlsbad,
CA, USA). Cells were cultivated in RPMI 1640 cell culture medium
containing 10% fetal bovine serum, 4 mM L-glutamine and 150 mg
mL−1 gentamycine in a humidified 5% CO2/95% air atmosphere at
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37°C and were subcultured by trypsination. Differentiated Caco-2 cell
monolayers were obtained by seeding of 120 µL of cell suspension
(1.05 x 105 cells mL−1) in ThinCertTM tissue culture inserts (0.4 µm
pore size, translucent; Greiner Bio One, Kremsmünster, Austria) and
cultivation for 21 days.
Pulse-chase incubation of cell monolayers withWGA-horseradish
peroxidase (HRP) The cell culture medium was removed from the
monolayers and replaced with isotonic HEPES/NaOH buffer pH 7.4
(isoHEPES) that had been cooled to 4°C. Upon incubation of the cell
layers for 15 min at 4°C, the buffer was replaced with 120 µL of a
precooled solution of WGA-HRP (20 µg mL−1) in isoHEPES followed
by incubation for 15 min at 4°C. Subsequently, the Caco-2 monolayers
were washed with isoHEPES twice. For chase-incubation, 120 µL of
isoHEPES warmed to 37°C was added and the cells were incubated
for 30 min or 60 min at 37°C. After one washing step with isoHEPES,
pulse- and chase-incubated cells were fixed by addition of 120 µL of a
2 % (v/v) solution of glutaraldehyde in PBS for 60 min at 4°C.
Preparation for electron microscopy The filters with attached
Caco-2 monolayers were excised from the insert and left to react with a
solution of 3,3’-diaminobenzidine (DAB; 0.5 mg mL−1) in TRIS/HCl
buffer pH 7.6 for 15 min under protection from light. The DAB was
removed and upon addition of a 1 % (v/v) solution of H2O2 and
reaction for 30 min the sample was washed thrice with distilled water.
Subsequently the sample was postfixed for 15 min with a 1:1 mixture
of aqueous solutions of potassium ferrocyanide (3%) and osmium
tetroxide (2%). After incubation with a 1% solution of osmium tetroxide
in veronalacetate buffer for 30 min at 4°C the cells were dehydrated
in a graded series of ethanol (70 % overnight at 4°C, 70 % for 10
min, 80 % for 10 min, 96 % for 10 min, 2 x 100 % for 10 min). The
dehydrated samples were embedded in Epon 812 epoxy resin (Serva,
Heidelberg, Germany) which was hardened for 2 days at 40°C followed
by 2 days at 60°C. Sections (80-100 nm) were cut with an UltraCut-UCT
ultramicrotome (Leica Inc., Vienna, Austria) and transferred to copper
grids.
Electron microscopy The cell samples were inspected in a Tecnai-
20 transmission electron microscope (Tecnai-20 LaB6, FEI Company,
Eindhoven, The Netherlands). Digital images were recorded with a
slow-scan CCD camera (MSC 794, 1k x 1k pixel, Gatan Inc., Pleasanton,
USA).
1.1.3.3 Results and Discussion
WGA extensively binds to the apical membrane of enterocyte-like
Caco-2 cells To be able to analyze the association of WGA with
Caco-2 cell monolayers, a conjugate of WGA with HRP was used. HRP
catalyzes the oxidation of the chromogenic substrate DAB and thus
enables indirect histological localization of WGA.
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Figure 5: Caco-2 cell monolayer incubated with wheat germ agglutinin (WGA)-
horseradish peroxidase (HRP) conjugate at 4°C. Nucleus (1), WGA-
HRP (blackening) predominantly bound to apical membrane with
microvilli (arrowheads). Filter (￿) and no staining observed at the
basolateral membrane (arrows) .
The 21-day old Caco-2 monolayers were cooled to 4°C in order to re-
duce the cellular metabolism and the fluidity of the plasma membrane.
At this temperature cytoadhesive agents are expected to bind to the
cellular membrane but no internalization will occur. As illustrated by
the blackening in Figure 5 (arrowheads), WGA was densely associated
with the apical side of the polarized cell monolayer upon loading for 15
min at 4°C. The homogenous staining of the apical plasma membrane
including the microvilli indicates a rather uniform distribution of carbo-
hydrate binding sites within the glycocalyx. At the intracellular region
proximal to the apical plasma membrane no blackening of endosomes,
multivesicular bodies or lysosomes was observed. This indicates no or
only minimal uptake of WGA-HRP into the cell in course of loading
at 4°C. The lack of staining of the lateral and basolateral plasma mem-
brane (Figure 5, arrows) underlines the functional integrity of tight
junctions and their barrier function for macromolecules dissolved in
the fluid phase or associated with the membrane. Interestingly, when
equimolar quantities of HRP were used in the same experimental setup,
no blackening of the apical membrane of the Caco-2 monolayer was
observed. This underlines the cytoadhesive properties of WGA which
can be transferred onto HRP by chemical conjugation with the lectin.
Regarding the predictive value of the employed cell model it has to be
highlighted that Caco-2 cells do not produce mucus and thus do not en-
tirely reflect the intestinal epithelial barrier in vivo. Binding of lectin to
mucus will at least partially result in its removal from the gastrointesti-
nal tract by mucus shed. However, WGA binding to mucus is reversible
and competitive with the binding to cell surface carbohydrates.[357]
Consequently, although mucus might initially capture WGA or WGA-
conjugated carrier systems, a reallocation to enterocytes is expected to
occur.
Membrane-bound WGA is internalized via endosomes Upon
removing of non-bound WGA-HRP and increasing the incubation
temperature to 37°C for 30min, the apical part of the cell membrane was
still occupied with a dense layer of WGA-HRP (Figure 6, arrowheads).
However, endosomes were already positive for WGA and fusion of
endosomes to multivesicular bodies had occured. This underlines that
membrane-bound WGA is indeed taken up by Caco-2 cells. The time
70 bioadhesive micro- and nanoparticles
Figure 6: Caco-2 cell monolayer loaded with WGA-HRP at 4°C and post-
incubated for 30 min at 37°C. Nucleus (1), early endosomes and
multivesicular bodies (2), apical membrane with microvilli (arrow-
heads), and filter (￿). Speckles of WGA-HRP (blackening) localized at
the lateral and basolateral membrane (arrows).
scales for internalization to occur are probably even shorter than 30
min. This is illustrated by the fact that WGA-positive endosomes were
already found after incubation for 15 min at 37°C (data not shown).
While no localization of WGA-HRP was observed at the lateral and
basolateral membrane after 15 min, isolated patches were detected after
30 min (Figure 6, arrows). Consequently, while most of the internalized
WGA was localized in singular and multivesicular endosomes, a small
fraction had already been transported to the (baso-)lateral plasma
membrane within 30 min.
Transcytosis of WGA The localization of WGA in Caco-2 monolay-
ers chase-incubated for 60 min at 37°C was similar to that observed
after 30 min. However, the quantities of WGA-HRP associated with the
different compartments had shifted. When comparing the blackening of
the apical plasma membrane (Figure 7 and Figure 8 (top image), arrow-
heads) with that after loading at 4°C (Figure 5, arrowheads), a slight
decrease in intensity is monitored. This indicates that the high concen-
tration of apically bound WGA-HRP is decreased by internalization
into the cytoplasm. At the apical side of the cytoplasm a considerable
number of WGA positive endosomes, multivesicular bodies and also
some lysosomes (Figure 8 (bottom image), 3) was observed. Moreover, a
pronounced accumulation of WGA-HRP was detected at the basolateral
side of the Caco-2 monolayer. This is exemplified by the intense and
continuous blackening of the basolateral plasma membrane in Figure 7
(arrows) and 8 (bottom image, arrows). Importantly, neither equimolar
nor fluid phase marker quantities of HRP (500 µg mL−1) led to any
contrasting of the basolateral membrane. This underlines that WGA
can mediate transcytosis of a protein which otherwise would not reach
the basolateral side of a polarized epithelial cell monolayer. A quantifi-
cation of the amount of WGA localized in lysosomes and transported
to the basoloateral side is difficult. Due to the enzymatic conversion
of DAB and variations in contrasting during sample preparation, only
semi-quantitative estimates are possible. As reported by Wirth et al. the
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Figure 8: Close-up view of apical part (top image) and basolateral side (bottom
image) of Caco-2 monolayer loaded with WGA-HRP at 4°C and post-
incubated for 60 min at 37°C. Nucleus (1), multivesicular bodies (2),
lysosome (3). Note the blackenings at the apical (arrowheads) and
basolateral membrane (arrows).
fraction of WGA in lysosomes after 60 min amounts to about 50 % of
the internalized lectin.[358]
It remains to be answered in future studies whether the basolaterally
localized WGA-HRP remains membrane-bound or is released into the
intercellular space. Regardless of the latter, it is illustrated by the present
study that WGA can serve as a shuttle that mediates transcytosis of
proteins across a model of human intestinal epithelium. The HRP type
VI conjugated to WGA has a MW of ~44 kDa and thus well in the
size range of therapeutically relevant proteins like insulin (MW ~5.8
kDa), granulocyte colony-stimulating factor (G-CSF, MW ~19.6 kDa) or
erythropoietin (MW ~34 kDa). However, it remains to be resolved if
these proteins can similarly endure the intracellular transport pathway
as HRP.
1.1.3.4 Conclusions
As illustrated by the presented results, WGA extensively binds to Caco-
2monolayers which are an accepted in vitro model for human intestinal
epithelium. This underlines that conjugation with WGA could be used
to improve the cell-binding properties of particles and macromolecules
which per se are not bioadhesive. Moreover, as indicated by the rapid in-
ternalization of membrane-bound WGA within ~15 - 30 min, increased
uptake of drug conjugates into enterocytes could be achieved. These
results corroborate the fluorescence-based studies by Wirth et al. who
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observed similar time scales and pathways for the uptake of WGA by
Caco-2 cells.[358] Finally, the use of WGA as a mediator of transcyto-
sis bears promising potential for increasing the absorption of poorly
bioavailable drugs. While HRP conjugated to WGA retained its activity
during passage through the Caco-2 cell in the present study, it remains
to be shown if more sensitive biomacromolecules bound to WGA can
pass the cytoplasm similarly unaffected.
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1.2 specific topics
1.2.1 Bionanoprobes to study particle-cell interactions
Christian Fillafer, Daniela S. Friedl, Adina K. Ilyes, Michael Wirth,
Franz Gabor. Bionanoprobes to study particle-cell interactions. Journal
of Nanoscience and Nanotechnology, 9:3239-3245, 2009.
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1.2.1.1 Abstract
A variety of research reports have provided evidence that the interplay
between nanoparticles and biological systems is strongly dependent
on the composition as well as on the size of the particles. However,
irrespective of that a fine tuning of the interaction characteristics can be
attained by functionalisation of the particle surface. In order to be able
to monitor such interactions, an analytically accessible model system for
potentially target-specific therapeutically relevant nanoparticles (NP)
was generated by encapsulation of the highly hydrophobic fluorophore
BODIPY® 493/503 (BOD) into PLGA nanodroplets. Analyses of the
mean particle size and zeta potential revealed that plain and HSA
conjugated NP can be stored without agglomeration for at least 28
days at 4°C as well as -80°C. Although transfer of the particles into
commonly used buffers and cell culture medium did not affect the
system’s stability, protein-containing dispersants should not be used for
experiments demanding high sensitivity as distinct quenching effects
were observed. Concerning liberation of the fluorescent marker, no
release occurred when incubating the suspension for 7 days at 4°C,
while an onset of release was expectedly detected after 3 h at 37°C.
These experimental limitations were taken into account for the particle-
cell interaction studies which, as a consequence of the more hydrophilic
particle surface, showed an enhanced adhesion of HSA-conjugated
colloids to Caco-2 cells by means of flow cytometry and fluorescence
microscopy.
1.2.1.2 Introduction
The interaction characteristics between particles in the nanometer
range and biological systems have been increasingly investigated is-
sues of interest.[359, 19] Intensive research in this field partly results
from the possible toxicological consequences inflicted with nanoscaled
materials,[13] but mainly has been driven forward in order to exploit
the promising features of submicron particles for diagnostic and drug
delivery purposes.[360] At this, the suitability of a specific nanopar-
ticulate system for therapeutic applications is highly influenced by
several key characteristics of the colloids, most important the actual
size, core and surface composition. While the core material is rather
limited to a range of biocompatible and biodegradable substances, a
high number of potential bioactive targeting moieties can be introduced
to the particle surface in order to alter the biodistribution profile of the
nanomedicine.[361] Consequently, analytical platforms for the study
of targeted nanoparticle interactions with biological systems need to
be highly sensitive probes and have to consist of pharmaceutically
approved materials which offer the possibility of surface functionali-
sation. In the process of tracking the association and distribution of
colloids at the cellular and tissue level, efficient analytical access poses
another crucial parameter. At this, fluorescent marking has been widely
preferred due to the comparably simple handling of the substances and
the qualitative as well as quantitative information obtained from these
experiments.[362] Generally, the marker substance is either covalently
conjugated with the polymer forming the particle matrix or physico-
chemically encapsulated into the colloids by appropriate preparation
techniques. Ongoing from the latter approach and considering the pre-
viously discussed prerequisites, the aim of this study was to design a
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highly sensitive analytical bionanoprobe. This was practically attained
by incorporation of a 4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-
diaza-s-indacene (BOD; BODIPY® 493/503) in biocompatible as well as
biodegradable PLGA nanoparticles via an oil-in-water (o/w) solvent
evaporation procedure. The main objectives for the experimental part
of the present study encompassed a detailed characterisation of the
colloids’ stability in various media under commonly used storage condi-
tions as well as leakage of fluorescent marker from the nanoparticles in
order to evaluate the suitability of the system for routine analytical pur-
poses. To exemplarily investigate the potential of BOD-nanoparticles
(BOD-NP) as a tool to study the nanoparticle-cell interaction, HSA-
conjugated colloids were prepared and compared to plain BOD-NP
regarding cytoadhesivity to Caco-2 cells. This epithelial cell line is
highly relevant as a point of application for targeted nanomedicines,
since it represents an accepted model which can be used to investigate
drug delivery via the human intestinal barrier.[356]
1.2.1.3 Materials and Methods
Materials 4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-in-
dacene was obtained from Molecular Probes (Invitrogen Corp., Carls-
bad, California, USA). Resomer® RG503H (PLGA; lactide/glycolide
ratio 50:50, inherent viscosity 0.32-0.44 dL g−1, acid number >3 mg
KOH g−1) was bought from Boehringer Ingelheim (Ingelheim, Ger-
many). HSA, EDAC, NHS and Pluronic® F-68 were purchased from
Sigma Aldrich (Vienna, Austria). All other chemicals used were of
analytical purity.
Preparation of BOD-loaded PLGA-nanoparticles (BOD-NP) The
fluorescence-labelled PLGA-nanoparticles were produced by an o/w
solvent evaporation procedure. Briefly, 1 mg BOD and 400 mg PLGA
were dissolved in 2 g ethyl acetate. This solution was emulsified with
a 10% aqueous solution of Pluronic by sonication for 50 s yielding
the o/w emulsion (sonifier: Bandelin electronic UW 70/HD 70, tip:
MS 72/D, Berlin, Germany), which was poured into a 1% aqueous
solution of Pluronic. After mechanical stirring (600 rpm) for 1 h at
room temperature, the residual ethyl acetate was removed under re-
duced pressure resulting in the hardening of nanodroplets. The final
particle suspension was filtered (1 µm pore size) in order to eliminate
aggregates.
Particle Size and Zeta Potential Analysis Prior to all measure-
ments the nanoparticle suspensions were diluted 1:20 with double
distilled water. The mean particle size and size distribution were de-
termined by DLS on a Zetasizer Nano ZS (Malvern Instruments Ltd.,
United Kingdom). Zeta potential analyses were carried out at 25°C in
disposable folded capillary cells and were performed in triplicate.
Modification of the Particle Surface The model protein HSA was
conjugated to the nanoparticle surface by a commonly used carbodiimide-
mediated coupling procedure.[363] 20 mL of the nanoparticle sus-
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pension were purified with 40 mL of 20 mM HEPES/NaOH buffer
pH 7.4 (HEPES) on a tangential flow filtration system (Vivaflow 50;
100,000 MWCO PES, Sartorius Vivascience GmbH, Goettingen, Ger-
many) to adjust the pH and to eliminate PLGA monomers as well as
non-encapsulated BOD. Subsequently, 240 mg EDAC and 10 mg NHS,
each dissolved in 1mL of the same buffer, were added to the suspension
and incubated end-over-end for 2 h at room temperature. To remove
excess cross-linking agent, the suspension was washed twice with 40
mL HEPES followed by addition of 1.22 mg HSA in 1 ml HEPES. After
end-over-end incubation at room temperature overnight, unreacted
coupling sites were saturated by addition of 300 mg glycine in 1 mL
HEPES and further incubation at room temperature for 1 h. Finally
, the surface modified nanoparticles were washed five times with 20
mL HEPES to remove excess coupling agents and the suspension was
concentrated to 15 mL during the last purification step.
Storage stability of nanoparticles In order to assess the storage
stability, plain BOD-NP and HSA-BOD-NP suspended in HEPES were
incubated for up to 28 days at 4°C and -80°C. After one, seven, four-
teen, twenty one and twenty eight days aliquots were drawn from the
suspensions stored at 4°C and subjected to mean particle size-, poly-
dispersity index- and zeta potential analysis. The suspensions stored
frozen at -80°C were thawed after twenty eight days, sonified for 30 s
and analysed accordingly.
Stability of nanoparticles in water, buffers, and cell culture
medium In order to identify suitable dispersants for the particle-
cell interaction studies, BOD-NP were transferred to commonly used
buffers and cell culture medium. After diluting the BOD-NP suspension
1:20 with isoHEPES, aliquots were taken and mixed 1:1 with double
distilled water, isoHEPES, PBS, RPMI 1640 cell culture medium (+10%
fetal bovine serum) (RPMI+FBS) and a 0.1% as well as 1% solution of
HSA in HEPES. The mean particle size and fluorescence intensity of
the suspension were determined immediately and after incubation for
90 min at 37°C.
Release of fluorophore The BOD-NP suspension was diluted 1:20
with PBS and divided into 1 mL aliquots, which were incubated end-
over-end at 4°C and 37°C respectively. After 1, 3, 5, 24, 48, 72 and 168
h, 900 µL were transferred into centrifuge tubes and spun down on
an ultracentrifuge (100,000 rpm/30 min/9°C; Optima™ MAX Ultra-
centrifuge, Beckmann Coulter Inc., Fullerton, USA). To quantify the
amount of label which leaked from the particles the fluorescence in-
tensity of the supernatant after centrifugation was determined on a
microplate reader (ex/em: 480/525 nm; Infinite™ 200, Tecan Group
Ltd., Grödig, Austria). Each sample was analysed in triplicate.
Cell culture The Caco-2 cell line was purchased from the American
Type Culture Collection (Rockville, MD, USA) and used between pas-
sage 28 and 39. Tissue culture reagents were obtained from Sigma (St.
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Louis, USA) and Gibco Life Technologies Ltd. (Invitrogen Corp., Carls-
bad, California, USA). Cells were cultivated in RPMI 1640 cell culture
medium containing 10% fetal bovine serum, 4 mM L-glutamine and
150 g mL−1 gentamycine in a humidified 5% CO2/95% air atmosphere
at 37°C and subcultured by trypsination.
Flow cytometry The association of plain and HSA-BOD-NP with
Caco-2 single cells was investigated using flow cytometry. To grant
comparability between the nanoparticle suspensions, dilutions exhibit-
ing the same relative fluorescence intensity were used. These were
prepared with isoHEPES prior to all experiments and controlled on
a microplate reader. For the binding studies 50 µL trypsinated cell-
suspension (5×106 cells mL−1) were mixed with 50 µL of the respective
nanoparticle suspension and incubated for 30, 60 and 120 min at 4°C.
Following incubation, unbound and loosely associated particles were
removed by centrifugation and washing with 500 µL HEPES (Cen-
trifuge 5804R, Eppendorf; 1000rpm/5 min /4°C). The cell pellet was
resuspended in 1000 µL PBS-buffer and analysed on an EPICS XL-MCL
analytical flow cytometer (Coulter, Miami, USA) using a forward ver-
sus side scatter gate for inclusion of the single cell population and
exclusion of debris and cell aggregates. Fluorescence was detected
at 525 nm (10 nm bandwidth) and the mean channel number of the
logarithmic intensities of individual peaks was used for further cal-
culations. Amplification of the fluorescence signals was adjusted to
put the autofluorescence signal of unlabelled cells in the first decade
of the 4-decade log range. Data of 3000 cells were collected for each
measurement.
Fluorescence microscopy In order to visually identify the binding
characteristics of plain and surface modified BOD-NP to Caco-2 cells,
fluorescence microscopy was performed. Following incubation of 50
µL trypsinated cell suspension (5×106 cells mL−1) with 50 µL of plain
or HSA-BOD-NP for 60 min at 4°C and washing with HEPES, the
Caco-2 single cells were analysed on a Nikon Eclipse 50i microscope
(Nikon Corp., Japan) equipped with an EXFO X-Cite 120 fluorescence
illumination system. The focus was set to the middle of the cell and
the pictures taken were subjected to deconvolution processing by the
Image Analyser software.
1.2.1.4 Results and Discussion
Characterisation of plain BOD-NP and HSA-BOD-NP The la-
belling of polymeric nanoparticles with fluorescent marker molecules
has frequently been employed as a strategy to render colloids trackable
and to consecutively enable an investigation of their fate in biological
systems.[364] Hereby, mainly two approaches are being pursued. Firstly,
a labelled conjugate, which is subsequently used for the production
of nanoparticles, can be synthesised by introduction of a fluorescent
head group to a polymer backbone.[363, 364, 292, 227] This technique
offers the advantage of covalent linkage of the dye molecule, which
ensures enhanced attachment of the label, but often involves elaborate
synthesis, laborious purification and analytically challenging charac-
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terisation of the conjugate. Secondly, the fluorophore can be physico-
chemically entrapped in the polymeric matrix via suitable preparation
techniques.[227] At this, the hydrophobicity of the marker molecule has
to be selected according to that of the polymer core, since the resulting
interactive forces determine stability of the labelling. Exploiting the
latter principle, a simple and effective approach for the preparation of
fluorescence-marked biodegradable and biocompatible nanoparticles
has been developed. The highly hydrophobic compound BOD, which
exhibits fluorescein-like spectral properties as well as high photosta-
bility and quantum efficiency, was embedded into PLGA cores by a
o/w solvent evaporation procedure. This method yielded colloids with
a mean particle size of 120±1 nm and a narrow size distribution rep-
resented by a PdI of 0.087 (Table 1). As illustrated by zeta potential
measurements, plain BOD-NP exhibited a negative surface charge of
-39.2±0.2 mV due to free carboxyl groups of the H-type PLGA present
at the particle-dispersant interface. These carboxylate moieties provide
potential grafting points for covalent ligand-attachment on the particle
surface, which was exemplified by immobilization of the model protein
HSA via a carbodiimide-mediated active ester method. As a conse-
quence of the successful conjugation with proteinaceous ligand, an
increase in mean particle size by about 4 nm was observed concurrent
with a decrease of the zeta potential to -30.7±0.8 mV. This reduction
of surface potential can be attributed to direct amidation of carboxyl
groups as well as shielding of remaining charges by the protein layer.
Importantly, despite the surface modification and the slightly lowered
zeta potential, the size distribution of HSA-BOD-NP remained narrow
throughout the coupling process as indicated by a PdI of 0.092.
Storage stability of BOD-NP In order to grant that a series of
particle-cell interaction studies can be performed with the same batch of
nanoparticle suspension, sufficient short-term storage has to be granted.
Consequently, plain and HSA-BOD-NP were continually analysed re-
garding their mean particle size, PdI and zeta potential as stability
parameters, in course of storage over a period of 28 days at 4°C and
-80°C. As illustrated in Table 5, these parameters remained constant for
plain and modified nanoparticles incubated at 4°C. Obviously, despite
bearing a layer of immobilised protein molecules and thus slightly
lower zeta potential of about -30 mV, the HSA-BOD-NP had not ag-
glomerated after 28 days which is underlined by the low PdI of 0.087.
This might be due to a combination of the possibly sufficient electro-
static repulsive forces with steric stabilisation by residual Pluronic from
the preparation process.[24] Although storage for four weeks at -80°C
involved freezing and thawing of the colloids, the suspensions exhibited
similar stability as compared to incubation at 4°C. This is illustrated by
consistently constant mean particle sizes of 123±1 nm and 126±1 nm
for plain- and HSA-BOD-NP respectively, which underline that plain
and surface modified suspensions stored at 4°C or -80°C can serve as
stable reservoirs for comparable long-term studies.
Stability of BOD-NP in water, buffers, and cell culture medium
Generally, the dispersant’s properties like ionic strength, pH-value,
and presence of charged macromolecules have to be optimized for the
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Figure 9: Mean particle size (bar) and fluorescence intensity (line) of plain
BOD-NP in selected dispersants at room temperature (closed) and
after 90 min at 37°C (open).
preparation procedure and further storage in order to efficiently prevent
the formation of aggregates.[365] However, these suspension media
in most cases lack physiological pH conditions as well as isotonicity
and therefore do not comply with cells or tissues. Thus, transfer into
a cell-friendly dispersant for the studied system is often deemed to
be necessary. To meet this issue, destabilising tendencies and possible
effects on the fluorescence intensity of BOD-NP were assessed after
dilution of a stock suspension in selected, commonly used media for
cell and tissue culture studies.
As illustrated in Figure 9, the mean particle size of BOD-NP re-
mained rather constant, immediately upon mixing and after further
incubation for 90 min at 37°C, with all buffers and media used. Inter-
estingly, the higher concentration of HSA in the dispersant medium
led to a slight reduction of the mean particle size as determined by
DLS. This effect is very likely due to the presence of large amounts
of protein in the medium bearing relatively high diffusion coefficients.
Since the DLS-system calculates the mean particle size via the average
diffusion coefficient determined in course of the measurement, the size
of the BOD-NP is only apparently reduced by the presence of rapidly
diffusing proteins, but actually expected to be the same as in water.
Regarding the fluorescence intensity of the nanoparticle suspension,
rather drastic effects were observed in dispersants containing proteins.
While diluting the particles with isotonic HEPES and PBS did not
lead to an alteration of the suspension’s mean fluorescence intensity
as compared to water, the presence of proteins obviously resulted in
highly reduced quantum yields. This is explicated by an average re-
duction of the mean fluorescence intensity by 36% immediately after
mixing, which is even increased to 81% after incubation for 90 min at
37°C. Since similar quenching effects have been reported for BOD dyes
covalently conjugated to proteins,[366] the clear drop in fluorescence
intensity is expected to be due to physical contact between fluorophore
and protein. From this it is inferred, that immediate adsorption of HSA
molecules or serum proteins to the nanoparticle surface results in a
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rapid drop of the suspension’s mean fluorescence intensity, which is
further enhanced by additional adsorption in course of incubation at
37°C. While posing a distinct disadvantage for studies to be performed
in cell culture medium supplemented with serum, this effect has in
contrast been shown to be beneficial for the interpretation of cellular
uptake studies.[285] Since cytoinvasion via vesicular internalisation is
associated with membrane proteins densely enwrapping the colloid, a
reduction of the mean cell associated fluorescence can serve as an indi-
cator to discriminate between sole membrane binding and intracellular
uptake.
Release of fluorescent marker from BOD-NP Undesired release
of the fluorescent marker from particles due to insufficient attachment
and due to the high surface area available for dissolution has posed a
main challenge for the characterisation of a colloid’s interaction with
biological systems.[307] Especially in the case of particle-cell interaction
studies the interpretation of the results is hampered by the presence of
freely diffusing marker and possibly generated artefacts thereoff. Thus,
as a highly important preliminary step, the liberation of fluorescent
marker has to be determined under experimental conditions and ac-
cordingly, limits for further studies have to be set in order to minimise
misinterpretations.
The release of BOD from unmodified BOD-NP was determined in
course of incubation for seven days at 4°C and 37°C. In order to solely
detect released fluorophore and to exclude particle-associated fluores-
cence, aliquots of the suspension were subjected to ultracentrifugation
at each time point of the analysis. According to fluorescence measure-
ments of the supernatant after centrifugation, 4.1 ng mL−1 of free BOD
were detectable at the start point of the incubation, which represents the
quantity of fluorophore not encapsulated in course of the solvent evap-
oration procedure. When stored at 4°C, this amount remained constant
over the whole incubation period pointing at no release of BOD from
the PLGA-nanospheres (Figure 10). Upon incubation at 37°C, similarly
low quantities of free marker were detected during the first three hours.
Following this time lag, a steady increase of non-encapsulated fluores-
cence was determined which seemed to reach a plateau after 72 h. This
markedly higher liberation of fluorophore from the nanoparticles at
37°C is supposed to be due to increased swelling of the polymer matrix
and thus increased solubility and diffusion of BOD to the dispersant
phase. Consequently, these results imply that quantitative as well as
qualitative measurements using BOD-NP can be performed for at least
seven days at 4°C and about three hours at 37°C without major artefacts
due to released fluorescent label.
Interaction of plain- and HSA-BOD-NP with Caco-2 cells In
order to investigate the applicability of plain and surface-conjugated
BOD-NP as a model system for a detailed analysis of the nanoparticle-
cell interaction, binding studies for 30 to 120min at 4°C were performed
with Caco-2 single cells using plain and HSA-modified colloids. As
the cellular metabolism and fluidity of the membrane is reduced to a
minimum at 4°C, nanoparticles can only associate with the cell surface,
but are not actively taken up into the cytosol.8 Following the incubation
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Figure 10: Release of BOD from nanoparticles in course of incubation at 4°C
and 37°C.
and washing of the cells, flow cytometry was used to determine the
mean cell associated fluorescence intensity. As illustrated in Figure 11,
the binding of plain nanoparticles remained constantly low over the
Figure 11: Mean cell associated fluorescence intensity of Caco-2 cells incubated
with plain (-∆-) and HSA-BOD-NP (-￿-) at 4°C.
whole incubation period and ranged just slightly above the cellular
autofluorescene. In contrast, when incubated with HSA-BOD-NP, a dis-
tinctly increasing amount of mean cell associated fluorescence intensity
was monitored over time. As compared to plain BOD-NP, this difference
was reflected by a 58% higher association rate after 30 min. Upon incu-
bation for 120 min, binding of HSA-BOD-NP to Caco-2 cells is even 3.5
times higher, which might be explained by non-specific protein–protein
interactions between the HSA-conjugated colloids and the cell mem-
brane, while the low binding in the case of plain BOD-NP is supposed
to be a consequence of the poorly cytoadhesive characteristics of the
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Figure 12: Caco-2 cells incubated with plain (A) and HSA-BOD-NP (B) for
60 min at 4°C. The centre of the cell is marked with an “x” for
orientation. Scale bar represents 20 µm.
PLGA-polymer. The amount of cell associated plain- and HSA-BOD-NP
after incubation for 60 min at 4°C was also investigated by fluorescence
microscopy. As is clearly illustrated by the green fluorescent dot-like
structures in Figure 12 A, only few unmodified nanoparticles had as-
sociated with the cell membrane. In contrast, a denser corona was
visualised for HSA-BOD-NP under the same experimental conditions
(Figure 12 B) which confirmed the higher cell-binding potential of albu-
min modified particles as detected in the flow cytometric experiments.
These results are especially interesting since HSA is generally known
as a model protein mediating only low, non-specific interactions which
thus further underlines the potential of BOD-NP as probes to detect
slight alterations of the interactive forces between particle and target
cell.
1.2.1.5 Conclusions
In this work, a novel method to label biodegradable and biocompatible
nanoparticles via encapsulation of the compound 4,4-difluoro-1,3,5,7,8-
pentamethyl-4-bora-3a,4a-diaza-s-indacene in PLGA-nanoparticles is
presented. The colloids prepared by a o/w solvent evaporation proce-
dure can readily be conjugated with proteins and were shown to be
stable for at least 28 days upon storage at 4°C and −80°C. Interestingly,
transfer of the BOD-NP into protein-containing media leads to drastic
quenching of the suspensions’ mean fluorescence intensity and thus
should be avoided if high analytical sensitivity is desired. Regarding
the release of fluorescent label over time it has to be highlighted, that
BOD-NP are to be considered stably-labelled when used at 4°C and
that liberation of the fluorophore is negligible for 3 hours at 37°C. Most
importantly and as revealed by binding studies with Caco-2 cells, BOD-
NP can serve as highly sensitive probes to analyse alterations in the
cell-binding characteristics of nanoparticles as a result of surface conju-
gation with targeting molecules. At this, it was exemplarily shown that
plain BOD-NP exhibit clearly lower membrane binding than colloids
surface-modified with HSA.
In conclusion it can be denoted, that the stability of BOD-NP, com-
bined with the ease of covalent surface immobilisation of bioactive
molecules, suggests broad applicability of the system to investigate
ligand-dominated nanoparticle-cell interactions. Accordingly, BOD-
labelled colloids are expected to represent an effective and analytically
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sensitive tool to study potential biotargeting moieties for site-specific
diagnostics and nanoparticulate drug delivery.
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1.2.2 Fluorescent bionanoprobes to characterize cytoadhesion and cytoinva-
sion
Fluorescent bionanoprobes
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Fluorescent Bionanoprobes to Characterize Cytoadhesion
and Cytoinvasion**
Christian Fillafer, Daniela S. Friedl, Michael Wirth, and Franz Gabor*
To overcome current limitations in diagnostic imaging and targeted drug
delivery, a highly versatile tool is presented that can be used to represen-
tatively investigate the effects of submicroparticles intended for the use in
biological systems. An effective approach to render colloids trackable is
developed by stable attachment of the fluorescent probe BODIPY 493/503
(BOD: 4,4-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene)
to a biodegradable and biocompatible particle core matrix. BOD submi-
croparticles are shown to be stable, can be surface modified, and exhibit high
fluorescence emission. Upon conjugation with human serum albumin
(nonspecific) and wheat germ agglutinin (biorecognitive) as model ligands
explicit differences are found in the cytoadhesive and cytoinvasive
characteristics of the submicroparticles using Caco-2 cells. These results
demonstrate the potency of BOD-labeled colloids as a versatile analytical
platform for a multifaceted investigation of cell-particle interactions in
biological systems.
1. Introduction
The intensive research in all fields of micro- and nanoscale
science has generated a variety of approaches for the
engineering of submicroparticles with tailored properties.
These efforts are driven forward in order to elucidate and to
gain control over the interaction characteristics of such devices
with biological systems. The immobilisation of appropriate bio-
active ligands such as antibodies,[1] peptides,[2] or aptamers[3] to
the submicroparticles’ surface is expected to overcome
existing limitations in a number of fields such as cancer
therapy, drug targeting, or diagnostic imaging. When bearing
future medical applications in mind however, the matrix of the
particles has tomeet certain requirements in order tominimise
side effects and to avoid possibly toxic accumulation in the
body. Consequently, the use of several inorganic components
or nondegradable polymers such as polystyrene is limited for
these applications. Considering this it seems rather preferable
to revert to materials that have been intended to be used in
organisms due to their biodegradable and biocompatible
nature.[4] Poly(D,L-lactic-co-glycolic)acid (PLGA) is a repre-
sentative of this class of polymers that has been shown to
comply with the food and drug administration (FDA), FDA
regulations and thus is permitted to be used for medical
applications in humans.[5] Nano- and microparticles can be
produced from PLGA in various sizes by solvent-evaporation
techniques and have mainly been investigated for drug-
delivery purposes.[6]
In order to address these requirements and to engineer
an analytically versatile particulate system for biological
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1.2.2.1 Abstract
To overcome current limitations in diagnostic imaging and targeted
drug delivery, a highly versatile tool is presented that can be used to
representatively investigate the effects of submicroparticles intended
for the use in biological systems. An effective approach to render col-
loids trackable is developed by stable attachment of the fluorescent
probe BOD to a biodegradable and biocompatible particle core matrix.
BOD submicroparticles are shown to be stable, can be surface modified,
and exhibit high fluorescence emission. Upon conjugation with human
serum albumin (nonspecific) and wheat germ agglutinin (biorecogni-
tive) as model ligands explicit differences are found in the cytoadhesive
and cytoinvasive characteristics of the submicroparticles using Caco-2
cells. These results demonstrate the potency of BOD-labeled colloids
as a versatile analytical platform for a multifaceted investigation of
cell-particle interactions in biological systems.
1.2.2.2 Introduction
The intensive research in all fields of micro- and nanoscale science
has generated a variety of approaches for the engineering of submi-
croparticles with tailored properties. These efforts are driven forward
in order to elucidate and to gain control over the interaction character-
istics of such devices with biological systems. The immobilisation of
appropriate bioactive ligands such as antibodies,[367] peptides,[368] or
aptamers[369] to the submicroparticles’ surface is expected to overcome
existing limitations in a number of fields such as cancer therapy, drug
targeting, or diagnostic imaging. When bearing future medical applica-
tions in mind however, the matrix of the particles has to meet certain re-
quirements in order to minimise side effects and to avoid possibly toxic
accumulation in the body. Consequently, the use of several inorganic
components or nondegradable polymers such as polystyrene is limited
for these applications. Considering this it seems rather preferable to
revert to materials that have been intended to be used in organisms
due to their biodegradable and biocompatible nature.[370] PLGA is a
representative of this class of polymers that has been shown to comply
with the food and drug administration (FDA) regulations and thus is
permitted to be used for medical applications in humans.[371] Nano-
and microparticles can be produced from PLGA in various sizes by
solvent-evaporation techniques and have mainly been investigated for
drug delivery purposes.[372]
In order to address these requirements and to engineer an analyti-
cally versatile particulate system for biological applications, a methodol-
ogy has been elaborated to generate fluorescence-labelled and surface-
modified colloids that can subsequently be used to investigate cell-
submicroparticle interactions. While PLGA was used as a core material
in order to ensure biocompatibility and biodegradability of the particles,
a novel approach for detectability was developed via encapsulation of
the hydrophobic fluorophore BOD. These stably labelled and therefore
trackable colloids were investigated as a tool to monitor different stages
of the cell-submicroparticle interaction. The particles were conjugated
with HSA as a model protein for nonspecific protein–protein interac-
tions and WGA as a model ligand for specific protein-carbohydrate
interactions.[373, 208, 209] Following the characterization of the protein-
immobilisation step, the analytical applicability of BOD-labeled sub-
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Table 6: Mean particle size, PdI, and zeta potential of plain BOD-SMP, HSA-
BOD-SMP, and WGA-BOD-SMP.
Mean particle
size [nm]
Polydispersity
index
Zeta potential
[mV]
plain BOD-SMP 120±1.0 0.087 -39.2±0.23
HSA-BOD-SMP 124±1.2 0.092 -30.7±0.75
WGA-BOD-SMP 159±1.2 0.153 -33.9±1.03
microparticles (BOD-SMP) for discrimination of the cytoadhesive and
cytoinvasive properties of plain and surface-modified colloids was in-
vestigated using a combination of flow cytometry and fluorescence
microscopy.
1.2.2.3 Results
Characterization of BOD-SMP The mean particle size, PdI, and
zeta potential of the BOD-SMP were determined prior to and after
the surface modification. As represented by a PdI of 0.087 the submi-
croparticles produced by the solvent-evaporation procedure were nearly
monodisperse with a mean particle size of 120±1.0 nm (Table 6). The ac-
tivation of the submicroparticles’ surface carboxyl groups, conjugation
with HSA or WGA, and saturation of unreacted NHS intermediates
with glycine resulted in slightly increased mean particle sizes. A narrow
size distribution was retained throughout the coupling as illustrated
by PdIs of 0.092 for HSA-BOD-SMP and 0.153 for WGA-BOD-SMP. In
order to confirm successful immobilisation of HSA and WGA, the zeta
potential of the colloids was monitored. In the case of plain BOD-SMP
the high density of surface carboxyl groups led to a strongly negative
potential of -39.2±0.23 mV. As a consequence of the modification step
the surface charge was lowered by derivatization as well as inherent
shielding of the carboxyl groups of PLGA by covalently attached pro-
teins. This is reflected by a decrease in zeta potential to -30.7±0.75 mV
and -33.9±1.03 mV, respectively. Despite these lowered values due to
the successful immobilisation of HSA and WGA to the submicropar-
ticle surface, the still clearly negative zeta potentials are expected to
enhance stability of the suspension by electrostatic repulsion between
the colloids.[374]
Interaction of plain and modified BOD-SMP with Caco-2 cells
Time dependency In order to assess time dependency of the binding
of plain and surface-modified BOD-SMP to Caco-2 single cells, incu-
bation with the particles was performed for up to 300 min at 4°C. As
indicated by the mean cell-associated fluorescence intensities in Fig-
ure 13, the quantity of cell-bound plain BOD-SMP remained consistently
low over the entire incubation period and ranged just slightly above
the cellular autofluorescence. A similarly low binding was observed
for HSA-BOD-SMP. As compared to the unmodified colloids only a
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Figure 13: Mean cell-associated fluorescence intensity of Caco-2 cells in course
of time incubated with WGA-BOD-SMP, HSA-BOD-SMP, and plain
BOD-SMP (25 ng mL−1 corresponding concentration of BOD) at
4°C.
marginally increased mean cell-associated fluorescence intensity of 0.48
was detected after 60 min, which remained rather constant at this level
over the course of further incubation for 240 min. In contrast, the quan-
tity of WGA-BOD-SMP associated with Caco-2 cells strongly increased
over time. As illustrated by the steep onset of the slope in Figure 13,
rapid binding of the surface-modified submicroparticles had occurred
within 30 min. After incubation for 60 min the mean cell-associated
fluorescence intensity corresponded to about 54% of the total number
of particles bound at the end of the assay. Over the course of prolonged
incubation the binding seemed to reach a plateau, probably indicating
saturation. As compared to HSA-BOD-SMP and plain BOD-SMP the
cell-association of WGA-BOD-SMP with Caco-2 cells was determined
to be 14.2 times (60 min) to 19.8 times (300 min) higher than HSA-
BOD-SMP and 49.3 times (60 min) to 73.2 times (300 min) higher than
plain BOD-SMP. These differences in the time-dependent association
rates indicate that the cell binding of plain and HSA-BOD-SMP might
mainly be based on nonspecific interactions, while a specific mechanism
underlies the WGA-BOD-SMP binding to the Caco-2 cell surface.
Concentration dependency Dilution series of plain, HSA- and WGA-
BOD-SMP were used to investigate concentration-dependent interaction
profiles with Caco-2 single cells. As determined by flow cytometry, the
mean cell-associated fluorescence intensity concurrently increased with
higher concentrations of the submicroparticle suspensions (Figure 14).
This effect was on a distinctly lower level for plain and HSA-BOD-SMP,
starting at minimal mean cell-associated fluorescence intensities of 0.1
and 0.11, respectively, for the lowest concentration used. With eightfold
higher quantity, a maximum of only 0.92 and 1.04, respectively, was
reached. As opposed to this, the interaction of WGA-BOD-SMP with
Caco-2 cells is characterized by high association rates already at the
lowest concentration used. This is illustrated by a mean cell-associated
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Figure 14: Mean cell-associated fluorescence intensity of Caco-2 cells incubated
with a diluted series of WGA-BOD-SMP, HSA-BOD-SMP, and plain
BOD-SMP for 60 min at 4°C.
fluorescence intensity of 1.9, which concurrently increased up to 20.2
and 36.3, respectively, for the two highest concentrations. As compared
with plain BOD-SMP and HSA-BOD-SMP the interaction of WGA-BOD-
SMP with Caco-2 cells was 18.6 times and 17.2 times higher, respectively,
at the lowest concentration. This difference increased up to 35.1 and 39.5
times, respectively, at the highest quantities used. Interestingly, no signs
of saturation of the cell binding were observed with increasing amounts
of WGA-BOD-SMP, which points to the presence of a rather high
number of accessible binding sites for lectin-carbohydrate interactions
on the cell surface.
Internalization of WGA-BOD-SMP A pulse-chase incubation was
performed in order to investigate whether bound WGA-BOD-SMP are
internalised into Caco-2 cells. At 4°C the fluidity of the membrane and
the cellular metabolism are reduced to a minimum. As a consequence,
only binding takes place. Under these conditions single cells were
loaded with submicroparticles at 4°C for 60 min resulting in a mean
cell-associated fluorescence intensity of 8.1 (0 min, Figure 15). When
further incubated at 4°C, the mean cell-associated fluorescence intensity
did not noticeably vary over 240 min. This indicates that WGA-BOD-
SMP initially associated with the cells did not detach upon successive
incubation at 4°C. By raising the temperature to 37°C energy-consuming
transport processes are enabled and thus uptake of membrane-bound
materials can proceed. During this chase incubation for 240 min at
37°C, the mean cell-associated fluorescence intensity rapidly decreased
by 36.8% within 10 min. However, possible release of WGA-BOD-
SMP from their binding sites on the cell membrane was excluded as
only minor amounts of fluorescence were detected in the supernatants
of the cell suspension during washing. After incubation for 60 min
the initially detected mean cell-associated fluorescence intensity had
decreased by 60.5% to 3.08 and remained at this plateau for the last
180 min of the experiment. These results indicate that WGA-BOD-SMP
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Figure 15: Mean cell-associated fluorescence intensity of Caco-2 cells loaded
with WGA-BOD-SMP for 60 min at 4°C in course of further incuba-
tion at 4°C and 37°C.
were internalized by Caco-2 single cells by energy-consuming transport
processes at 37°C while no internalization took place at 4°C due to the
minimized cellular metabolism.
Binding specificity of WGA-BOD-SMP In order to estimate the
extent to which the binding of WGA-BOD-SMP to Caco-2 cells is
mediated by the specific interaction of the immobilized lectin with
carbohydrate moieties of the cells’ glycocalyx, an inhibition assay was
performed. Since WGA specifically binds to N-acetyl-neuraminic acid
and N-acetyl-D-glucosamine, N,N’,N”-triacetylchitotriose was used as a
complementary carbohydrate.[375] As illustrated in Figure 16, addition
of increasing amounts of the inhibitor led to a corresponding decrease
of the mean cell-associated fluorescence intensity. In the presence of
high amounts of complementary carbohydrate, the binding of WGA-
BOD-SMP to Caco-2 cells was inhibited by 89.48±0.58%, suggesting that
at the most 10.5% of the submicroparticles were bound via nonspecific
interactions. Consequently, the bulk of WGA-BOD-SMP attached via
specific lectin-carbohydrate binding mediated by the WGA immobilized
on the particle surface.
Fluorescence microscopy of Caco-2 cells incubated with plain
and modified BOD-SMP Complementary information on the asso-
ciation and uptake characteristics of plain and modified BOD-SMP by
Caco-2 cells was collected via fluorescence microscopy. Single cells were
incubated with plain, HSA-, and WGA-BOD-SMP for 60 min at 4°C. As
illustrated in Figure 17, only low amounts of plain (Figure 17 A) and
HSA-BOD-SMP (Figure 17 B) were associated with the cell membrane
after incubation at 4°C, while a high density of bound WGA-BOD-SMP
was detected as dotlike structures (Figure 17 C–F). By raising the incu-
bation temperature to 37°C, however, active transport processes were
Figure 16: Mean cell-associated fluorescence intensity (-￿-) and percentage of
inhibition (-￿-) in course of competitive inhibition of WGA-BOD-
SMP binding to Caco-2 cells by addition of increasing amounts of
the complementary carbohydrate N,N’,N”-triacetylchitotriose at 4°C.
Figure 17: Fluorescence microscopy images of Caco-2 cells incubated with plain
BOD-SMP (A), HSA-BOD-SMP (B), and WGA-BOD-SMP (C) for
60 min at 4°C. The center of the cell is marked with an ‘‘x’’ for
orientation. Optical cross sections of Caco-2 cells incubated with
WGA-BOD-SMP at 4°C taken at the top (D), center (E), and bottom
(F) of the cell. Incubation for a further 30 min at 37°C and staining
of the cell membrane with FM 4-64 (G). Scale bar represents 10 µm.
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enabled, resulting in the uptake of WGA-BOD-SMP into intracellular
compartments, which appear as vesicles in the cytosol (Figure 17 G).
1.2.2.4 Discussion
For a comprehensive investigation of the cytoadhesive and cytoinvasive
characteristics of plain and ligand-conjugated submicroparticles, a sta-
ble and versatile fluorescence-labelled colloid is required. In this regard,
as most analytical methods in cell and tissue research are based on fluo-
rescence detection, labeling of the submicroparticle with a fluorophore
is preferable.[362] In the present approach the hydrophobic photochem-
ical probe BODIPY 493/503 was encapsulated in a hydrophobic PLGA
matrix in order to produce colloids labeled by strong hydrophobic
interactions between dye and polymer. The utilized member of the
BODIPY series was chosen due to its highly nonpolar structure and is
characterized by a fluorescein-like emission spectrum and exceptional
photostability. As illustrated by the polydispersity index in Table 6, the
solvent-evaporation procedure yielded stable submicroparticles with
a mean diameter of 120 nm and high fluorescence emission with no
leakage of the dye during the course of the experiments. Particularly
for drug delivery purposes it has to be considered that particle sizes
around 100 nm are required to achieve sufficient load of active agent
for a therapeutical response. Although particles with similar size are
commercially available, the constituents of these, such as polystyrene
or inorganic materials, are of limited usability for the screening of
effects in biological systems. For such purposes, consequences owing
to the submicroparticle itself or possibly toxic accumulations have to be
excluded, which suggested the use of the biodegradable and biocom-
patible polyester polymer PLGA.[371] This generated a highly useful
model for studying the cell-particle interaction of colloids intended
for medical and pharmaceutical applications. Furthermore, the conse-
quences owing to covalently conjugated bioeffective molecules on the
preformed submicroparticles were investigated.
In this study the two model proteins HSA and WGA were coupled to
free carboxyl groups at the surface of the fluorescent BOD-SMP followed
by an analysis of the cytoadhesive and cytoinvasive properties of the
colloids using Caco-2 cells. While HSA was chosen due to its widely
nonspecific protein-protein interactions, WGA was selected as a specific
ligand that binds to membrane-associated glycoproteins.[373, 208, 209]
Furthermore, plain BOD-SMP were used as a negative control allowing
discrimination between the association of submicroparticles alone and
the proteinaceous component of the interaction.
When Caco-2 cells were incubated with plain and modified BOD-
SMP, distinctly different association rates were observed. Generally,
plain BOD-SMP were shown to exhibit very low binding (Figure 17 A),
which is in concordance with previous reports on the poor cytoadhesive
characteristics of hydrophobic, unmodified PLGA.[363] Interestingly,
although supposedly bearing altered—more hydrophilic—surface fea-
tures due to the immobilized protein molecules, similar results were
observed for HSA-BOD-SMP (Figure 17 B). In contrast, studies with
WGA-BOD-SMP revealed high and fast association rates for the sub-
microparticles as evidenced by flow cytometry and fluorescence mi-
croscopy. An inhibition assay with N,N’,N”-triacetylchitotriose showed
that 89.48% of the binding of WGA-BOD-SMP to Caco-2 cells was
due to specific lectin-carbohydrate interactions (Figure 16), which sug-
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gests that the bioactive conformation of wheat germ agglutinin was
retained over the course of the covalent coupling to the submicropar-
ticles’ surface. Upon incubation at 4°C this highly specific attachment
was illustrated by a dense occupation of the cell membrane with dot-
like fluorescent particles (Figure 17D–F). A quantitative relation to the
visually explicit differences was provided via flow cytometric detection
of the mean cell-associated fluorescence intensity. Results from these
analyses underline the cytoadhesive potency of the WGA-BOD-SMP as
compared to plain and HSA-BOD-SMP. This is explicated by 49 and 14
times higher binding rates, respectively, after 60 min incubation at 4°C
and was confirmed upon alteration of the submicroparticle concentra-
tion (Figures 13 and 14). Besides the increase in mean cell-associated
fluorescence intensity, the strong cytoadhesivity of WGA-BOD-SMP
was also exemplified by distinctly higher granularity of the cells (see
Figure S1 of the Supporting Information). This parameter was moni-
tored by the side-scattering signal from flow cytometry and provides
fluorescence-independent information on the cell binding of particles.
These sub-items contribute to a comprehensive characterization of
the cytoadhesive properties of stably fluorescence-labeled and surface-
engineered submicroparticles. Beyond the binding process of modified
colloids to cells or tissues, possible cytoinvasion, its mechanisms and
the subsequent intracellular fate are also considered to be paramount
questions.[20] In this regard it was shown that BOD-SMP can further-
more serve as a valuable analytical tool for the investigation of these
processes. However, it has to be highlighted that a sufficient number of
submicroparticles need to be membrane bound in order to be able to
qualitatively and quantitatively analyze cytoinvasion. Considering the
mean cell-associated fluorescence intensities in Figure 13, the critical
threshold would correspond to a relative fluorescence intensity of about
2. Although this poses a slightly limiting factor for the assay, this re-
quirement needs to be fulfilled for a reliable detection of internalization
via flow cytometry and fluorescence microscopy. Since that was not
granted for plain and HSA-BOD-SMP due to their low cell association,
an analysis and judgment of their cytoinvasive properties would be
rather speculative from the data obtained.
After loading Caco-2 cells with WGA-BOD-SMP at 4°C, where the
fluidity of the membrane and cellular metabolism are reduced, raising
the temperature to 37°C was found to result in uptake of the membrane-
bound submicroparticles (Figure 17 G). This was not only visualized
but also supported by data from flow cytometric analyses, which show
a decrease of the mean cell-associated fluorescence intensity upon incu-
bation at higher temperature. Considered in conjunction with evidence
from fluorescence microscopy studies, it appears that the particles’ in-
tracellular constriction to vesicular compartments might be accountable
for this observation due to quenching effects between the fluorophores
and shielding by the membrane as well as other intracellular structures.
1.2.2.5 Conclusions
The entrapment of the fluorophore BOD into PLGA submicroparticles
yields stably labeled and highly fluorescent colloids whose surface
can readily be conjugated with bioactive ligands. These particles with
biocompatible and biodegradable core material were shown to be suit-
able tools for an investigation of submicroparticle-cell interactions. By
combination of fluorescence microscopy and flow cytometry it was
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possible to analyze the cytoadhesive characteristics of plain and surface
modified BOD-SMP as well as the cytoinvasion of WGA-BOD-labeled
submicroparticles. Hydrophobic plain BOD-SMP exhibited only very
low binding to the Caco-2 cells, similar to HSA-BOD-SMP which were
presumed to possess altered surface hydrophobicity due to the attached
protein molecules. In contrast, immobilization of WGA onto BOD-SMP
resulted in highly cytoadhesive as well as cytoinvasive submicropar-
ticles due to specific binding of the lectin to carbohydrate moieties
of the cells’ glycocalyx. Currently, efforts are put forth in order to
extend the presented analysis beyond the limits of uptake towards a
comprehensive investigation of the consecutive subcellular localiza-
tion of the submicroparticles. In addition, further studies with various
cytoinvasive molecules attached to the ‘‘centerpiece’’, BOD-SMP, are
expected to shed light on the intracellular fate of colloidal substances
as a consequence of surface functionality. Based on these results it
can be concluded, that BOD-labeled submicroparticles will provide a
versatile and valuable platform for biocompatible screening of novel
ligands with broad applicability in labeling, drug delivery, and targeted
contrast agents.
1.2.2.6 Experimental section
Materials BOD was obtained from Molecular Probes (Invitrogen
Corp., Carlsbad, CA, USA). Resomer® RG503H (PLGA; lactide/glycol-
ide ratio 50:50, inherent viscosity 0.32– 0.44 dL g−1, acid number >3mg
KOH g−1) was bought from Boehringer Ingelheim (Ingelheim, Ger-
many). Wheat germ agglutinin from Triticum vulgare was obtained from
Vector laboratories (Burlingame, USA). HSA, EDAC, NHS, Pluronic®
F-68, and N,N’,N”-triacetylchitotriose were purchased from Sigma
Aldrich (Vienna, Austria). All other chemicals used were of analytical
purity.
Preparation of BOD-SMP The BOD-SMP were prepared by an oil-
in-water (o/w) solvent-evaporation technique under protection from
light to prevent photobleaching of the fluorophore. Briefly, BODIPY
(1 mg) and PLGA (400 mg) were dissolved in ethyl acetate (2 g). This
solution was emulsified with a 10% aqueous solution of Pluronic (6
mL) by sonication for 50 s yielding the o/w emulsion (sonifier: Ban-
delin electronic UW 70/HD 70, tip: MS 72/D, Berlin, Germany), which
was poured into a 1% aqueous solution of Pluronic (100 mL). After
mechanical stirring (600 rpm) for 1 h at room temperature, the resid-
ual ethyl acetate was removed under reduced pressure. The resulting
submicroparticle suspension was filtered (1-µm pore size) in order to
eliminate aggregates.
Particle size and zeta-potential analysis Prior to all measure-
ments the submicroparticle suspensions were diluted 1:20 with double-
distilled water. The mean particle size and size distribution were deter-
mined by dynamic light scattering on a Zetasizer Nano ZS (Malvern
Instruments Ltd., UK). Zeta-potential analyses were carried out at 25°C
in disposable folded capillary cells using the same instrument. All
measurements were performed in triplicate.
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Modification of the particle surface 40 mL of the submicropar-
ticle suspension was purified with HEPES (80 mL) on a tangential
flow filtration system (Vivaflow 50; 100,000 MWCO PES, Sartorius Vi-
vascience GmbH, Goettingen, Germany) to adjust the pH value and
to eliminate PLGA monomers as well as non-encapsulated BOD. Sub-
sequently, EDAC (480 mg) and NHS (20 mg), each dissolved in the
same buffer (1 mL), were added to the suspension and incubated end-
over-end for 2 h at room temperature. To remove excess cross-linking
agent, the suspension was washed twice with HEPES (80 mL). After
division into two parts (20 mL), solutions of WGA (0.67 mg) in HEPES
(1 mL) and HSA (1.22 mg) in HEPES (1 mL) were added, respectively.
Following end-over-end incubation at room temperature overnight,
unreacted coupling sites were saturated by addition of glycine (300
mg) in HEPES (1 mL) and further incubation at room temperature for
1 h. The surface-modified submicroparticle suspensions were washed
five times with HEPES (20 mL) to remove excess coupling agents and
concentrated to 15 mL during the last purification step.
Cell culture The Caco-2 cell line was purchased from the Ameri-
can Type Culture Collection (Rockville, MD, USA) and used between
passage 28 and 39. Tissue culture reagents were obtained from Sigma
(St. Louis, USA) and Gibco Life Technologies Ltd. (Invitrogen Corp.,
Carlsbad, CA, USA). Cells were cultivated in RPMI 1640 cell culture
medium containing 10% fetal bovine serum, 4mM L-glutamine and 150
mg mL−1 gentamycine in a humidified 5% CO2/95% air atmosphere
at 37°C and subcultured by trypsination.
Flow cytometry The association of plain and surface-modified BOD-
SMP with Caco-2 single cells was investigated using flow cytometry.
Briefly, 50 µL cell suspension (5x106 cells mL−1) were mixed with 50
µL of the respective submicroparticle suspension and incubated un-
der varied conditions. To grant comparability between plain, HSA-,
and WGA-BOD-SMP, dilutions to standardized relative fluorescence
intensities were used. These were prepared with isoHEPES prior to all
experiments and controlled on a microplate reader (e/e: 480/525 nm;
Infinite 200i, Tecan Group Ltd., Grödig, Austria). Following incubation,
unbound and loosely associated particles were removed by centrifuga-
tion and washing with 500 µL HEPES (Centrifuge 5804R, Eppendorf;
5 min/1000 rpm/4°C). The cells were resuspended in PBS (1000 µL)
and analyzed on an EPICS XL-MCL analytical flow cytometer (Coulter,
Miami, USA) using a forward-versus-side scatter gate for inclusion of
the single-cell population and exclusion of debris and cell aggregates.
Fluorescence was detected at 525 nm (10 nm bandwidth) and the mean
channel number of the logarithmic intensities of individual peaks was
used for further calculations. Amplification of the fluorescence signals
was adjusted to put the auto fluorescence signal of unlabeled cells in
the first decade of the four decade log range. Data of 3000 cells were
collected for each measurement.
Binding specificity of WGA-BOD-SMP Binding specificity of the
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carbohydrate-lectin interaction between WGA-BOD-SMP and the Caco-
2 cell surface was assessed by a competitive assay with N,N’,N”-
triacetylchitotriose. Caco-2 cell suspension (50 µL), WGA-BOD-SMP
suspension (50 µL), and 100 µL solution of N,N’,N”-triacetylchitotriose
(100, 50, 25, 12.5, 6.25, 3.125, 1.57 µg/ 100 µL) in isoHEPES were mixed
and incubated for 60 min at 4°C. After washing with isoHEPES, the
mean cell associated fluorescence intensity was determined by flow
cytometry. Each concentration was analysed in triplicate with isoHEPES
(100 µL) as a negative control.
Internalization of WGA-BOD-SMP A pulse-chase incubation at
different temperature levels was performed in order to investigate
uptake of bound WGA-BOD-SMP into Caco-2 cells. The single cells
were loaded with WGA-BOD-SMP for 60 min at 4°C and washed once
with HEPES. The mean cell-associated fluorescence intensity at this
point in time represents the start of the chase incubation. Following
this, the loaded Caco-2 cells were incubated at 4°C/37°C and analysed
regarding the mean cell associated fluorescence intensity in course of
an incubation time up to 240 min.
Fluorescence microscopy In order to visually investigate binding
and uptake of plain and modified BOD-SMP into Caco-2 cells, a 50
µL cell suspension (5x106 cells mL−1) was incubated with 50 µL of a
suspension of plain BOD-SMP, HSA-BOD-SMP, and WGA-BOD-SMP
in isoHEPES for 60 min at 4°C. For the internalization experiments the
cells were washed twice with HEPES (500 µL) and incubated for 30
min at 37°C followed by staining of the cell membrane with a solution
of FM® 4-64 in HEPES. Imaging of the BOD-SMP with live cells was
performed on a Nikon Eclipse 50i microscope (Nikon Corp., Japan)
equipped with an EXFO X-Cite 120 fluorescence illumination system.
Except for the stack, the focus was set to the middle of the cell and
the pictures taken were subjected to deconvolution processing by the
Image Analyser software.
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1.2.3 Binding of positively and negatively charged micro- and nanoparticles
to an epithelial and endothelial cell model
Christian Fillafer, Bettina Luser, Manuela Prantl, Winfried Neuhaus,
Renate Hofer-Warbinek, Michael Wirth, Franz Gabor. to be submitted.
1.2.3.1 Introduction
The most prominent biological barriers encountered by particulate drug
carriers upon administration to the human body are represented by
epithelial and endothelial cells. Hence, a strong interaction with these
tissues is essential to prolong the residence time of particles in the
body or to achieve their absorption. Aside from surface modification
with biorecognitive ligands,[4] coating of colloids with cationic poly-
electrolytes has been discussed as a potential strategy to enhance the
interaction with epithelial and endothelial cells.[4, 186] This rationale is
based on the observation that all cell types of multicellular organisms
are characterized by negatively charged cell surfaces.[6] The charges in
the cell membrane largely derive from of sialic acid carboxy groups and
phosphates of phospholipid head groups. Aside from negative groups,
cationic charges also exist which probably can be attributed to ε-amino
groups of lysine side chains of membrane proteins.[6] It is not clear
whether these charged moieties in the plasma membrane are evenly
distributed or clustered, but generally negative groups seem to prevail.
As indicated by several studies, ionic interactions between the parti-
cle surface and the cell might indeed mediate improved bioadhesion.
Thiele et al. showed that clearly higher quantities of PLL-coated PS
microspheres were associated with and internalized into APCs in vitro
as compared with negatively charged beads.[86] Moreover, positively
charged particles were phagocytosed in endosomes which showed
considerable interactions between the particle surface and the vesicle
membrane.[90]
That positively charged carriers are also characterized by an altered
biodistribution as compared to their negatively charged counterparts
has been shown in in vivo studies. Polystyrene latices sized 1.3 µm,
which had been surface modified with polylysyl gelatine, were pref-
erentially located in the lung 15 min after injection.[347] However,
it was not clear if this altered biodistribution was essentially due to
altered bioadhesion of positively charged colloids. Rather than that
the authors argued that positively charged particles might be more
prone to the formation of aggregates in whole blood. These aggregates
might subsequently be trapped in the extensive capillary bed of the
lung. More concrete evidence of enhanced bioadhesion of positively
charged particles to the endothelium was provided by Labhasetwar et
al.[186] PLGA nanoparticles sized ~100 nm that had been coated with
the cationic excipient DDAB delivered 7-10 fold higher drug levels to
isolated artery segments ex vivo than negatively charged colloids. Even
more interesting in regards to potential targeting via charge, Thurston
et al. reported that cationic liposomes preferentially bind to and are
taken up by angiogenic endothelial cells in mouse tumor models and
in a mouse model of chronic inflammation.[348]Thus, modifying the
surface charge of particles might not only lead to increased bioadhe-
sion, but might also represent an approach for targeting to specific cell
populations.
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From most studies in the literature it is difficult to deduce whether
bioadhesion of charged particles is mediated by the charge itself, by
proteins specifically adsorbed from serum or by other factors such as
aggregate formation in whole blood. In this study, plain carboxylated
PS nano- and microspheres and the same particles coated with the
cationic polyelectrolyte PEI will serve as model colloids, since they
resemble micro- and nanoparticulate drug carriers in size and charge.
Caco-2 and human umbilical vein endothelial cell (HUVEC) monolayers
will be employed as epithelial and endothelial cell models respectively
which are highly relevant for drug delivery. Using these particle and cell
types in a controllable in vitro setting, it will be investigated if positively
charged carriers are indeed characterized by higher bioadhesion than
their negative counterparts.
1.2.3.2 Materials and methods
Materials Yellow-green fluorescent carboxylated polystyrene parti-
cles with diameters of 500 nm and 2000 nm as well as PEI (branched,
MW~ 10 kDa) were obtained from Polysciences Europe GmbH (Eppel-
heim, Germany). All other chemicals used were of analytical purity.
Cell culture The Caco-2 cell line was purchased from DSMZ (Braun-
schweig, Germany) and was used for the experiments between passage
41 and 57. Tissue culture reagents were obtained from Sigma (St. Louis,
USA) and Gibco Life Technologies Ltd. (Invitrogen Corp., Carlsbad,
CA, USA). Cells were cultivated in RPMI 1640 cell culture medium con-
taining 10% fetal bovine serum, 4 mM L-glutamine and 150 mg mL−1
gentamycine in a humidified 5% CO2/95% air atmosphere at 37°C and
were subcultured by trypsination. Confluent Caco-2 cell monolayers in
96-well polystyrene microplates were obtained by seeding of 1.7 x 104
cells/160 µL/well and cultivation for 5-6 days.
HUVECs were isolated from human umbilical cords by treatment
with collagenase Type I and were used for the experiments between pas-
sage 2 and 4. The tissue culture flasks and microplates used for HUVEC
cultivation were coated with a 1% (w/v) aqueous solution of gelatin
for 30 min at 37°C prior to seeding of the cells in endothelial growth
medium-2 (EGM-2, Lonza, Basel, Switzerland). Confluent monolayers
in 96-well polystyrene microplates were obtained by seeding of 1.7 x
104 cells/160 µL/well and cultivation for 3 days.
Caco-2 and HUVEC cell monolayers for fluorescence microscopy
were grown on glass cover slips in 24-well microplates. For cultivation
of endothelial cells the glass slips were coated with a 100 µg mL−1
solution of fibronectin (from BD Biosciences Europe) in PBS for 30 min
at 37°C prior to seeding of the cells.
Coating of carboxylated nano- and microparticles with PEI
Coating of carboxylated polystyrene particles with diameters of 500 nm
(PS500) and 2000 nm (PS2000) was achieved by a technique modified
from [82]. 100 µL of a 5 mg mL−1 suspension of PS500 or 100 µL of
a 20 mg mL−1 suspension of PS2000 were added dropwise to a 5 mg
mL−1 solution of PEI in 100 mM phosphate buffer pH 5.8 in a tube
placed in an ultrasonic bath. In principle, the coating protocol can be
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adapted to various particle sizes as long as the ratio of total particle
surface area (Atotal): PEI concentration is held constant. The surface
area A [m2] of a sphere with radius r [m] is calculated according to 1.3
A = 4r2π (1.3)
If the total particle mass M [kg] is known, the total number of particles
N can be obtained from 1.4
N =
M
m
(1.4)
where m [kg] is the mass of a single particle as given by 1.5
m = ρpV (1.5)
with ρp [kg m−3] as the density of the particle material and V [m3] as
the volume of a single particle 1.6.
V =
4r3π
3
(1.6)
Accordingly, Atotal [m2] can be calculated from 1.7
Atotal = NA (1.7)
and by substituting, the simplified expression 1.8 is obtained.
Atotal =
3c
rρp
(1.8)
Upon reaction of PEI with the particles under sonication for 10 min,
1300 µL of 100 mM phosphate buffer pH 5.8 were added and the
particles were spun down on a centrifuge (Eppendorf 5804R).
As a rough guide, the centrifugation parameters for particle washing
can be calculated according to 1.9
tmax =
9
2
η
(ρp − ρs)r2ω2
ln
Re
Ra
(1.9)
where tmax [s] is the time needed to spin down all particles, η [kg m−1
s−1] is the viscosity of the suspension1, ρp [kg m−3] and ρs [kg m−3]
are the densities of the particles2 and suspension medium3 respectively,
r [m] is the particle radius, ω [s−1] is the angular frequency and Ra [m]
is the distance from the rotor axis to the upper level of the suspension
and Re [m] to the bottom level of the suspension respectively4.[377]
The angular frequency ω can be obtained from 1.10
ω = 2πvrot (1.10)
with vrot [s−1] as the rotation velocity. For PS500 and PS2000 this
results in centrifugation times of 3 min and 1 min respectively at 14000
rpm.
The pellet was washed with 100mM phosphate buffer pH 5.8 and was
finally resuspended in 1 mL HEPES under sonication for 15 s (sonifier,
Bandelin electronic UW70/HD 70; tip, MS 72/D, Berlin, Germany).
1 water at 10°C: 0.0013 kg m−1 s−1, water at 20°C: 0.001 kg m−1 s−1, water at 25°C: 0.0009
kg m−1 s−1, water at 30°C: 0.0008 kg m−1 s−1, glycerine: 1.16 kg m−1 s−1
2 polystyrene: 1050 kg m−3, PLGA: ~1280 kg m−3 [376]
3 water at 25°C: 997 kg m−3, 1% aqueous solution of Poloxamer 188: 1000 kg m−3, glycerine:
1260 kg m−3
4 for Eppendorf 5804R with rotor F45-30-11: ra= 0.07 m, re= 0.095 m
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Control particles were treated as described above, but without PEI in the
coating solution. The zeta potential of PEI-coated and control particles
was determined upon dilution in HEPES (conductivity ~0.69 mS cm−1)
by laser Doppler electrophoresis with a ZetaSizer Nano ZS (Malvern
Instruments Ltd., U.K.). Prior to the binding studies on Caco-2 and
HUVEC cell monolayers a small sample of all particle suspensions was
drawn and checked for agglomerates under a fluorescence microscope.
Binding studies on cell monolayers The stock suspensions of
negatively and positively charged PS500 and PS2000 in HEPES were
diluted with isoHEPES + 0.1 % of Poloxamer 188 or PBS + 0.1 % of
Poloxamer 188 to yield the working concentrations. All binding studies
were performed with suspensions containing 16 µg/100 µL, 8 µg/100
µL, 4 µg/100 µL, 2 µg/100 µL, 1 µg/100 µL, and 0.5 µg/100 µL PS
particles. Upon removal of the cell culture medium each well was filled
with 100 µL of particle suspension or plain buffer as control. The homo-
geneity of loading between wells was checked via fluorimetry with a
microplate reader (ex/em: 440/485 nm; Infinite 200i, Tecan Group Ltd.,
Grödig, Austria). Following incubation for 30 min at 37°C the particle
suspension was removed and the cell monolayer was washed twice with
100 µL of buffer. Finally, the fluorescence of the cell monolayer which
corresponds to the amount of cell-associated particles was determined
by fluorimetry.
Fluorescence microscopy HUVEC and Caco-2 cell monolayers
grown on glass cover slips were used for fluorescence microscopy.
Upon incubation with positively or negatively charged polystyrene
particles for 30 min at 37°C the cell layers were washed twice with PBS.
Subsequently, the cells were fixed with ice cold methanol (-20°C) for 10
min at -20°C. After rehydration in PBS for 20 min at room temperature
the cells were washed with PBS containing 1% BSA. Then, 100 µL of a
1:200 dilution of the primary antibody were added followed by incuba-
tion for 1 h at 37°C. In case of Caco-2 cells, purified mouse-anti-human
ZO-1 antibody (250 µg mL−1, BD Transduction Laboratories) was used
to label tight junction associated protein ZO-1 while in case of HUVECs
a polyclonal goat-anti-human VE-cadherin (C-19) antibody (200 µg
mL−1, Santa Cruz Biotechnology) was used to label vascular endothe-
lial cadherin. After washing with PBS + 1% BSA, 100 µL of a 1:200
dilution of R-phycoerythrin (RPE)-labelled goat-anti-mouse antibody (1
mg mL−1, Dako) in case of ZO-1 staining and 100 µL of a 1:200 dilution
of rhodamine-labelled rabbit-anti-goat antibody (1 mg mL−1, Abcam)
in case of VE-cadherin staining were added to the cells and left to react
for 30 min at 37°C. Finally, the cell layers were washed twice with PBS
+ 1% BSA and embedded in a drop of FluorSave. All images were taken
on a Nikon Eclipse 50i or a Zeiss Observer.Z1 microscope.
1.2.3.3 Results and Discussion
Adsorption of PEI leads to positively charged particles The
PS particles which were used in this study are not biodegradable and
consequently not suitable for administration as drug carriers. However,
they can be prepared in precise size classes and with custom surface
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chemistry which makes them an advantageous model for systematic
particle studies.
Many polymers used as matrix materials for the preparation of bio-
compatible and biodegradable drug delivery systems are characterized
by carboxyl end groups which impose a negative charge on the pro-
duced particle. Similarly, carboxylated PS particles carry negatively
charged groups on the particle surface. As illustrated in Table 7, this
Table 7: Zeta potential of 500 nm and 2000 nm polystyrene particles before and
after surface modification with PEI.
Surface
chemistry
Zeta potential
[mV]
500 nm carboxyl groups -82.5±2.0
PEI 54.0±2.8
2000 nm carboxyl groups -82.7±4.0
PEI 60.5±4.9
results in clearly negative zeta potentials of > -80mV at pH 7.4. The neg-
ative charges on the particle surface can be used to drive the adsorption
of cationic polyelectrolytes. For this purpose, a series of natural, pro-
cessed natural, and synthetic polyelectrolytes can be employed. These
include protamine,[89] chitosan,[84, 88, 91, 92, 93, 94, 95, 96, 97, 98, 99]
gelatine,[100] diethylaminoethyl dextran,[101] Eudragit® RL/RS,[85]
PEI,[102, 103, 104, 105, 106] and PLL.[46, 87, 103, 107, 108, 109] In
this study, low molecular weight branched PEI was used due to its
high density of amino groups.[111] In slightly acidic buffer the amino
groups exist in their protonated and thus charged form. These cationic
groups are expected to interact with negatively charged carboxyls on
the particle surface by ionic interactions. At this, the composition of the
adsorption buffer is expected to influence the polyelectrolyte configu-
ration as well as adsorption efficiency. While PEI will exist as a rather
stretched molecule in water or low ionic strength buffers, it will adapt
a coiled configuration if the adsorption buffer’s ionic strength is suffi-
ciently high. Adsorption of coiled polyelectrolytes will not only result
in direct charge compensation and neutralization of a particle’s surface
potential. Moreover, surplus positive charges will be introduced and the
zeta potential will be inverted.[82] However, if the ionic strength of the
adsorption buffer is increased further, the charges of the polyelectrolyte
will be screened and electrostatic interactions with dissociated groups
on the particle surface will be reduced. 100 mM phosphate buffer has
proven to represent a suitable compromise in terms of ionic strength
and was successfully used for coating of colloids with PEI.[82] In the
present study, adsorption of PEI from 100 mM phosphate buffer onto
PS nano- and microparticles was achieved. This was confirmed by a
clear shift of the zeta potentials of PS particles to positive values as
illustrated in Table 7. However, it has to be highlighted that the protocol
by Trimaille et al. [82] had to be modified to generate satisfactory re-
sults with PS particles. While in the original study a PEI concentration
of less than 30 µg mL−1 was sufficient for introduction of a positive
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zeta potential, an about 50 fold higher PEI concentration had to be
employed in the present study. The increase in PEI concentration was
necessary since irreversible agglomeration of the particles occurred
at lower concentrations. A possible reason for this might lie in the
different quantities of carboxyl groups on the surface of PS and PLA
particles. PS particles might be characterized by a clearly higher surface
carboxyl group density. This could explain why a PEI concentration
in the range of 30 µg mL−1 led to aggregation of the particles. Due to
insufficient charge compensation on the particle surface colloids with
partially negative and partially positive surface sites might be created.
This would inherently reduce electrostatic stabilization of the disper-
sion and consequently favour the formation of aggregates. With higher
PEI concentrations, the particle surface charge is rapidly reversed and
thus the potential for aggregation is low. Generally, as observed by
fluorescence microscopy negatively charged particles used in this study
were free from agglomerates. Positively charged particles tended to
agglomerate upon dilution and prolonged storage in isotonic buffer.
At this, the suspension was sonified until the majority of colloids were
redispersed and ready to use for studies with cell monolayers.
Positively charged particles exhibit higher binding to Caco-2
cell monolayers The usability of micro- and nanoparticles for drug
delivery purposes depends on their delivery efficiency. To be able to
compare the cell binding efficiency of differently sized particles, the
mass deposition data will be presented in this study.
Upon incubation of negatively and positively charged colloids with
Caco-2 cell monolayers for 30min at 37°C in isoHEPES, clear differences
in the amount of cell-binding were observed. As illustrated in Figure 18,
negatively charged PS500 were only detected when at least 6 µg had
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Figure 18: Positively (closed symbols) and negatively charged particles (open
symbols) associated with Caco-2 cell monolayers upon incubation in
isoHEPES for 30 min at 37°C. Particle diameter 500 nm (∆) and 2000
nm (o). Each data point consists of n= 27 measurements.
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been added to the cell layer which resulted in 0.05 ± 0.1 µg of cell-
associated particles. In contrast, positively charged PS500 were already
unambiguously detected upon addition of ~1 µg which resulted in
0.017 ± 0.004 µg of cell-associated particles. At concentrations of ￿6 µg
of particles added per well, the amount of cell-bound PS500 particles
was constantly 4-5 fold higher in the case of positively charged colloids
as compared to their negative counterparts. This was also confirmed
by fluorescence microscopy as illustrated in Figure 19. Consistent with
Figure 19: Negatively (1) and positively charged (2) 500 nm particles (green)
associated with Caco-2 cells after 30 min incubation. Concentration
of particle suspension ~1 µg/100 µL (A) and ~8 µg/100 µL (B). Tight
junction associated protein ZO-1 labelled in red.
the quantitative results obtained by fluorimetry, almost no negatively
charged PS500 were observed on the Caco-2 cell monolayer upon incu-
bation with a suspension containing 1 µg/100 µL. (Figure 19 1A). At
the same concentration, positively charged PS500 were already clearly
visualized as regularly distributed green dots (Figure 19 2A). The quan-
titative data plotted in Figure 18 were still reflected in the visually
observed densities of bound particles when the concentration had been
increased 8-fold (Figure 19 B).
Similar observations as with PS500 were made in the case of PS2000.
Starting at a concentration of ~1 µg per well, cell-associated particles
were unambiguously detected. Over the whole concentration range
tested, the positively charged colloids were characterized by a 2.5 fold
higher cell binding than the negatively charged PS2000.
Particle binding studies with Caco-2 cells can be performed in iso-
HEPES without notable morphological alterations of the cells or dis-
integration of the monolayer. However, HUVEC monolayers proved
to be highly sensitive to the composition and type of the incubation
buffer. Thus, binding studies had to be performed in PBS. In order to
be able to compare the quantities of cell-associated particles between
the endothelial and epithelial cell model, particle binding studies with
Caco-2 cell monolayers were also performed in PBS. When comparing
the binding rates in isoHEPES (Figure 18) with those in PBS (Figure 20)
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it becomes obvious that in the latter case the amount of cell-associated
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Figure 20: Positively (closed symbols) and negatively charged particles (open
symbols) associated with Caco-2 cell monolayers upon incubation in
PBS for 30 min at 37°C. Particle diameter 500 nm (∆) and 2000 nm
(o). Each data point consists of n=6 measurements.
particles was clearly reduced in all cases. Interestingly, the effect of
PBS on cell-binding was more pronounced in case of PS2000. This was
exemplified by a consistent reduction of the the amount of cell-bound
positively and negatively charged particles by about 60%. In case of
PS500 the reduction was not as distinct as in the case of PS2000 but
nevertheless amounted to about 30 %. For both sizes, the effect was
neither dependent on the concentration nor on the surface charge of
the particles. This indicates involvement of a nonspecific mechanism
that probably either affects the particles’ detection via fluorimetry or
their ionic interaction with the cell monolayer. However, neither of
these reasons can be conclusively argued to be involved in this case.
Since the pH as well as osmolarity of PBS and isoHEPES were identical
according to measurements, buffer-induced fluorescence intensity al-
terations are unlikely. The interaction between two oppositely charged
species is known to depend on the concentration and type of ions
in the medium. Consequently, the buffer composition determines the
surface potential of dispersed colloids and charged groups in the cell
membrane and might alter the interaction between oppositely charged
species. Although PBS contains multivalent ions, the main component
contributing to its osmolarity and thus ionic strength is sodium chloride.
Calculations confirm that a similar ionic strength as for isoHEPES can
be expected. This probably precludes effects of multivalent ions on the
interface and thus interaction potential of colloids as well as cells.
Regardless of the different quantities of cell-bound particles in PBS
and isoHEPES, the results clearly demonstrate a particle size indepen-
dent preferential binding of cationic particles to Caco-2 cell monolayers.
Very likely, this can be attributed to ionic interactions between the
polycation-coated colloids and negative charges of the Caco-2 cell mem-
brane. Thus, with the epithelial cell model the hypotheses and reports
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in the literature according to which positively charged particles are
more bioadhesive than their negative counterparts were confirmed.
It should be borne in mind, however, that Caco-2 cells were originally
isolated from a colon carcinoma. Tumor or regenerating cells are charac-
terized by higher electrophoretic mobilities and thus higher cell surface
charge than their normal counterparts.[378, 379] As a consequence it
might be possible that the clearly preferential binding of positively
charged particles onto Caco-2 cells does not exactly reflect the bind-
ing to normal intestinal epithelium. Studies with primary intestinal
epithelial cells might help to clarify this issue.
Negative and positive particles equally bind to endothelial cells
In contrast to the results obtained with Caco-2 cell monolayers, no pref-
erential attachment of positively charged particles was observed on
HUVEC monolayers. As illustrated in Figure 21, the adhesion data
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Figure 21: Positively (closed symbols) and negatively charged particles (open
symbols) associated with HUVEC cell monolayers upon incubation
in PBS for 30 min at 37°C. Particle diameter 500 nm (∆) and 2000 nm
(o). Each data point consists of n=21 measurements.
for positively and negatively charged PS500 are clearly similar. When
both data sets are collectively fitted with a linear function, a coefficient
of determination (R2) of 0.99 is obtained. Similarly, no pronounced
differences between positively and negatively charged PS2000 were
observed. This was confirmed by fluorescence microscopy as illustrated
in Figure 22. These results indicate that HUVEC monolayers, unlike
Caco-2 cell monolayers, bear equal binding capacity for negatively
and positively charged particles. Related observations were reported
by Osaka et al., who investigated the uptake of positively and nega-
tively charged magnetite nanoparticles into MCF-7 breast cancer cells
and HUVECs.[380] While a preferential uptake of positively charged
nanoparticles into MCF-7 cells was detected, the data for HUVECs
revealed no difference between positively and negatively charged col-
loids. In connection with the presented results, this indicates that higher
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Figure 22: Negatively (1) and positively charged (2) 2000 nm particles (green)
associated with HUVECs after 30 min incubation. Concentration
of particle suspension ~1 µg/100 µL (A) and ~8 µg/100 µL (B).
Vascular endothelial cadherin (red).
bioadhesion of positively charged particles obviously can not be pre-
sumed for all cell types.
HUVEC monolayers bind more particles than Caco-2 monolay-
ers In terms of the quantities of cell-associated particles, HUVECs
obviously represent a comparatively affine cell substrate for particle
binding. Over the concentration range investigated, HUVEC monolay-
ers exhibit a 2-fold and 4-5 fold higher binding capacity than Caco-2 cell
monolayers for positively charged PS500 and PS2000 respectively. In the
case of negatively charged colloids, this was even more pronounced as
illustrated by 6-8 fold and 10-fold higher binding of PS500 and PS2000
respectively. This could be specific for endothelial cells. However, it is
also possible that primary intestinal epithelial cells differ from Caco-2
cells in terms of their binding capacity for positively and negatively
charged particles. This point and possible differences between primary
cells and cell lines should be clarified in future studies.
Higher binding efficiency of nanoparticles As illustrated by the
fluorescence microscopic images in Figure 19 and Figure 22, PS500 are
more uniformly distributed on the cell monolayer. In regards to drug
delivery this implies that the incorporated drug will be released more
homogenously to the cells if delivered in smaller carriers.
To be able to estimate the binding efficiency the theoretical particle
deposition rates during the experiment can be calculated. Deposition
rates for particles in the sedimentation controlled regime depend on
the sedimentation velocity vsed of the particles according to 1.11
vsed =
2
9
gr2(ρp − ρs)
η
(1.11)
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with g [m s−2] as the gravitational acceleration. For PS500 and PS2000
in aqueous buffer at room temperature a vsed of ~0.5 µm min−1 and
~7.7 µm min−1 respectively is expected. This leads to the assumption,
that the PS500 in the lower 15 µm and the PS2000 in the lower 230 µm
of suspension in the cylindrical well will have sedimented onto the cell
layer after incubation for 30 min. Considering the cylindrical form of
the microplate well with a base of 33 mm2 and a uniform distribution
of the particles, this amounts to deposition of 0.5 % of the added PS500
and 7.6 % of the added PS2000. Consequently, an about 15 times higher
deposition of PS2000 can be expected. For the highest concentration of
~16 µg/100µL/well this corresponds to deposition of 0.08 and 1.2 µg
of PS500 and PS2000 respectively.
These rough estimates indicate that only a small fraction of the
colloids actually deposits on the cell monolayer within 30 min. As
illustrated by the almost linear binding curves for all particle types on
Caco-2 and HUVEC monolayers, no saturation of the cell layer occurs
during the experiment. In the case of PS2000 the theoretical deposition
rates seem realistic if compared with the experimentally observed val-
ues for positively (1.46 ± 0.30 µg) and negatively charged particles (1.07
± 0.15 µg) on HUVECs. In case of PS500 however, the calculated depo-
sition rates seem to be rather inaccurate. All positively charged PS500
bind in higher quantities as expected on HUVEC and Caco-2 mono-
layers. A reason for this might be the formation of aggregates which
sediment at a higher vsed than single particles. However, aggregates
were never observed with negatively charged PS500 and nevertheless
0.67 ± 0.07 µg of particles were detected as cell-bound at a concen-
tration of ~14.8 µg added to HUVEC monolayers (Figure 21). This is
clearly higher than the calculated value of <0.1 µg. Thus, aggregation
is not solely responsible for the discrepancies between theoretical and
experimentally observed deposition rates in case of PS500. Transport
of particles to the cell layer by diffusion is likely to lead to additional
deposition, however this is not accounted for in the calculation above.
Larger particles are expected to expose a higher surface area per
particle to the cell monolayer. This should entail a higher probability
of interaction between oppositely charged groups and thus a higher
likelihood of cell-binding. A clear bias of the experimentally observed
cell-bound particle mass according to these considerations however
was not observed. Although PS2000 are generally characterized by
higher binding, it is at maximum only twice as high as that of the
corresponding PS500. This is in clear contrast to the theoretically pre-
dicted 15 times higher deposition of PS2000. The reasons for this are not
entirely clear. However, it is plausible that the increased surface area
available for binding does not necessarily lead to improved anchoring
of the particles. Possibly, this can be explained by the difference in
radius between the particles which affects their susceptibility to hy-
drodynamic stress. In the experiments presented, the washing steps
to remove non-bound particles might impose sufficient shear stress to
dissociate the interaction between PS2000 and the cells. At the same
time, PS500 could remain cell-bound since smaller colloids are relatively
unaffected by shear stress due to their smaller radius and thus exposed
surface area.[381] Consequently, efficient cell-binding could be attained
by working with particles at an optimal ratio of particle size to adhesion
area. Studies with parallel plate flow chambers (PPFC) [287, 381, 382] or
microfluidic devices [383, 384, 296] could help to precisely investigate
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the effect of hydrodynamic drag forces on the binding of positively and
negatively charged particles to cell monolayers. This would not only
improve the present understanding of particle binding studies in vitro,
but also might allow to deduce an optimal particle size for the targeting
of biological barriers with bioadhesive colloids.
1.2.3.4 Conclusions
As illustrated by the results presented, positively charged particles are
not generally characterized by higher cytoadhesion than negatively
charged particles. While binding studies with an intestinal epithelial
cell model indicated a preferential binding of cationic particles, no such
tendencies were observed on primary endothelial cells. In the future, it
would be highly interesting to perform the same studies with primary
intestinal epithelial cells. This could clarify if Caco-2 cells, despite
originating from a tumour, are representative of intestinal epithelium
in terms of cell membrane charges.
In the present study, the experiments were performed under station-
ary conditions. To investigate if the adhesive force of positively and
negatively charged nano- and microparticles is sufficient to mediate
binding under physiological conditions, experiments with dynamic
assays should be performed. In combination with experiments in the
presence of serum, it might be possible to elucidate if charged micro-
and nanoparticles could serve as bioadhesive and potentially targeted
drug carriers in vivo.
As indicated by the data presented, nanoparticles are characterized
by a higher binding efficiency as microparticles. This becomes clear
when the experimentally observed deposited particle mass is compared
with the theoretical deposition rates. Although microparticles can carry
a larger amount of drug due to their volume, nanoparticles might be
more efficient for drug delivery because they spread in the tissue evenly
and are less prone to removal by shear forces.
2SURFACE ACOUST IC WAVE (SAW) CHIPS :
INTEGRATING FLOW INTO MINIATURIZED
B IOPHARMACEUTICAL TEST SYSTEMS
2.1 background
2.1.1 Relevance of flow to drug delivery with particles
Micro- and nanoparticles have been extensively investigated as to their
potential utility as drug delivery systems. The interaction of drug-
loaded particulates in the nano- and micrometer range with the organ-
ism, however, is expected to clearly differ from that of dissolved drug
molecules. A parameter that might be of considerable importance in
this regard is the flow of materials under physiological conditions.[7]
Regardless of whether particles are administered perorally or par-
enterally, hydrodynamic forces will act on them. The peristaltic motion
in the gastrointestinal tract leads to streaming velocities of ~90 µm s−1
in the jejunum and ~60 µm s−1 in the ileum respectively.[385] As com-
pared to these values the flow velocities in the circulatory system are
considerably higher (Table 8). Characteristically, blood flow velocity cor-
relates with the vessel diameter. While the velocities are clearly lowest
in the capillary system they concurrently increase with increasing vessel
size in the arterial and venous system.[386] Interestingly, in tumors this
correlation is lost due to the morphologically aberrant vasculature.[388]
Colloidal drug carriers in a certain size range are preferentially retained
in tumor tissue due to the EPR effect.[389] However, it has to be high-
lighted that this is not a static and general but rather than that inter-
and intratumorally varying characteristic.[390] While vessel permabil-
ity changes over time, tumor growth also leads to compression of the
intratumoral vasculature which conseqently reduces blood supply.[391]
Thus, tumor targeting rationales might not be efficient in a multitude
of cases if they are exclusively based on abnormalities in microvascular
flow and vessel permeability.[392]
A direct comparison of the physiological flow rates in the circulatory
system with the gastrointestinal tract is not entirely meaningful due
to the different size scales of the systems. In order to be able to better
compare the flow rates despite the different diameters of blood vessels
and the intestine, the shear rate γ can be employed. For a Newtonian
fluid flowing in a pipe, γ can be calculated according to 2.1
γ =
8v
d
(2.1)
with ν as the fluid velocity and d as the inside diameter of the pipe.
Accordingly, the effective shear rate under normal conditions in the
small intestine is about 0.01 s−1 and thus clearly lower when compared
with the circulatory system (Table 8). These calculations are estimates
since mucus [393] and chyme behave non-Newtonian and blood is not
Newtonian either until shear rates higher than 100 s−1 are applied.
Based on the shear rate γ the shear stress τ can be calculated which is
111
Table
8:D
iam
eter,flow
velocity
and
totalcross
sectionalarea
ofblood
vessels
ofthe
hum
an
body
V
ESSEL
TY
PE
D
IA
M
ETER
a
[m
m
]
FLO
W
V
ELO
C
ITY
[m
m
s
−
1]
TO
TA
L
C
R
O
SS
SEC
TIO
N
A
L
A
R
EA
b
[m
m
2]
SH
EA
R
R
A
TE
[s
−
1]
elastic
arteries
>10
300
b
530
c
~
250
m
uscular
arteries
0.1
-10
2000
arterioles
0.01
-0.1
￿
30
-5
d
50000
-70000
~
2000
-4000
capillaries
0.004
-0.01
0.2
-1
b
350000
~
400
-800
venules
0.01
-0.1
￿
1
-￿
10
d
260000
~
800
veins
0.1
-￿
1
40
-60
b
4000
e
~
500
-3000
a
according
to
[386]
b
according
to
[387]
c
ofthe
aorta
d
according
to
[388]
e
oflarge
veins
112
2.1 background 113
a measure for the hydrodynamic force acting in the system. According
to 2.2 τ depends on the shear rate and viscosity of the medium (η).
τ = γ η (2.2)
While the shear rates in the gastrointestinal tract seem negligible when
compared with the circulatory system, the differences in shear stress
are considerably lower. This is due to the fact that the different vis-
cosities of mucus1 or chyme and blood2 respectively are accounted for.
As mentioned previously, these considerations should only serve as
approximations. Viscosity highly depends on shear rate.[393] Blood
viscosity is dependent on hematocrit and has been shown to vary along
the crosssection of vessels especially in tubes with diameters smaller
than 500 µm.[395] Pertaining to colloidal drug carriers, shear rate and
shear stress might be highly relevant parameters. In order for nano-
and microparticles to release their payload in the body the colloids
have to be retained for a sufficient period of time. In case of peroral
delivery, particles will have to localize to cells lining the gastrointestinal
tract. Subsequently, firm adhesion has to be established in the presence
of peristalsis which mixes the luminal contents. If particles can not
reach or bind to the lining cells, they will be removed by mucus shed.
Similarly, upon parenteral administration particles will be affected by
blood or lymph flow. Most likely the hydrodynamic forces occuring
in either system will affect adhesion of the particulate drug carriers to
vessel-lining tissue. This is underlined by theoretical and experimental
particle binding studies on healthy and inflamed endothelium. Sem-
inal contributions dealing with the effect of shear force on adhesion
have been published by Goetz et al.,[382, 396, 381] Lauffenburger et
al.,[397, 398] Hammer et al.,[203, 287] and others.[399, 400]
Under stationary conditions which normally occur in vitro the depo-
sition rate of particles onto cells primarily will be governed by sedimen-
tation and diffusion. However, this will not occur in a similar fashion in
vivo where extracellular material is in constant flux. As a consequence
flow might not generally decrease the binding of particles to cells but
also could enhance mass transport to the cell membrane in certain shear
regimes.[401]
The circulatory system consists of an immense system of vessels
with varying diameters. Collectively, the length of the blood vessels
amounts to about 95000 km in children and about 160000 km in adults.
An interesting fact in the face of current demographic developments
is that with every additional kilogramm of fat on top of the normal
body weight, 650 km of vasculature are developed.[386] At large, this
provides an immense inner surface area for adsorption of injected
drug carriers which is further increased by the presence of blood cells.
Similarly, diversification of the surface of cells lining the intestinal
lumen and folding of the tissue generates a considerable adsorptive
surface in the gastrointestinal tract. In the small intestine this amounts
to an inner surface area of about 200 m2. It is unclear whether the flow
in tissues with high cellular surface area will aid particle adsorption or
antagonize it.
In addition to potential non-specific adsorption highly efficient filtra-
tion mechanisms remove colloids from the bloodstream. The primary
1 up to 2000 mPa s [394], highly dependent on shear rate
2 at hematocrit of 40: 2.7 mPa s at 37°C; plasma viscosity: 1.5 mPa s at 20°C; alternative
reference: normal hematocrit at shear rate 100 s−1: 4 mPa s [395]
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organs for particle sequestration are the liver and spleen. Uptake of
particles in these organs is largely accomplished by cells of the RES
which recognize colloids via adsorbed complement proteins, antibodies
as well as other serum proteins 3.[261, 262] While particle sequestration
mainly relies on phagocytosis, a complementary mechanism based on
hydrodynamic filtration in the liver has been discussed.[256] According
to this hypothesis, white blood cells serve as plungers which cause the
filtration of material through fenestrations of liver capillaries into the
space of Disse. This might further contribute to the liver functioning as
a “sponge” which effectively removes colloids from the bloodstream.
Fluid flow in small tubes furthermore leads to counterintuitive phe-
nomena. As a consequence of the Fahraeus effect, erythrocytes are
not uniformly distributed over the vessel cross section. Rather, they
accumulate in the center thus creating a cell-depleted layer of plasma
at the vessel wall.[395] In vessels larger than 30 µm, white blood cells
are forced into this wall layer by collisions with erythrocytes. Thereby,
the interaction of leukocytes with endothelial cells, especially in post-
capillary venules, is enhanced .[402] This leads to leukocyte rolling
which is the first step in a cascade of events which finally enable the
recruitment of immune cells to inflamed tissue areas. This intrinsic
separation of cells by flow could certainly also affect the distribution of
particles in the bloodstream. While a margination into the cell-depleted
plasma layer could favour adhesion to endothelial cells, accumulation
in the center might lead to interaction with erythrocytes.
Hydrodynamic forces acting on particles might result in an overcom-
ing of colloidal repulsive forces.[403] This could ultimately increase
the likelihood of aggregate formation of injected particulate drug car-
riers, which might lead to vessel obstruction. Moreover, theoretical
considerations indicate that shear forces acting on polymer particles or
liposomes could result in deformation of the drug carriers and extru-
sion of the encapsulated payload.[404] Similarly, carrier elasticity will
influence passage of the particles through capillaries or fenestrations of
the endothelium.
As illustrated by this certainly incomplete list, a variety of factors
relating to flow will influence the performance of particulate drug carri-
ers upon adminstration in vivo. However, the majority of in vitro studies
dealing with the interaction between particles and cells are conducted
under stationary conditions. Thereby, the complexity encountered in
the human body is underestimated.[7]
To be able to investigate the effects of flow in preclinical biopharma-
ceutical test systems in vitro and to integrate the obtained knowledge
into the design of potential drug carrier systems, easy to handle and
versatilely adaptable techniques for flow generation have to be avail-
able. The main body of data on hydrodynamic shear effects has been
generated in parallel plate flow chambers. Similar systems have more re-
cently been made available in a simplified form for higher throughput4.
Vessel-like models such as non-transparent hollow-fibers [405] and
non-ionic surfactant microtubules also have been proposed for flow-
related studies.[406] Finally, recently developed microfluidic setups
and alternative pumping techniques bear high potential for preclinical
biopharmaceutical flow test systems.
3 see 1.1.2.4, section “Prolonged circulation time” for more details
4 http://www.ibidi.de/
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2.1.2 Acoustically-driven microfluidics
Waves on the surface of a solid already have been described theoretically
by Lord Rayleigh in 1885 as to their relation to earthquakes.[407] In the
meanwhile it has become possible to generate SAW on the nanometer
scale by use of chip technology. In a very effective and controlled
manner, these “nanoquakes” can be induced on piezoelectric materials.
At this, interdigital electrode structures (Figure 27) deposited on a
piezoelectric substrate serve as effective transducers. When an electrical
signal of proper frequency is applied to the transducer, a periodic
deformation of the underlying crystal surface is induced via the inverse
piezoelectric effect.[9] As illustrated in Figure 23 the resulting SAW
Figure 23: Surface deformation associated with surface acoustic wave (SAW).
Image by courtesy of T. Franke, University of Augsburg
is characterized by subsequent regions of compressed and expanded
material. All matter in the path of the SAW will be exposed to its
energy propagating which is largely of mechanical nature. If a liquid is
in contact with the substrate surface, the pressure difference exerted
by the SAW will excite a longitudinal sound wave in the fluid.[8] Due
to the differences in sound velocity between solid and liquid, the SAW
couples into the liquid under a diffraction angle Θr according to 2.3
Θr = arcsin
vs
vf
(2.3)
where vs and vf are the sound velocities in the solid and fluid respec-
tively. [8] The acoustic radiation pressure associated with the SAW
leads to the generation of pressure jets in the fluid (Figure 24) which
Figure 24: Dye at the interface between a piezoelectric substrate and a fluid is
ejected by pressure jets of a surface acoustic wave (SAW). Image by
courtesy of T. Franke, University of Augsburg
can be made use of for directional streaming. These jets constitute the
force-generating mechanism of SAW-pumps for liquid streaming. The
average force density exerted by the surface acoustic wave <fSAW> can
be calculated from the nonlinear term of the Navier-Stokes equation as
< fSAW >≈ −ρ(1+α
2
e)A
2ω2
l
(2.4)
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where ρ is the density of the piezoelectric material, αe a constant, l a
characteristic decay length,ω the frequency, and A the amplitude of the
wave. The amplitude A can be controlled by applying a voltage with
sub-Angström precision to the interdigital transducers (IDTs). From
2.4 the corresponding force generated near the chip surface can be
calculated using αe ≈ 2.46, l = 1 mm, ω = 150 - 375 MHz, and ρ = 5 x
103 kg m−3. This leads to an average force < F > that can be calculated
according to 2.5
< F >≈ 0.9f2A2 (2.5)
where f is the excitation frequency (ω = 2πf) of the SAW on the
substrate.
While SAW chips have been extensively used for RF signal process-
ing and filtering purposes in the telecommunication industry as well
as sensors,[408] several fields of application in fluid actuating have
been reported recently. One of the main advantages of the chip-based
technique is its high degree of miniaturization. This makes acoustic
streaming well suited for processes involving small liquid volumes
which are not easily handled by conventional pumping techniques.
Successful implementation of SAW-pumps for droplet mixing,[9] mi-
croarray hybridization,[409] PCR in nL-volumes on a chip5,[410] and
particle separation has been shown.[411, 412] If the chip surface is
chemically patterned a SAW can be employed to actuate droplets on
predefined tracks in a contact-free manner.[8] Furthermore, recently
developed techniques for the production of microfluidic devices have
allowed to channelize the flow generated by SAW-pumps.[413, 414] A
combination of the latter with cell culturing would represent an advan-
tageous approach for the mimicking of blood vessels, gastrointestinal
as well as urinary tract and thus more generally speaking: physiological
flow conditions in vitro. This application will be discussed further in
the specific topics.
5 the interested reader is referred to http://www.advalytix.com for more information on
already commercialized SAW-devices for biotechnology
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The interaction of targeted drug carriers with epithelial and endothelial barriers in vivo is largely
determined by the dynamics of the body fluids. To simulate these conditions in binding assays, a fully
biocompatible in vitro model was developed which can accurately mimic a wide range of physiological
flow conditions on a thumbnail-format cell-chip. This acoustically-driven microfluidic system was used
to study the interaction characteristics of protein-coated particles with cells. Poly(D,L-lactide-co-
glycolide) (PLGA) microparticles (2.9 ! 1 mm) were conjugated with wheat germ agglutinin (WGA-
MP, cytoadhesive protein) or bovine serum albumin (BSA-MP, non-specific protein) and their binding
to epithelial cell monolayers was investigated under stationary and flow conditions. While mean
numbers of 1500 ! 307 mm"2 WGA-MP and 94 ! 64 mm"2 BSA-MP respectively were detected to be
cell-bound in the stationary setup, incubation at increasing flow velocities increasingly antagonized the
attachment of both types of surface-modified particles. However, while binding of BSA-MP was totally
inhibited by flow, grafting with WGA resulted in a pronounced anchoring effect. This was indicated by
a mean number of 747 ! 241 mm"2 and 104 ! 44 mm"2 attached particles at shear rates of 0.2 s"1 and
1 s"1 respectively. Due to the compactness of the fluidic chip which favours parallelization, this setup
represents a highly promising approach towards a screening platform for the performance of drug
delivery vehicles under physiological flow conditions. In this regard, the flow-chip is expected to
provide substantial information for the successful design and development of targeted micro- and
nanoparticulate drug carrier systems.
Introduction
Physiological and pathological processes such as the site-specific
adhesion of platelets, leukocytes or metastasizing cancer cells are
based on sophisticated mechanisms in order to efficiently function
in the presence of hydrodynamic flow. Substantial knowledge
about these processes has been generated by simulating physio-
logical shear conditions with in vitro fluidic systems such as the
parallel plate flow chamber (PPFC) and the radial flowdetachment
assay (RFDA).1–4 Although primarily aimed at understanding
physiology, these fundamental studies also bear essential implica-
tions for the development of targeted colloidal drug carriers.1,3,5
Presently, the target effect of site-specific drugdelivery systems is by
default determinedwith in vitro cell bindingassaysunder stationary
conditions.However, regarding the extentand specificityofparticle
binding, recent reports have identified clear discrepancies between
the results obtained from stationary and more realistic, dynamic
models of the in vivo environment.6–8 Particularly, the presence of
substantial hydrodynamic drag forces upon application in vivo is
expected to explicitly affect the deposition characteristics of ligand-
coated particles.7,9,10 The most pronounced variations of flow
conditions in the human organism are expected in the circulatory
system. This is illustrated by effective shear rates ranging from1 s"1
in wide vessels to 105 s"1 in small arteries.11 Temporally high shear
rates of about 400 s"1 also have to be expected in the urethra upon
emiction.12 To attain preferential binding of the carrier to the
diseased tissue in these environments, the size and ligand coating
density of the colloids has to be adjusted according to the flow
conditions as well as the expected receptor density and affinity at
the target tissue.1,2,5 In order to be able to practically optimize these
parametersofpotential drugdeliveryvehicles, parallelizable in vitro
bioassays have to be developed which offer the possibility of
controllable flow generation. At this, increased experimental
throughput is highly necessary in order to cope with the extensive
amount of samples which have to be processed to generate suffi-
cient data sets. Although well suited for specific questions, the
PPFC and RFDA are of limited use for such applications. When
multiple experiments are demanded at high reproducibility, the
complexity of these methods’ tubing and chambers becomes
cumbersome to handle. Microfluidic pumping techniques might
allow for approaching these shortcomings successfully. The most
common methods to generate flow in miniaturized systems are
thermophoresis (viaMarangoni forces), electrochemical reactions,
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2.2.1.1 Abstract
The interaction of targeted drug carriers with epithelial and endothelial
barriers in vivo is largely determined by the dynamics of the body
fluids. To simulate these conditions in binding assays, a fully biocom-
patible in vitro model was developed which can accurately mimic a
wide range of physiological flow conditions on a thumbnail-format
cell-chip. This acoustically-driven microfluidic system was used to
study the interaction characteristics of protein-coated particles with
cells. PLGA microparticles (2.9±1 µm) were conjugated with wheat
germ agglutinin (WGA-MP, cytoadhesive protein) or bovine serum
albumin (BSA-MP, non-specific protein) and their binding to epithelial
cell monolayers was investigated under stationary and flow conditions.
While mean numbers of 1500±307 mm−2 WGA-MP and 94±64 mm−2
BSA-MP respectively were detected to be cell-bound in the stationary
setup, incubation at increasing flow velocities increasingly antagonized
the attachment of both types of surface-modified particles. However,
while binding of BSA-MP was totally inhibited by flow, grafting with
WGA resulted in a pronounced anchoring effect. This was indicated
by a mean number of 747±241 mm−2 and 104±44 mm−2 attached
particles at shear rates of 0.2 s−1 and 1 s−1 respectively. Due to the
compactness of the fluidic chip which favours parallelization, this setup
represents a highly promising approach towards a screening platform
for the performance of drug delivery vehicles under physiological flow
conditions. In this regard, the flow-chip is expected to provide substan-
tial information for the successful design and development of targeted
micro- and nanoparticulate drug carrier systems.
2.2.1.2 Introduction
Physiological and pathological processes such as the site-specific ad-
hesion of platelets, leukocytes or metastasizing cancer cells are based
on sophisticated mechanisms in order to efficiently function in the
presence of hydrodynamic flow. Substantial knowledge about these
processes has been generated by simulating physiological shear con-
ditions with in vitro fluidic systems such as the PPFC and the radial
flow detachment assay (RFDA).[381, 415, 382, 416]Although primarily
aimed at understanding physiology, these fundamental studies also
bear essential implications for the development of targeted colloidal
drug carriers.[381, 382, 287] Presently, the target effect of site-specific
drug delivery systems is by default determined with in vitro cell bind-
ing assays under stationary conditions. However, regarding the extent
and specificity of particle binding, recent reports have identified clear
discrepancies between the results obtained from stationary and more
realistic, dynamic models of the in vivo environment.[363, 384, 417] Par-
ticularly, the presence of substantial hydrodynamic drag forces upon
application in vivo is expected to explicitly affect the deposition char-
acteristics of ligand-coated particles. The most pronounced variations
of flow conditions in the human organism are expected in the circula-
tory system. This is illustrated by effective shear rates ranging from 1
s−1 in wide vessels to 105 s−1 in small arteries.[418] Temporally high
shear rates of about 400 s−1 also have to be expected in the urethra
upon emiction.[419] To attain preferential binding of the carrier to
the diseased tissue in these environments, the size and ligand coating
density of the colloids has to be adjusted according to the flow condi-
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tions as well as the expected receptor density and affinity at the target
tissue.[381, 415, 287] In order to be able to practically optimize these pa-
rameters of potential drug delivery vehicles, parallelizable in vitro bioas-
says have to be developed which offer the possibility of controllable flow
generation. At this, increased experimental throughput is highly neces-
sary in order to cope with the extensive amount of samples which have
to be processed to generate sufficient data sets. Although well suited
for specific questions, the PPFC and RFDA[384, 7, 400] are of limited
use for such applications. When multiple experiments are demanded
at high reproducibility, the complexity of these methods’ tubing and
chambers becomes cumbersome to handle. Microfluidic pumping tech-
niques might allow for approaching these shortcomings successfully.
The most common methods to generate flow in miniaturized systems
are thermophoresis (via Marangoni forces), electrochemical reactions,
surface patterning methods, electro-osmosis, induced charge electro-
osmosis as well as several mechanical pumping strategies.[420, 421]
However, these techniques’ suitability is limited for systems which
are required to comply with cell growth and cell viability. For such
applications a micropumping technology based on acoustic streaming
might represent a highly promising alternative.[8, 422, 423, 424] This
technique generates locally defined SAWs which, when coupled into
liquid, result in a defined pressure gradient that can be utilized for
streaming (Figure 25 A). In the work presented, the applicability of
Figure 25: Interdigital transducers (IDTs) on a piezoelectric substrate (PES)
generating SAWs which lead to the streaming of fluid over a cell
monolayer in a liquid-filled channel (A). SAW-pump consisting of the
high frequency connector (HF-input) and the IDTs on a PES which
are annulated in the bottom left corner of the 3D-microchannel. A
PDMS-cast attached to a glass coverslip confines a channel structure
for the cultivation of cells (B, for disassembled view see Figure 26,
for close-up view of IDTs see Figure 27). Cross section of the flow
velocity profile generated in the channel shown in (B) by acoustic
streaming (C). Horizontal (D, solid line) and vertical cut (D, dashed
line) through (C).
this technology to controllably produce fluid flow in a miniaturized
pharmaceutically relevant in vitro bioassay was tested. At this, the effect
of shearing on the cell-association of protein-decorated particles was in-
vestigated using monolayer forming Caco-2 cells as a frequently used in
vitro tissue model. Biocompatible PLGA microparticles conjugated with
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Figure 26: Acoustically-driven biochip and 3D-microchannel. Surface acoustic
wave (SAW) pump consisting of the high frequency connector (HF-
input) and piezoelectric substrate (PES) with interdigital transducers
(IDTs).
fluorescence-labeled wheat germ agglutinin (F-WGA) and bovine serum
albumin (F-BSA) served as representative targeted and non-targeted
model drug carrier systems. The combination of human epithelial cells
and surface-modified particles was chosen, since several studies have
shown that decoration with WGA mediates binding to the pharmaceuti-
cally relevant Caco-2 cell line under stationary conditions.[285, 425] The
extent of a targeting effect in the presence of low to moderate shear rates
between 0.2 s−1 and 1 s−1 was investigated using the micropumping
SAW-chip (Figure 25 B) to simulate flow conditions.
Figure 27: Interdigital transducers (IDTs). Bar represents 100 µm.
2.2.1.3 Results and discussion
The acoustically-driven microfluidic system Similar to conven-
tional flow assays such as the PPFC and RFDA, the biochip is based on
a fluidic channel which is directly accessible during the experiment via
microscopy. However, in contrast to the previously mentioned assays
that are driven by external mechanical pumps, the developed microflu-
idic chip makes use of planar, non-invasive SAW-pumping for flow
generation. IDTs structured on a piezoelectric substrate (Figure 25 B
and 27) are excited when a high frequency signal is applied. This leads
to deformation of the substrate and results in a surface acoustic wave.
When the acoustic radiation pressure exerted by the SAW couples into
a fluid, a pressure gradient is generated which leads to directional
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streaming.[8, 422, 423, 424] Thereby, contamination-free pumping of
liquid volumes as small as a few microliters can be realized at shear
rates between 0.01 s−1 and 1000 s−1 depending on the system’s geom-
etry. As a consequence of the high frequency signal based generation
of the SAW, the pumping performance is continuously actuated and
varied via the parameters of a conventional signal generator (see video
S1).[413] By channelizing the streamed liquid into 3D-microchannels,
which are readily fabricated in almost arbitrary geometries by elas-
tomeric molding, a flow chamber can be created. In this study, a rather
simple 44 mm x 4 mm x 3 mm (length x width x height) racetrack-
format poly(dimethylsiloxane) (PDMS)-cast was used (Figure 25 B).
The channel was dimensioned in such a manner that sufficient medium
could be included for uncomplicated cell culturing of epithelial Caco-
2 monolayers. Thus, the usually necessary transfer of a cell-covered
substrate to the flow chamber or alignment of an elastomeric cast on
the cultured cells can be avoided. However, the pumping technique is
not limited to rectangular casts of this size, but can be easily adapted
to drive flow in smaller structures with constrictions or bifurcations.
Channels including the latter geometries could be exceptionally insight-
ful tools for a realistic simulation of the complex vessel flow in the
circulatory system.[7] At this, it is additionally helpful, that not only
continuous flow modes can be accurately mimicked on the SAW-chip,
but also precisely defined pulsed pumping is possible. While being
hardly achievable with mechanical pumps, this streaming mode is
controllably induced by amplitude modulation of the high frequency
signal (see video S2). Thereby, the effects of pulsating flow combined
with defined shear rates could be collectively investigated regarding
their impact on distribution and adhesion processes in the branched
circulatory system.[7] Besides its compliance with microfluidic chan-
nels, which allows for reducing the necessary amount of reagents to
a minimum, the chip-based setup additionally bears the advantage
of omitting tubing and connectors which are otherwise necessary to
pipeline liquid within the system. Consequently, the dead volume asso-
ciated with mechanical pumps is avoidable and the entire device can be
downsized notably (Figure 25 B). This feature is essential, as it permits
parallelization of several SAW-chips in one platform thus increasing
the amount of samples which can be processed simultaneously. Even a
setup with multiple SAW-pumps and channels in a microplate format is
realizable, entailing the possibility of using microplate readers for anal-
ysis. Such an extension to more sensitive analytical methods could be a
powerful tool to gain information on adhesion phenomena involving
nanoparticles or proteins, since analyses based on microscopic imaging
hit on their limits in this size regime.
Cell-binding of surface-modified microparticles under station-
ary conditions To establish reference values for the experiments
involving fluid flow, the extent of binding of BSA- and WGA-MP to
Caco-2 monolayers was primarily determined in a stationary setup
(flow velocitymax = 0 µm s−1). For the used microparticles with a
mean size of 2.9±1 µm and a density of 1.28 g cm−3 a sedimentation
controlled particle deposition is expected.[376] In the equilibrium state
between frictional force and gravitation, settling of the colloids occurs
with a constant z-velocity of 1.4 µm s−1. Consequently, 83% of the ho-
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mogenously distributed particles are assumed to deposit on the surface
within 30 min leading to a maximum coverage of 3500 mm−2. In prac-
tice, however, only 94±64mm−2 BSA-MP were detected after stationary
loading (30 min), washing and stationary chase-incubation (30 min)
(Figure 28, stars). The rather low number of cell-associated particles,
Figure 28: Mean number of WGA- (squares) and BSA-MP (stars) associated
with Caco-2 monolayers after loading for 30 min at stationary con-
ditions, washing and chase-incubation under stationary or flow
conditions. Each set of data points was obtained from independent
experimental series.
which corresponds to 3% of the theoretical load, can be explained by
the reportedly low affinity of albumin-coated PLGA-particles to Caco-2
cells.[363, 285] Due to the lack of interactive strength the washing steps
resulted in the detachment of all except a few non-specifically bound
particles. In contrast, conjugation with WGA led to a clearly enhanced
adhesion of colloids to the monolayer. This is in line with previous
studies which have identified WGA as an agent for enhancing adhe-
sion to Caco-2 cells. Following[426, 285] incubation under stationary
conditions a mean number of 1500±307 mm−2 cell-associated particles,
which corresponds to 43% of the maximum load, were detected. This
16-fold increased interaction as compared to BSA-MP is explicitly il-
lustrated in Figure 29 and can be attributed to specific binding of the
lectin to membrane-associated N-acetyl-D-glucosamine and N-acetyl-
neuraminic-acid residues.[427, 373] WGA-MP which had not bound to
the cell membrane were removed in course of the washing steps.
Impact of flow on cell-bound particles To investigate the effect
of different shear rates on cell-associated BSA- and WGA-MP, station-
ary particle-loaded Caco-2 monolayers were chase-incubated under
flow conditions. At this, acoustic streaming induces laminar fluid flow
in the channel and thereby generates hydrodynamic forces acting on
the attached microparticles. If the adhesive bonds break and do not
re-establish elsewhere, the fluid flow transports the colloids to the cou-
pling region of the SAW, where the considerable lift forces redisperse
them in the channel cross-section. Consequently, most of these parti-
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Figure 29: Cell-associated microparticles (green) after stationary loading,
washing and chase-incubation under stationary conditions (flow
velocitymax= 0 µm s−1;WGA-MP (A); BSA-MP (C)). Same load-
ing procedure but chase-incubation under flow conditions (flow
velocitymax= 1700 µm s−1; WGA-MP (B); BSA-MP (D)). Tight junc-
tion associated protein ZO-1 (red). Bar represents 20 µm.
cles are not available for reattachment to the cells. Using this setup, a
shear rate dependent reduction of the number of cell-bound particles
was monitored for both types of surface-modified colloids (Figure 28).
While low shear rates (flow velocitymax= 300 µm s−1 and 800 µm s−1)
led to the detachment of 30% and 50% respectively of the initially cell-
associated BSA-MP, incubation at higher shear rates (flow velocitymax=
1200 µm s−1 and 1700 µm s−1) almost completely removed the albumin-
conjugated colloids from the cell-surface (Figure 29 D). Obviously, the
few BSA-MP, which were associated with the Caco-2 monolayer after
stationary loading and washing, are characterized by low adhesivity
which is not sufficient to anchor the particles in the presence of shear
forces. In contrast, conjugation of microparticles with carbohydrate-
binding protein not only led to higher cell binding under stationary
conditions but also enhanced retention on the Caco-2 monolayer in
the presence of flow (Figure 28, squares). This is illustrated by a mean
number of 1057±351 mm−2 and 400±168 mm−2 monolayer-associated
colloids at the lowest and highest flow velocity studied. Consequently,
as compared with BSA-MP, WGA-MP were characterized by at least
17-fold increased retention over the whole range of flow velocities
investigated. Interestingly, in the case of the highest shear rates, the
effect of the lectin corona was even more pronounced as exemplified
by 39-fold and 44-fold improved adhesion over albumin-conjugated
colloids (Figure 29 C). Regarding reproducibility of the binding assays
on the SAW-chip, it should be highlighted that the three data series
for each particle type plotted in Figure 28 were obtained from separate
experiments. The low deviation between the curves underlines the
SAW-pump’s ability to controllably and reproducibly generate flow in
the 3D-microchannels, which is a crucial prerequisite that determines
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the practical usability of the system. The standard deviation of each
data point is comparable with those in similar studies and very likely
a result of the image-based quantification combined with the cellular
substrate inherent characteristics.[384] To minimize this, homogenous
receptor-coated surfaces could be used, albeit at the cost of setting
aside the complexly constituted cell membrane. Hence, when prob-
ing the interaction of targeted drug carriers with biological barriers,
a substitution of the cell monolayer by an artificial substrate is not
expedient since it reduces the relevance for comparisons with the in
vivo conditions.[382, 384, 417] When studying isolated adhesion phe-
nomena, however, the incorporation of precisely surface-engineered
substrates is certainly realizable as well as preferable in terms of analyt-
ical accuracy.[287, 418, 383]
Cell-binding of surface-modified microparticles under flow con-
ditions
Impact of flow on particle sedimentation in the channel. To estimate whether
flow affects the calculated sedimentation rate of particles in the 3D-
microchannels, the stationary condition was compared with streaming
(Calculation S5).The experimental microfluidic setup is characterized
by Reynolds numbers of Re = 1 and Re = 6 for the lowest and high-
est velocity respectively which indicates laminar flow. As determined
by computational fluid dynamics simulations the flow profile in the
channel is parabolic (Figure 25 C, D). Considering these conditions and
that the images used for quantification of the adherent particles were
taken in a small central region of the channel, the lateral y-component
of the velocity was assumed to be widely independent from the vertical
z-component. Therefore, a particle’s trajectory in the flowing fluid con-
tains components in the direction of flow (x) as well as in the vertical
direction (z) with the former one depending on the latter. At the start of
the experiment, the 3D-microchannels are filled with buffer containing
7.5 x 105 homogenously distributed microparticles which sediment
with a constant z-velocity. Upon engaging the flow, these particles are
travelling for one channel length until again reaching the coupling zone
of the SAW-pump where they are homogenously redistributed over the
cross-section of the channel. On each of these rotations, only particles
below a critical height (zcrit) settle out on the cell monolayer. For a
flow velocitymax (vmax) of 1700 µm s−1 the critical height zcrit is
determined to be 224 µm. Taking into account that the particle density
in the channel decreases with duration of the experiment, 56% of the
microparticles are expected to have deposited on the cell monolayer
after 30 min. This corresponds to a theoretical surface coverage of 2400
mm−2 which is clearly lower than that of 3500 mm−2 under stationary
conditions. Calculations also showed that the increased critical heights
zcrit in the case of lower flow velocities (vmax from 300 µm s−1 to
1200 µm s−1) do not lead to higher deposition rates since their effect is
widely levelled out by the proportionally lowered particle flux densities.
Consequently, almost equal particle deposition rates on the cell mono-
layer would be expected under all investigated flow conditions if flow
only had an effect on particle sedimentation. Any further deviations
between the numbers of cell-associated particles at the different flow
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conditions, however, would indicate an additional effect of flow on the
particle–cell interaction.
Binding of BSA- and WGA-MP to epithelial monolayers under flow condi-
tions. In order to investigate the binding of BSA- and WGA-MP from
a streaming medium to epithelial model monolayers, the particle sus-
pension was transferred to the 3D-microchannels and fluid flow was
instantly engaged. As illustrated in Figure 30 (open symbols), incu-
Figure 30: Mean number of WGA-MP (squares) and BSA-MP (stars) associated
with Caco-2 monolayers upon incubation under stationary and flow
conditions. Monolayers pre-loaded with microparticles for 30 min
under stationary conditions (filled symbols). Direct incubation of
microparticles with monolayers under stationary and flow conditions
(open symbols).
bation under flow conditions led to clearly decreased cell binding of
the ligand-conjugated colloids. Partially, this effect is inherent to the
system and can be attributed to the previously discussed reduction of
particle sedimentation due to the parabolic flow in the channel. Tak-
ing this into account and considering the binding potential of 3% and
43% as determined in the absence of hydrodynamic forces, a maximal
surface coverage of 70 mm−2 and 1000 mm−2 is expected for BSA-
and WGA-MP respectively under flow conditions. In case of the lowest
shear force studied, this estimate seems quite realistic as illustrated by
77±31 mm−2 and 747±241 mm−2 respectively bound particles. How-
ever, aside from the generally lowered base deposition, the number
of cell-bound colloids was additionally diminished by the antagoniz-
ing effect of flow on particle-surface bonds.[416, 287] For BSA-MP,
increased hydrodynamic drag resulted in a nearly complete inhibition
of the association with the Caco-2 monolayer. This is explicated by a
marginal surface coverage of 34±16 mm−2 cell-associated particles at
the highest shear rate. Apparently, albumin-modified particles which
are deposited on the monolayer under flow conditions do not notably
interact with the cell membrane. Similar effects have been described
in a recent study where a gas lift driven Ussing chamber setup was
used to simulate the impact of flow on particle binding.[363] WGA-MP
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exhibited higher binding in comparison to albumin-conjugated colloids
at all investigated flow-conditions. The advantage of lectin-conjugation
was clearest at low shear rates. However, even at the highest flow ve-
locities studied at least threefold more particles associated with the
cell monolayer as compared with BSA-MP. These observations lead
to the conclusion that colloids lacking appropriate surface chemistry
do not notably attach to the cell layer at relatively moderate shear
rates ranging from 0.2 s−1 to 1 s−1. When considering this combined
with the very low cytoadhesion under stationary conditions, the use of
BSA-MP as drug carriers is limited. The use of plain colloids for most
pharmaceutically relevant applications has to be relativized even more
due to the reportedly marginal cytoadhesion of unconjugated PLGA
particles.[285] To efficiently compliment the advantageous biocompati-
bility and biodegradability of particles made from PLGA and similar
polymers, surface modification with targeting ligands is essential. In
this regard, however based on stationary studies, wheat germ agglutinin
is a promising candidate to serve this purpose for peroral applications.
Due to its carbohydrate binding properties, which mediate adhesion
to enterocytes as well as mucus, a prolonged gastrointestinal residence
time of sustained release drug carriers might be achieved.[363, 427, 5]
Using the SAW-driven microfluidic device, it was possible to show that
the interaction between WGA and the Caco-2 cell’s glycocalyx is indeed
sufficient to mediate the binding of 3 µm-sized particles in the pres-
ence of low hydrodynamic drag. This observation further underlines
the potential of wheat germ agglutinin for peroral delivery, where the
peristaltic motion in the small intestine only generates rather low shear
forces. However, the physiology and motility of the gastrointestinal
tract is complex and not yet fully resolved, so this conclusion is only
based on current estimates indicating shear rates of about 0.01 s−1.[385]
In the presence of higher flow velocities, the studied WGA-MP exhibit
a propensity to detach from the cell monolayer, possibly limiting their
applicability for delivery to the endothelium or urinary tract epithelium.
This could be counteracted by using smaller particles in the nanome-
ter size range, since the effective hydrodynamic drag forces decrease
with particle diameter.[381] Moreover, conjugation of particles with
alternative targeting moieties could lead to enhanced cytoadhesion
in the presence of higher shear rates. In this regard, the underlying
mechanisms of shear-activated proteinic ligands like the FimH subunit
of Type-1 fimbriae of E. coli or von Willebrand factor might lead the
way for the engineering of site-specific drug carriers that efficiently
adhere under flow conditions.[419, 428]
2.2.1.4 Experimental
Materials Sylgard® 184 Silicone Elastomer Kit was purchased from
Baltres (Baden, Austria). Resomer® RG502H (PLGA, lactide/glycolide
ratio 50:50, inherent viscosity 0.22 dL g−1, acid number 9 mg KOH
g−1) was obtained from Boehringer Ingelheim (Ingelheim, Germany). F-
WGA (molar ratio fluorescein/protein (F/P) = 2.9) from Triticum vulgare
was bought from Vector laboratories (Burlingame, USA). F-BSA (F/P
= 12), EDAC, NHS, and Pluronic® F-68 were purchased from Sigma
Aldrich (Vienna, Austria). All other chemicals used were of analytical
purity.
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Preparation of functionalized microparticles PLGA microparti-
cles with a mean diameter of 2.9±1 µm were prepared by spray drying
of a 6.5% (w/v) solution of PLGA in dichloromethane with a Buechi
Mini Spray Dryer B-191 (Buechi, Flawil, Switzerland) as previously
described.[426] For surface modification, 100 mg of the PLGA micropar-
ticles were suspended in 20 mM HEPES/NaOH buffer pH 7.0 (10 mL)
and activated with solutions of EDAC (360 mg in 1.5 mL) and NHS
(15 mg in 1 mL) in the same buffer for 2 h under end-over-end rota-
tion at room temperature. In order to remove excess coupling reagent,
the suspension was diluted threefold with HEPES and centrifuged (10
min, 2500 rpm, 4°C). The resulting pellet was resuspended in HEPES
(10 mL). Upon addition of F-WGA (1.00 mg) and F-BSA (1.83 mg) re-
spectively, end-over-end incubation was performed overnight at room
temperature. The remaining active ester intermediates were saturated
by addition of glycine (450mg) in HEPES (6mL) and further incubation
for 30 min. Subsequently, the microparticles were washed three times
by centrifugation (3200 rpm/10 min/4°C) and resuspension in HEPES
(30 mL). After the last centrifugation step, the particles were suspended
in a solution of 0.1% Pluronic® F-68 in isoHEPES (10 mL).
Fabrication of sterile 3D-microchannels Base (10 g) and curing
agent (1 g) of the silicone elastomer kit were mixed in a test tube,
vigorously stirred and evacuated for 30 min to remove gas bubbles.
After pouring the liquid prepolymer into pre-structured aluminium
molds and hardening over night at 70°C, the PDMS replicas were peeled
from the master and placed on 24 x 24 mm (length x width) glass
coverslips. Following assembly, the 3D-microchannels dimensioned 44
x 4 x 3 mm (length x width x height; see Figure 25 B) were transferred
to glass Petri dishes and autoclaved for 50 min at 121°C (1 bar).
Cell culture in 3D-microchannels The Caco-2 cell line was pur-
chased from DSMZ (Braunschweig, Germany). Tissue culture reagents
were obtained from Sigma (St. Louis, USA) and Gibco Life Technolo-
gies Ltd. (Invitrogen Corp., Carlsbad, USA). Cells were cultivated in
RPMI 1640 cellculture medium containing 10% fetal bovine serum, 4
mM L-glutamine and 150 mg mL−1 gentamycine in a humidified 5%
CO2/95% air atmosphere at 37°C and subcultured with Tryple Select
from Gibco (Lofer, Austria). For the microfluidic experiments, each
sterile 3D-microchannel was filled with 500 mL of Caco-2 single cell
suspension (1.36 x 105 cells mL−1) and cultivated under standard cell
culture conditions until a confluent cell monolayer had formed.
Preparation of SAW-chip LiNbO3 slides (128°-cut-propagation)
dimensioned 15 x 15 x 0.4 mm (length x width x height) were used
as piezoelectric substrates. IDTs were structured on these slides by
standard lithographic processes in order to predominantly generate
(Rayleigh-mode) SAWs.[429] The used IDTs had 45 fingerpairs, an
aperture of 400 µm and a periodicity of 25 µm, resulting in a resonance
frequency of about 152 MHz (Figure 27). To enhance the resistance
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against mechanical cleaning procedures, the fingers were additionally
coated with a radio frequency (RF)-sputtered SiO2 protective coating.
Microparticle–cell interaction studies at stationary and flow
conditions For the interaction studies the BSA-MP and WGA-MP
were suspended in isoHEPES at a concentration of 7.5 x 105 particles
per 500 µL. Shortly before the experiment, the cell culture medium was
removed from the 3D-microchannels and the monolayers were washed
once with isoHEPES (500 µL). Subsequently, the microparticle suspen-
sion was added and the channels were covered with a glass coverslip.
In order to grant efficient transmission of the SAWs, 50 µL of water
were pipetted onto the piezoelectric chip as a coupling fluid before
the 3D-microchannel was placed on top of it. This setup was mounted
on a fluorescence microscope and connected to the high frequency
generator, which had been configured to supply preset energy inputs
corresponding to flow velocities of 0 µm s−1, 300 µm s−1, 800 µm s−1,
1200 µm s−1, and 1700 µm s−1 respectively. This corresponds to shear
rates of 0.2 s−1, 0.5 s−1, 0.7 s−1, and 1 s−1 respectively. Following incu-
bation at either stationary or flow conditions for 30min, the monolayers
were washed three times with isoHEPES (500 µL) and embedded as de-
scribed below. For an alternative set of experiments, monolayers loaded
for 30 min under stationary conditions were washed and subsequently
subjected to stationary or flow chase-incubation. After two additional
washing steps with isoHEPES (500 mL) the PDMS-structure was peeled
off. The glass coverslips with the adherent monolayers were embedded
in a drop of FluorSave (Calbiochem, USA and Canada) and were stored
at 4°C for 12 hours until further analyzed.
Quantification of cell-associated microparticles The embed-
ded Caco-2 monolayers were analyzed on a Nikon Eclipse 50i mi-
croscope (Nikon Corp., Japan) equipped with an EXFO X-Cite 120
fluorescence illumination system. A random series of non-overlapping
fluorescence microscopic images (n = 6) was acquired over the channel
area. At this, care was taken to analyze monolayer parts located in
the centre of the 3D-microchannels, in order to allow for comparison
of the experimental and theoretically calculated deposition rates. To
grant comparability, the settings of the fluorescence lamp and exposure
time were left constant during the data acquisition process. Finally,
the number of cell-associated microparticles in every image was de-
termined with the threshold-dependent automated particle analysis of
ImageJ (NIH, USA). The number of cell-associated particles represents
the mean value which was calculated from the images acquired in
independent channels (n = 2).
Antibody staining After incubation at stationary and flow condi-
tions respectively, the monolayers were fixed with a 2% solution of
paraformaldehyde for 15 min at room temperature and were washed
with PBS (500 µL). Upon treatment with a 50 mM solution of NH4Cl
for 15 min and with a 0.1% solution of Triton X-100 for 10 min, the cells
were washed again with PBS (500 µL). The tight junction associated
protein ZO-1 was stained for 1 h at 37°C with a primary antibody (BD
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Biosciences, San Jose, USA) diluted 1 : 100 in a 1% solution of BSA
in PBS. Upon washing thrice with a 1% solution of BSA in PBS, the
monolayers were incubated with a 1 : 100 dilution of a secondary Anti-
Mouse Immunoglobulin-RPE antibody (Dako Denmark A/S, Glostrup,
Denmark) for 30 min at 37°C. Finally, the cell layer was washed three
times with a 1% solution of BSA in PBS and mounted in a drop of
FluorSave.
2.2.1.5 Conclusion
Stationary binding assays have become the current standard in pre-
clinical biopharmaceutical testing due to the rather simple handling
and lack of alternative in vitro models. To approach this shortcom-
ing, an acoustically-driven thumbnail-sized microfluidic chip was de-
veloped that can controllably and reproducibly generate flow in 3D-
microchannels which are compatible with cell culture. This SAW-chip
was used to investigate the binding properties of albumin- and wheat
germ agglutinin-conjugated microparticles to an epithelial cell layer
under flow conditions. As illustrated in the present work, the results
obtained from binding assays under stationary conditions notably dif-
fer from those obtained in systems simulating the dynamic in vivo
environment. It was found that non-targeted microparticles possess a
very low propensity to bind and are detached in the presence of flow,
while conjugation with WGA led to a distinctly improved adhesion of
particles to the cell-layer at shear rates ranging from 0.2 s−1 to 1 s−1.
In conclusion, these results clearly underline the importance of surface
functionalization for the design of nano- and microparticulate drug
delivery vehicles. Elaborate models of the in vivo conditions are neces-
sary in order to realistically predict and optimize the performance of
such systems prior to animal studies. In this context, the developed mi-
crofluidic SAW-chip is expected to provide a highly versatile platform
for an investigation of flow-associated effects on particle–cell adhesion
processes. Fundamental information distilled from studies using this
technology will deeply benefit the engineering of artificial drug carrier
systems which perform with high efficiency in the dynamically complex
physiological environment.
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Calculation 5. Calculation of sedimentation rate
The calculation of the critical height for particle sedimentation (zcrit) is
based on a parabolic flow velocity profile vx(z) (2.6) which is justified
by numerical simulation.
vx(z) = a · z2 + b · z+ c (2.6)
The sedimentation of a microparticle is primarily affected by gravity.
Stoke’s law leads to a constant sedimentation velocity (vz) which leads
to a linear diminution of the particles’ z-position in the 3D-microchannel
(2.7).
z(t) = z0 − vsed · t (2.7)
Upon substitution of z in (2.6) with z(t), an expression vx(z0; t) is
obtained. Time integration from zero to τ leads to (2.8) with α = av2sed,
β = 2az0vsed + bvsed, γ = bz0 + c+ az20.
x(τ) =
α
3
τ3 +
β
2
τ2 + γτ (2.8)
When a particle is deposited on the surface at time τ, z(τ) (2.7) will
be zero. Shifting round, we can substitue τ with z0vsed . Since it is as-
sumed that the SAW leads to a homogeneous redistribution of the
microparticles near the IDTs, sedimentation has to occur within one
cycle corresponding to the length of the channel L. Therefore, a third
order equation for z0 has to be solved which leads to the critical height
zcrit. It turns out that the number of deposited particles should be
independent from the maximum value of vx. This estimation is only
valid, as long as zcrit is below half the height of the channel.
Video 1. Variation of the fluid flow velocity in a 3D-microchannel
by controlling the input power of the SAW-pump. Fluo-
rescence labelled polystyrene beads (3 µm, Polysciences
Inc., Germany) were used as indicators of flow. Observa-
tion with a Nikon Labophot microscope (magnification 2x)
equipped with a low light sensitive video camera (Pho-
tonic Science); recording on digital video tape (Sony). http:
//www.youtube.com/watch?v=hmM98T3Nqkk
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Video 2. Generation of constant and pulsating fluid flow in a 3D-
microchannel by amplitude modulation of the high fre-
quency signal. No modulation (“no pulse”), modulation
of the signal amplitude with 0.5 Hz (“pulse frequency: 30
min−1), 1Hz (“pulse frequency: 60min−1) and 2Hz (“pulse
frequency: 120 min−1). Fluorescence labelled polystyrene
beads (3 µm, Polysciences Inc., Germany) were used as
indicators of flow. Observation with a Nikon Labophot
microscope (magnification 4x) equipped with a low light
sensitive video camera (Photonic Science); recording on dig-
ital video tape (Sony). http://www.youtube.com/watch?v=
kBzdqh4GkRM
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2.2.2 A SAW-platform for parallelized microfluidic applications
2.2.2.1 Setup of the chip and system
In order to integrate flow as a standard parameter into preclinical bio-
pharmaceutical test systems, flow models have to be available which
grant reproducibility, versatile applicability and acceptable throughput.
Classical flow systems widely depend on tubing for transport of the
medium between a reservoir and the flow channel. In order to achieve
parallelization, additional tubing or pumps have to be introduced which
notably increases the complexity of the setup. This can be circumvented
with SAW-modules. As a consequence of the different operation princi-
ple, which enables direct pumping of liquid in the channel, no tubing is
needed. Moreover, the parallelization of SAW-pumps will be facilitated
due to the fact that transducer structures and electrode connections on
a chip require very little space. To make use of these advantages and
to illustrate feasibility of the concept, a SAW-platform was developed
which can be used to pump liquid in four microfluidic channels in
parallel (Figure 31). At this, four IDTs were glued into a prestructured
Figure 31: Platform with four integrated SAW-pumps for flow studies in mi-
crochannels.
aluminium block and were connected with ports for cabling. Holes in
the aluminium block allow microscopic observation with inverted or
upright microscopes during flow experiments. The system is operated
via a radio frequency generator (SMB100A, Rohde&Schwarz GmbH,
Austria) connected in series to a coaxial amplifier (LZY-1, Mini Cir-
cuits, Brooklyn, USA) and a fixed attenuator (VAT-3W2+, Mini Circuits,
Brooklyn, USA). Finally, the RF signal is distributed to the four IDTs by
a 4-way divider (D1572-102, Werlatone, Brewster, USA).
The setup of the microchannels used for the flow experiments can
be based on the work described in 2.2.1. However, instead of attaching
the PDMS microchannels on glass coverslips with a size of 24 x 24 x 0.1
mm (length x width x height, Figure 26), four channels are placed on a
glass plate dimensioned 127 x 85 x 1.1 mm (length x width x height).
This allows for a high degree of versatility with channel structures since
the size of the glass support does not limit the channel size. Moreover,
the dimensions of the glass plate match the dimensions of standard
microplates. This allows for compatibility with microplate readers.
Thereby the detection of channel-associated luminescence, absorbance
or fluorescence is possible. This will represent a clear improvement
over currently used detection techniques. Typically, quantification of
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cell-bound analytes in flow chambers is achieved by counting from
fluorescence microscopic images 2.2.1.4.[384] While being reliable, this
method is time consuming and thus mainly applicable if the number
of samples is small. Due to the compatibility with automated read-
out the SAW platform is expected to fully harvest the advantages of
parallelization. The geometry of the microchannels can be digitized
and programmed into a microplate reader’s software. Thereby, precise
readout from predefined regions in the channels can be achieved within
a minimum of time. Preliminary experiments with aqueous solutions of
sodium fluorescein have shown that parallelized quantitative readout
from different positions in the microchannels via fluorimetry is indeed
possible. Since the glass plates used are fully transparent and optically
high grade, it is to be expected that similar detection limits as with
conventional microplate assays can be attained.
2.2.2.2 Flow velocity measurements
In order to characterize if the four IDTs on the SAW-platform indeed op-
erate constantly and comparably, the flow velocities generated in the dif-
ferent microchannels were monitored. This was accomplished by using
fluorescence-labelled polystyrene microparticles (3µm, FluoresbriteTM,
Polysciences Inc., Warrington, USA) as tracers of fluid flow. The flow
velocity was determined in the center of the channel by measuring the
translational velocity of the particles via fluorescence microscopy on a
Zeiss Observer.Z1 microscope. As illustrated in Figure 32 a clear rela-
tion exists between the input power delivered to the SAW-pumps and
the resulting flow velocities in the channels. The input power is given
in [dBm] since this scale is preferrable for adding up the power contri-
butions of multiple components in the RF generation chain. Conversion
to the commonly used [mW]-scale can be attained by substituting in 2.9
P = Pref10
x
10 (2.9)
where P is the power in [mW] Pref is the reference power (1 mW) and x
is the power in [dBm]. For the setup used in these experiments a range
of total power inputs from 25 mW (14 dBm) to 1400 mW (31.5 dBm)
was investigated. Every transducer is operated with a fourth of the total
input power. This results in the generation of flow velocities between
0.3 mm s−1 and 10 mm s−1. As illustrated by the similar slopes of the
curves for the individual IDTs, almost identical velocities were observed
in the four 3D-microchannels after 15 min of operation (Figure 32, top
graph). Upon continued streaming for 15 min, the velocities had not
changed as illustrated in Figure 32 (bottom graph). This underlines
that temporally constant flow velocities can be generated in parallel
channels by integrating several SAW-pumps in a platform. Although
higher input powers and thus higher streaming velocities are possible
in principle, experimental problems occur at powers above 30 dBm.
Due to the generation of radiative energy by the SAW the system heats
considerably leading to evaporation of the water film which is used
as a coupling medium between the chip surface and the glass plate.
This drastically reduces the coupling efficiency of the SAW into the
3D-microchannels and can ultimately lead to the cessation of flow. Thus,
the platform should primarily be operated up to a maximal input power
of about 30 dBm. Input powers lower than 14 dBm can certainly be
applied and will lead to flow velocities below 0.3 mm s−1.
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Figure 32: Flow velocities generated by four IDTs in microchannels on a SAW-
platform for parallelized microfluidics. Channels 1-4 represent the
respective microchannels arranged on top of the four IDTs of the
chip (Figure 31). Flow velocities of n= 10 particles per channel were
determined after 15min (top graph) and 30min of operation (bottom
graph).
In order to be able to routinely use the SAW-platform for flow ex-
periments, reproducible generation of streaming has to be granted. A
decisive parameter that might affect the reproducibility of flow genera-
tion by the SAW-pumps is the localization of the IDTs underneath the
3D-microchannels. This potential issue was accounted for in the chip
architecture. Two framing bars were structured on the aluminium block
which allow fixation of the glass plate which in turn ensures that the
SAW-pumps are reproducibly positioned underneath the microchan-
nels. As illustrated in Figure 33 this setup is indeed characterized by
minimal variations of the generated flow velocities between experiments
performed on different days.
Aside from the generation of flow in plain channels, the SAW-
platform can certainly also be used for the generation of constant6
and pulsatile flow7 in cell-lined 3D-microchannels as described in 2.2.1.
2.2.2.3 Culturing of endothelial cells in 3D-microchannels
HUVECs represent an established in vitro cell model for endothelial
cells which has been used for studies in flow chambers.[399] Since
6 constant flow of 6 µm sized fluorescent microparticles (orange) over a pre-confluent
Caco-2 monolayer (green); http://www.youtube.com/watch?v=VivswokWaGo
7 pulsatile flow of 6 µm sized fluorescent microparticles (orange) over a pre-confluent
Caco-2 monolayer (green); http://www.youtube.com/watch?v=gggPiSwJY4I
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Figure 33: Flow velocities generated by one of the four IDTs of the SAW-
platform in a microchannel on four different glass plates on consecu-
tive days. Flow velocities of n= 10 particles were determined after 15
min of operation.
HUVECs do not attach and proliferate on plain glass, standard coating
techniques with gelatine (10 mg mL−1 in PBS), collagen (0.14 mg mL−1
in PBS), FBS and fibronectin (0.1 mg mL−1 in PBS) were investigated.
Among the different proteins tested, fibronectin proved to be superior
for mediating the binding of HUVECs to the glass substrate and for
providing a suitable growth substrate for the cell monolayer (Figure 34).
Figure 34: HUVEC monolayer grown in 3D-microchannels. VE-cadherin im-
munostained according to the procedure described in 1.2.3.2 (red).
Note the border of the cell monolayer at the right as structured by
the wall of the PDMS channel.
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2.2.3 Transport studies under flow: metal grids as growth supports for cell
monolayers
2.2.3.1 Potential improvements of currently used systems for permeation
studies
Transport studies across cell monolayers in vitro are not only of interest
for studying the processing of novel drug carrier systems by cells. More-
over, they are standard tools for determining permeation of drugs and
prodrugs in the framework of the BCS. Typically, in vitro models for
transport systems consist of an apical compartment which is separated
from a basolateral compartment by a filter membrane. At this, the filter
membrane serves as a growth support for cells which simulate the
intestinal epithelial barrier in vitro. The entire cup-like device fits into a
microplate well and thus is optimally suited for parallelization and high
throughput. Transport experiments in microplates are frequently per-
formed under stationary conditions. Regardless of the route of transport
by which the drug permeates through the cell monolayer, its delivery
from the apical medium to the cells will widely be controlled by diffu-
sion. Systems for permeation studies which simulate peristaltic motion
in the apical compartment might be beneficial. Thereby, the transport
rate of drug molecules to the cell monolayer could be improved. As
underlined by drug permeation studies with Caco-2 monolayers per-
formed under stationary and dynamic conditions, higher permeabilities
are attained indeed under dynamic conditions.[356]
Since SAW-modules can induce constant as well as at pulsatile
flow (2.2.2.2, 2.2.1.3), they might be well suited for the generation
of peristalsis-like motions in transport systems. Due to the chip-based
nature of the pump a dynamic transport system could certainly be
developed in similar if not smaller dimensions as those of currently
available devices.
Another parameter which deserves consideration concerning the
currently used systems for transport studies is the filter membrane. The
essential function of the filter membrane is to provide a growth support
for the cell monolayer. Several filter materials with a wide range of pore
sizes are available. For transport studies with low molecular weight
drugs filter membranes with pore diameters of 0.4 µm are mostly
used. At this, different materials are characterized according to the
filter membrane thicknesses (hpore) and pore densities (β) (Table 9).
In combination with the pore radius rpore, these specific parameters
determine the area available for filtration according to 2.10.
Afiltration = β(r
2
pore π) (2.10)
As can be deduced from Table 9 the filtration areas for 0.4 µm filters are
in the range of 0.003 - 0.126 mm2 per 1 mm2 of filter membrane. This
consequently amounts to a maximum filtration area of about 12.6 %.
Similar orders of magnitude are calculated for filter membranes with
pore radii of 1 and 3 µm respectively. In turn this means that more than
87% of filter material can not contribute to transport of drug molecules
which pass across the cell monolayer. The situation is schematically
illustrated in Figure 35. Moreover, it can be assumed that a gradient
of transported drug molecules will build up inside the filter pores
which leads to decelerated diffusion of analyte into the basolateral
compartment.
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Figure 35: Transport of drug molecules from an apical compartment through
a polarized cell monolayer grown on a filter membrane into a ba-
solateral compartment. Insufficient filtration area due to low pore
densities will result in the buildup of a concentration gradient inside
the filter.
Adsorption of drug molecules to the polystyrene components of trans-
port systems has been shown to bias results of permeability assays.[430]
It is not clear from the literature to which extent substances are ad-
sorbed by the filter material itself. However, it seems possible that upon
transport across the cell monolayer a substantial amount of drug might
be sequestered before it reaches the basolateral compartment. The sur-
face area of the filter membrane available for adsorption Atotal can be
calculated from 2.11
Atotal = Aout +Apores (2.11)
with Aout as the area of the apical and basolateral sides of the filter
excluding Afiltration according to 2.12
Aout = 2[r
2
filter π−Afiltration] (2.12)
and Apores as the total surface area of the cylindrical pores that can be
calculated from 2.13.
Apores = β(2rpore πhpore) (2.13)
rfilter and rpore are the radii of the filter membrane and pore re-
spectively. β is the number of pores per filter area and hpore is the
height of the pore which is equivalent to the membrane thickness. As
illustrated in Table 9, appreciable Atotal are obtained for several of
the commercially available filter materials. In case of filters with 0.4
µm pore size and high pore densities, which are most frequently used
for drug permeation studies, Atotal amounts to about 14 and 30 mm2
per 1 mm2 of growth area. According to these rough estimates, a 24-
well microplate insert with a growth area of about 33 mm2 actually is
characterized by a surface area of 4.5 and 10 cm2 of filter material.
In order to facilitate comparison of Afiltration and Atotal between
different types of filters, the filter quotient δ is introduced 2.14.
δ =
Afiltration
Atotal
(2.14)
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If adsorption of analyte to the filter material indeed poses a problem,
suitable alternatives could be identified by choosing a filter with higher
δ.
Individually or in combination the above discussed issues indicate
that in addition to the cell layer the filter membrane used as growth
support might constitute a barrier to drug permeation in transport
studies.
2.2.3.2 Metal grids as high porosity growth supports for cell monolayers
Considering the above it is expedient to investigate potential alter-
natives to conventional filter membranes which could be integrated
into a dynamic transport system. A high pore density metal grid with
25 µm mesh width (Bückmann GmbH, Mönchengladbach, Germany)
might represent a suitable alternative. The metal grid is a comparably
unexpensive woven stainless steel fabric which can be obtained in re-
producible and large quantities. In terms of Afiltration this material is
superior to commercially available filter membranes (see Table 9).
To be able to compare the grid with filter membranes regarding the
total surface area available for adsorption of drug, Agrid is calculated
(2.16). Agrid can be obtained by treating each pore as an elementary
cell which is lined by four half cylinders. At this, Acell is the total
surface area of the wire forming an elementary cell where rwire is the
radius of the wire and l is the height of one cylinder 2.15.
Acell = 4 rwire π l (2.15)
Agrid = βAcell (2.16)
Agrid can be substituted for Atotal in 2.14 to yield δ. δ of the grid can
be directly compared with that of commercially available filters. From
Table 9 it is deduced that the grid provides notable advantages over
filters as illustrated by an at least 2-fold and 8-fold higher δ respectively
as that of 3 µm and 0.4 µm pore size membranes.
To study if growth of a cell layer with characteristic transepithelial
electrical resistance (TEER) can also be attained on a highly porous
substrate, Caco-2 cell monolayers were cultivated on metal grids. To
enable direct comparison with commercially available systems, the filter
membrane was excised from a polystyrene cup of ThinCertTM 24-well
inserts. Subsequently, a similar sized piece of metal grid was attached
to the cup with Microset 101FF glue (Microset Products Ltd., Nuneaton,
UK). Normally, Caco-2 cells with a diameter of 17 - 20 µm would pass
through the pores of the grid upon seeding. To accumulate the cells
on the wires, Caco-2 cells in RPMI-1640 medium (1.25 x 104 cells/120
µL) were pipetted into the apical compartment and importantly no
basolateral medium was added for the first 24 hours of incubation.
Thus, the Caco-2 cells sedimented towards the grid where a liquid-
gas interface was formed due to the high surface tension. This led to
complete deposition of the cells at or close to the wires where they had
the possibility to attach to the stainless steel surface. Upon addition
of 600 µL of medium to the basolateral compartment on the next day
the cells were incubated for 14 days with exchange of the medium at
regular intervals.
To assess if a confluent and potentially polarized cell monolayer with
appropriate resistance had formed, the TEER and localization of tight-
junction associated protein ZO-1 was investigated. At this, the TEER
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was determined with chopstick electrodes of an EVOMX voltmeter
(World Precision Instruments, Sarasota, USA). In the absence of cells the
metal grid itself had a resistance of 75 Ω cm2 in plain medium. This is
similar to 64Ω cm2 of 3 µm transparent filter membranes (ThinCertTM,
Greiner Bio One, Kremsmünster, Austria). Upon incubation of Caco-
2 cells for 14 days on the commercially available filter membrane
a resistance of 533 Ω cm2 was observed. This indicates formation
of a confluent monolayer with a TEER that is typically observed on
filter membranes. Interestingly, comparable resistances of about 480
Ω cm2 were observed for Caco-2 cells grown on metal grids which
indicates that a cell layer had formed. These results were underlined by
immunostaining of ZO-1 which was consistently localized at the cell
Figure 36: Caco-2 layer grown on metal grid with mesh width of 25 µm. Tight-
junction associated protein ZO-1 (green, top image) and cell nuclei
stained with propidium iodide (red, bottom image). The steel wires
appear as dark structures in the background.
borders (Figure 36, top image). This is characteristic for confluent Caco-
2 monolayers (see Figures 19 and 29). Moreover, staining of the cell
nuclei with propidium iodide illustrated that the Caco-2 cells indeed
proliferate and form a confluent monolayer on metal grids (Figure 36,
bottom image).
As illustrated by the presented experiments, cell growth can be
attained on materials with high pore density and pore size. Future
work will have to resolve if the Caco-2 layer on the metal grids is
indeed a morphologically and functionally polarized tissue that can be
used for permeation studies. Ultimately, the grid or similar materials
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might represent highly beneficial alternatives as growth supports for
transport studies in academic and industrial research.
CONCLUS IONS
Micro- and nanoparticles differ from small molecules in size by orders
of magnitude. While this brings with it potential benefits, it at the same
time represents the central challenge for their use in drug delivery.
Owing to their physical dimensions and surface properties, colloids
are characterized by peculiar interactions with structures at the cellular,
tissue as well as systemic level. These properties can be masked or
intensified by appropriate engineering of the particle structure and
particle surface functionality. One of the fundamental aims of drug
delivery research is to harvest this potential in order to achieve specific
or nonspecific bioadhesion of micro- and nanoparticles.
A variety of strategies have been employed to modify the interaction
properties of particles with cells.[4, 360] The rationales involved and
techniques employed for this purpose were reviewed in the present
thesis for particles made from the biodegradable and biocompatible
polymer PLGA. Generally, to achieve cytoadhesion the chemical prop-
erties of the cell membrane can be exploited. All eukaryotic cells are
negatively charged on their surface.[6] Moreover, in regenerating tissue
and upon malignant transformation the density of charged moieties
in the plasma membrane is altered.[379, 378] This ubiquitary existence
of anionic groups suggests that the introduction of opposite charges
at the surface of particles will increase their binding potential for the
cell membrane. Since cell surfaces are negatively charged, particles
coated with cationic polyelectrolytes are expected to exhibit increased
interactions. However, as illustrated by the experimental data in the
present thesis, this rationale is not generally applicable. In contrast to
literature reports, it was found that the specificity and quantity of bind-
ing do not generally correlate with particle surface charge. Positively
charged micro- and nanoparticles were characterized by a 3-fold and
5-fold higher binding to artificial intestinal epithelium as compared
to their negative counterparts. In contrast, no differences between the
interaction properties of positively and negatively charged colloids
were observed on primary endothelial cells. Accordingly, the approach
of improving bioadhesion by introduction of positive surface charges
has to be relativized. This only seems to be possible for certain cell
types.
In terms of specificity, bioadhesion mediated by biorecognition is
superior over ionic interactions. In principle, any molecules in or as-
sociated with the cell membrane which are sterically accessible can
serve as potential targets. Membrane-associated carbohydrates, which at
large make up the cellular glycocalyx, can be addressed with lectins.[5]
WGA, which is a representative of this class of proteins, specifically
binds to N-Acetyl-D-glucosamine and N-acetylneuraminic acid. As
illustrated by histological ultrastructure studies in the present thesis,
WGA is characterized by advantageous interaction properties with
epithelial monolayers. Once bound to the apical membrane, WGA
is quickly internalized via endosomes which subsequently fuse with
multivesicular bodies. Interestingly, a considerable amount of the in-
ternalized lectin is transported to the lateral and basolateral side of
the cell membrane within relatively short timescales. In combination
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with previous reports in the literature this indicates that conjugation
of drugs or prodrugs with WGA represents a potent approach for
shuttling poorly bioavailable molecules across the intestinal epithelial
barrier. In addition, at least the cytoadhesive properties of WGA could
be transferred to particulate drug carriers. Since WGA is a dimeric
protein with two high affinity and two low affinity binding sites for
the complementary carbohydrates, it is well suited for the conjugation
with micro- and nanoparticles. Independent of the orientation of the
immobilized molecule on the particle surface it is likely that at least one
binding pocket will be available for interaction with sugar residues of
the glycocalyx. These considerations were experimentally corroborated
in the present thesis. By using nanoparticles that had been labelled
with the fluorophore BOD, the bioadhesive effect resulting from sur-
face modification with ligands can be detected at a highly sensitive
level. When conjugated with WGA, these particles are characterized
by 73-fold increased binding to epithelial cells as compared to plain
colloids. Moreover, inhibition experiments with the complementary
carbohydrate N,N’,N”-triacetylchitotriose demonstrated that at least 90
% of the particles are bound via specific lectin-sugar interactions. These
findings underline that lectins in general and WGA in particular can
serve as mediators of bioadhesion when immobilized on the surface of
particles.[5, 431] This potential could be further exploited for targeted
delivery of drug carriers, since the quantitative and qualitative compo-
sition of the glycocalyx differs between cell types and is altered upon
malignant transformation.[351]
Generally, the total affinity of the particles for a tissue is the essential
factor which determines if binding will occur and be sustained. The
affinity required for firm attachment of a particle to a specific tissue will
widely depend on the local microenvironment. In this regard, shear
forces might play a decisive role.
In the gastrointestinal lumen, a viscous mass of chyme and mucus
is transported by directional flow due to peristalsis. Upon peroral ad-
ministration, particulate drug carriers will have to firmly bind to cells
lining the intestinal tract in order to resist premature removal from
the body by this mechanism. Similar considerations apply to parenter-
ally administered drug carriers. Particularly in case of i.m., s.c. and
i.p. injection particles have to bind to cells at or close to the site of
injection. Otherwise, the colloids will be distributed in the body by
lymph- and bloodstream. While this might allow translocalization to
distant tissue sites, it also increases the probability of sequestration of
the particles by the liver, spleen or other parts of the RES.[262, 254] The
mechanisms which will influence the behavior of micro- and nanoparti-
cles during these dynamic processes are not entirely clear. However, it
is very probable that hydrodynamic effects take a substantial part.[7]
Systematic studies dealing with the effect of flow on particles them-
selves and on their interaction with cells have to be conducted in order
to better understand its impact on drug delivery. A microfluidic flow
model for this purpose was developed in the present thesis. The con-
trolled actuation of fluid in this system is achieved by a chip-based
planar SAW-pump.[8, 9, 413] In contrast to conventional flow chambers,
no tubing is needed due to the contact-free pumping principle. This
allows for a high degree of miniaturization of the device. Moreover,
it facilitates parallelization as was successfully demonstrated by inte-
gration of multiple SAW-pumps in one platform. The system is fully
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compatible with tissue culture. This was achieved by use of polymeric
microchannels in which tissues can be cultivated. The latter was success-
fully demonstrated for epithelial and endothelial monolayers. Amongst
other potential applications, this chip-tissue hybrid can be used to
study the effects of flow on the bioadhesion of drug carrier systems. As
indicated by data presented in this thesis, hydrodynamic shear forces
indeed reduce the binding of surface-modified microparticles to cell
monolayers. WGA-conjugated particles (diameter ~3 µm) pronouncedly
interact with artificial intestinal epithelium under stationary conditions.
In the presence of hydrodynamic drag, however, a shear rate dependent
reduction of binding was observed. Similar observations were made
by others with particles targeted to inflamed endothelium.[399, 382]
Collectively, these results underline the influence of shear forces on the
adhesion process of particles to cells. In the face of this, the current
practice of conducting bioadhesion assays under stationary conditions
in vitro has to be scrutinized.
It is important to highlight that the physical size of particles will in-
fluence their exposure and thus susceptibility to shear forces.[381, 399]
Particles in the nanometer range are expected to be considerably less
influenced by hydrodynamic drag. It needs to be clarified if this prop-
erty constitutes one of the major advantages of submicron particles for
drug delivery. As discussed herein, when assessing potential benefits of
different particle sizes and particle types it will be expedient to account
for the different deposition characteristics of colloids onto cells. This ap-
plies to in vivo as well as in vitro assays and includes possible influences
of the environment on particle stability. The latter is especially relevant
in vivo since protein adsorption as well as hydrodynamic effects likely
lead to flocculation.[7, 432] Finally, it remains to be resolved if the
particle surface properties that have been engineered and optimized in
vitro are conserved upon administration in vivo.[433]
In conclusion, the results presented underline that surface functional-
ization with proteins and polyelectrolytes can improve the bioadhesion
of micro- and nanoparticles. Integration of flow as a parameter in
preclinical biopharmaceutical test systems is expected to allow more
realistic estimates of the bioadhesive effects resulting from surface
modification. This might ultimately facilitate the development of par-
ticulate drug carriers for medical conditions which are not efficiently
addressable by conventional formulations.
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